

CURRICULUM VITAE

FULL NAME: Sunil J. Wimalawansa, MD, PhD, MBA, DSc

CURRENT POSITION: Cardio Metabolic Institute (Hon.)

ADDRESS: Somerset, New Jersey, U.S.A.

E-mail: suniljw@hotmail.com

LinkedIn Profile: <https://www.linkedin.com/in/sunilwimalawansa>

Web profiles: http://www.researchgate.net/profile/Sunil_Wimalawansa/publications
<http://skillpages.com/sunil.wimalawansa>
<https://www.bark.com/s/sunil.wimalawansa/>
<http://sunil-wimalawansa.branded.me/>
<https://www.visualcv.com/sunil-wimalawansa-md-phd-mba>

Successfully completed the National Faculty Education Initiative “Lean Six-Sigma”, Green Belt certification (in completion) at the Rutgers Business School, New Jersey, U.S.A.

Previous Appointment: University Professor (2001-2013)
Professor of Medicine, Endocrinology, Metabolism, & Nutrition
Professor, Graduate School of Physiology & Integrative Biology
Director, Osteoporosis Center

Chief of Endocrinology, Metabolism, & Nutrition (2001–2008)
Department of Medicine
Division of Endocrinology, Metabolism, and Nutrition
New Jersey, U.S.A

HOME ADDRESS: * 661 Darmody Avenue (* preferred address)
North Brunswick, NJ, 08902-4548, USA

CLINICAL ADDRESS: Cardio Metabolic Institute
Somerset, New Jersey, U.S.A.

HOSPITAL PRIVILEGES: Endocrinology, Metabolism, and Nutrition
Robert Wood Johnson University Hospital (RWJUH)
New Brunswick, New Jersey

EDUCATION: Royal Postgraduate Medical School/Hammersmith Hospital
Postgraduate London, United Kingdom (1982–1992)

Qualifications: Fellowship from the Royal College of Physicians, Royal College of Surgeons; Royal College of Pathologists, United Kingdom; and Fellowship of Ceylon College of Physicians; American College of Physicians; American College of Endocrinologists
Doctor of Philosophy (PhD); Endocrine Pathology, Uni. of London
Doctor of Science (D.Sc.); University of Peradeniya, Sri Lanka,
Masters of Business Administration (Executive MBA Program), Rutgers Business School, Newark, New Jersey

United States citizen

2011	Certified Research Contract Professional (CRCP)
2009	Master of the American College of Diabetes Specialists (MACDS)
2009	Fellow of the American College of Endocrinology (FACE)
2008	Fellow of the Royal College of Pathologists (FRCPath)
2008	Fellow of the American College of Physicians (FACP)
2007	Fellowship of the American College of Diabetes (FACD)
2006	Executive MBA Program (Major in Leadership and Marketing); Rutgers School of Business, Newark, NJ (MBA)
2002	Certified Clinical Densitometrist (CCD) from ISCD
2001	Doctor of Science (DSc), University of Peradeniya, Sri Lanka
2000	Graduate Certification, Diploma in Business of Medicine diploma, Johns Hopkins University, School of Business, Baltimore, MD
1995	Fellowship in Royal College of Physicians, London, United Kingdom (FRCP)
1993	Membership of Royal College of Pathologists, United Kingdom (MRCPath.)
1988	Doctor of Philosophy, Biochemistry and Molecular Biology, University of London, United Kingdom (PhD)
1986	Diploma Course in Aviation Medicine, Royal Air Force Base, Farnborough, United Kingdom
1982	Membership in Royal College of Physicians, United Kingdom (MRCP)
1981	Licensure in Royal College of Physicians, London, United Kingdom (LRCP)
1981	Membership in Royal College of Surgeons, United Kingdom (MRCS)
1976	Acupuncture Foundation of Sri Lanka (M.Ac.F.)
1975	Bachelor of Medicine and Bachelor of Surgery, University of Peradeniya, Sri Lanka
1966–1970	Ananda College, Colombo, Sri Lanka

EDUCATION:

Training, Fellowships and Graduate Studies

- Bachelor of Medicine and Bachelor of Surgery; Medical School, University of Peradeniya, Sri Lanka
- Master of Sociology: Faculty of Arts, University of Peradeniya, Sri Lanka (MA, Medical Sociology), pending
- Diploma course in Aviation Medicine, United Kingdom, 1989
- Fellowship in General Internal Medicine, Sri Lanka & United Kingdom (1978–1981)
- Fellowship in Geriatric Medicine & Rehabilitation, Manchester, United Kingdom (1981–1983)
- Fellowship in Chemical Pathology; Endocrinology & Metabolism, Royal Postgraduate Medical School/Hammersmith Hospital, London, United Kingdom (1983/1986)

ADMINISTRATIVE QUALIFICATIONS AND EXPERIENCE

Administrative MBA—Executive MBA; Major in Leadership and Marketing

Qualifications: Rutgers Business School, Rutgers University, New Jersey (2006)

Graduate course, Business in Medicine Diploma, Johns Hopkins University (2000)

Administrative Experience: Chief of Endocrinology, Metabolism & Nutrition (2001–08), Robert Wood Johnson Medical School and the Robert Wood Johnson University Hospital, New Jersey University Professor, Director, Osteoporosis Center (2001-2013)
Executive Masters in Business Administration (2006)
Founding Director, VasoGenix Corporation (2001–2006)
Diploma in Medical Administration, Johns Hopkins University, School of Business ('00)
Chairing multiple local, state, national and international committees
Director, University Osteoporosis Center, Univ. of Texas Galveston (1994–2001)
Acting Head, Department of Chemical Pathology, Hammersmith Hospital, London, United Kingdom (1991)
Director, Biochemical Endocrinology Unit, Royal Postgraduate Medical School London, United Kingdom (1987–1992)
Director, Diabetes Center, Enfield, North London, United Kingdom (2002–2003)

Scientific Business: Member or a Board of Directors of several national and international scientific societies (2000–Present)

Social Business: President or a Board of Directors of several philanthropic foundations and charitable organizations (1997–Present)

RESEARCH AND DEVELOPMENT ACTIVITIES

Broad Areas of Research and Interests

1. Poverty alleviation and disease prevention

- Provision of basic health solutions in developing countries.
- Promote maximum cost-effective usage of resources and policy implementation.
- Provide strategic vision and leadership to organizations, foundations, and NGOs.
- Develop a novel, highly cost-effective methods for water purification for human consumption.
- Promote healthy sanitation and provision of safe, clean water for human consumption.
- Develop cell-phone–based network technology for provision of health education, immunizations, and broader preventative health care in remote villages.

2. Basic scientific and clinical studies in osteoporosis and metabolic bone diseases

- Development of novel combined therapies for osteoporosis (novel anabolic and anti-osteoclastic agents).
- Development of new classes of cost-effective, therapeutic agents for prevention and treatment of osteoporosis (vitamin E, nitric oxide donors, etc.).
- Development of hybrid-peptide molecule and peptide mimetic for human disease.
- Studying effects of oxidative stresses and aging on bone cells.
- Development of novel pharmacologic approaches for prevention of disuse- and weightlessness-induced (i.e., microgravity) and burn-associated musculoskeletal losses.
- *In vitro* and *in vivo* studies to understand common disorders of calcium metabolism.
- Bone cell biology, molecular biology, and gene therapy.
- Sponsored and investigator-initiated randomized controlled clinical studies related to osteoporosis and other metabolic bone diseases.

- General endocrinology and metabolism.

3. Biochemical and molecular biological approaches to basic cardiovascular disorders

- Development of novel therapeutic agents (non-peptide mimetics) based on calcitonin gene-related peptide, adrenomedullin, amylin, receptor activity-modifying peptide (RAMPs), based on the peptide and their receptor structures.
- Structural biological approaches for new drug development using nuclear magnetic resonance (NMR), crystallography, and knowledge-based molecular modeling to obtain 3-D information on the binding domains of receptors.
- Involvement of CGRP and RAMPs (genes, peptides, and their receptors) in the regulation of pregnancy, labor, and ischemia.
- Development of a novel and effective method to treat pre-eclamptic toxemia of pregnancy and premature delivery.
- Male and female sexual health: erectile dysfunctions in men and female sexual dysfunctions (endocrine and locally mediated therapies).
- Studying effects of oxidative stresses and aging on endothelial cells.
- Gene-therapy using calcitonin, gene-related peptide, and its receptor gene for coronary artery disease and primary pulmonary hypertension.

LICENSURE INFORMATION

- Full, unrestricted Medical License, United States of America:
 - New Jersey (active)
 - Texas, Pennsylvania, and Tennessee (inactive)
- Full Registration, General Medical Council, United Kingdom (No: 2764140) (Active)
- Full Registration, Sri Lanka Medical Council (No: 6221) (Active)
- Federal Licensing Examination (FLEX), United States of America, 1992
- ECFMG permanent certification (No: 0-359-533-7), United States of America, 1982
- American Board of Internal Medicine (Board Eligible), 1996

Experience in the Development of New Clinical and Research Units

- Osteoporosis Unit, Hammersmith Hospital, Royal Postgraduate Medical School, 1986
- Biochemical Endocrinology Unit, Hammersmith Hospital, 1988
- Diabetes and Endocrine Center, Southern Region, Saudi Arabia, 1992
- University Osteoporosis Program, University of Texas Medical Branch, Galveston, 1994
- Osteoporosis Center, UMDNJ–RWJMS, New Brunswick, New Jersey, 2002
- International Foundation for Developmental Disability - Medicine and Dentistry, 2008

Board of Directors:

- VasoGenix BioTech (1998-2003)
- International Society for Clinical Densitometry (ISCD) (2007-2009)
- American Association for Endocrinology (AAACE/national) (2011-2015)
- American Association for Endocrinology (AAACE/New Jersey) (2009-2014)
- Samadhi Buddhist Foundation (2009-2012)
- Turner Syndrome Foundation (2010-Cont.)
- X-test.us (2015)

RESEARCH GRANT SUPPORT

A. Past Grant Support

1. Nuffield Foundation, **S.J. Wimalawansa**, \$90,000
 2. British Heart Foundation, **S.J. Wimalawansa**, \$69,000 and \$215,000
 3. Leverhulme Trust, **S.J. Wimalawansa**, ~\$66,000
 4. Mason Medical Research Foundation, **S.J. Wimalawansa**, \$5,950
 5. Local Research Funds, **S.J. Wimalawansa**, \$14,500
 6. Medical Research Council, Canada, M. Bryer and **S.J. Wimalawansa**, \$10,000
 7. Texas Advanced Research Program, Cloning of NPY-Y₂ and Characterization of NPY Binding Site for New Drug Development, **S.J. Wimalawansa**, \$179,000
 8. Texas Advanced Research Program, **S.J. Wimalawansa**, High School Science Teacher Training Grant, \$8,100 (1999)
 9. University of Texas Medical Branch (UTMB) start-up funds, **S.J. Wimalawansa**, \$285,000
 10. Prevention of Estrogen-Deficiency and Steroid-induced Osteoporosis with Nitric Oxide (Pilot Clinical Study), UTMB Center for Aging, Seed Money Research Funding Program, **S.J. Wimalawansa**, \$9,700
 11. Calcitonin Gene-Related Peptide (CGRP) and Treatment of Pre-eclampsia with Magnesium, C. Cooper, **S.J. Wimalawansa**, T. Care, NATO Travel Grant, International Scientific Exchange Program, \$6,060 (1998–2000)
 12. Development of Novel Therapy for Osteoporosis Using Amylin-Calcitonin Chimeric Peptides, Texas Advanced Research Program, **S.J. Wimalawansa**, \$211,764 (1998–2000)
 13. Use of Bisphosphonates to Prevent Bone Loss in Pediatric Burn Patients, Gordon Kline, David Herndon, **S.J. Wimalawansa** (co-principal investigators [PIs]), \$25,000 from Shiners' Institute (1999–2002)
 14. IMPACT Clinical Study, Aventis Pharmaceuticals, **S.J. Wimalawansa**, \$79,000 (1999/2001)
 15. Hip Fracture Prevention Study, **S.J. Wimalawansa**, Novartis Pharma, \$236,500 (2002-04)
 16. UMDNJ–RWJMS start-up funds, **S.J. Wimalawansa**, \$200,000
 17. Evaluation of the efficacy of intravenous bisphosphonates in prevention of burn-associated bone loss in children, Gordon Kline (PI), **S.J. Wimalawansa** (Co-PI), David Herndon, \$125,000 from Shriners Burns Institute (2002)
 18. Use of Bisphosphonates to Prevent Bone Loss in Pediatric Burn Patients, Gordon Kline, David Herndon, **S.J. Wimalawansa** (Co-PI), \$25,000/year, Shiners' Institute (2003–2006)
 19. Depo-Provera and bone loss, **NIH-RO-1**, Abbey Berenson (PI), Carmen Radecki, **S.J. Wimalawansa** (Co-PIs), \$1,254,210 (2001–2006)
 20. Diabetes Education, **S.J. Wimalawansa**, Pfizer and Aventis Pharmaceuticals, \$10,000
 21. Sex-Steroid Hormones and Calcitonin Gene-Related Peptide, **NIH-RO-1** HL 58144 (NIH/NHLBI), C. Yallampalli (PI), **S.J. Wimalawansa** (Co-PI), \$853,367 (2001–2006)
 22. University Professor, NJ State funding for research and development, \$625,000
 23. UMDNJ Internal funding for Clinical Research Center-based clinical studies, \$49,000
 24. Prevention of Postmenopausal Bone Loss by Nitric Oxide, **S.J. Wimalawansa** (P.I.), **NIH-RO-1**, \$1,857,680; total grant award \$3.25 million (2001 through 2008)
 25. Prevention of Bone Loss with Nitric Oxide, **S.J. Wimalawansa** (PI), **NIH** Supplemental grant from NIAMS, \$150,000 (additional NIH supplements, 2007 and 2008)
 26. Area VII Physicians Review Organization, Endocrinology R & D Grant, \$5,000 (2009)
- Above-mentioned amounts are "direct costs" only.***

C. A co-applicant in the Following Successful NIH-Funded Grants, UMDNJ

- NIH Planning Grant for the NJ Center for Clinical and Translational Science (CTSA)–

UMDNJ (2007)

- Equipment grant, Micro-CT grant from NIH, UMDNJ–Rutgers University (2008)

D. Grants Submitted

1. Anti-resorptive agents following teriparatide therapy: A randomized controlled clinical study, **S.J. Wimalawansa** (PI), (40% salary support is requested for PI), NIH RO-1, \$3,585,000 (not funded)
2. Vitamin D deficiency in developmentally disabled patients: Muti-center clinical study, RO-1 grant, **S.J. Wimalawansa** (PI) (30% salary support is requested for PI), NIH RO-1, \$3,050,500 (not funded)
3. Economic cell-phone-based solution for immunization uptake. Gates Foundation, Innovation Grants, \$100,000 **S.J. Wimalawansa** (PI) (not funded)
4. Nitric oxide: Phase III, efficacy and dose-finding human clinical study. A Randomized controlled clinical study, **S.J. Wimalawansa** (PI), (35% salary support is requested for PI), NIH RO-1, \$3,750,000 (submission is on hold)

E. Grants in Preparation

1. Aging, oxidative stress, and osteoclastic activity, RO-1, **S.J. Wimalawansa** (P.I.), ~\$950,000 (15% salary support for PI)
2. Prevention of injuries and osteoporotic fractures in nursing homes in NJ; Retirement research foundation: \$100,000/year (for 3 years)
3. Novel pharmacological countermeasure to prevent musculoskeletal losses in microgravity, NASA, **S.J. Wimalawansa** (PI), ~\$250,000
4. Effects of herbal extracts on bone metabolism and BMD, National Institutes of Complementary and Alternative Medicine, **S.J. Wimalawansa** (PI), ~\$800,000
5. The role of dietary calcium supplementation in blood pressure regulation, National Research Initiative Competitive Grants–USDA, **S.J. Wimalawansa** (PI), ~\$600,000
6. Bone mineral density improvements by dietary interventions in adolescents (USDA), **S.J. Wimalawansa** (PI), ~\$750,000

TEACHER TRAINING

- 1978 WHO, Academic Teacher Training Course, University of Peradeniya, Sri Lanka
- 1998 Facilitator Training Workshop, UTMB, Galveston, Texas
- 1997-99 Faculty Development Seminars, UTMB, Galveston, Texas
- 2002-08 Faculty Development Seminars, RWJMS–UMDNJ, New Jersey

EMPLOYMENT AND PROFESSIONAL EXPERIENCE

- August 2001 – 2013 Tenured full Professor of Medicine
Chief of Endocrinology, Metabolism & Nutrition (2001–2008);
University Professor, and The Director, Osteoporosis Center
Professor, Graduate School of Biomedical Sciences: Physiology and Integrative Biology
Member, The Cancer Institute of New Jersey (since 2005);
UMDNJ–Robert Wood Johnson Medical School, New Brunswick, NJ
- October 1996 – August 2001 Tenured Professor of Medicine, Department of Medicine, Division of General Medicine and Endocrinology;

	Director, University Osteoporosis Program; Professor, Graduate School of Pharmacology, University of Texas Medical Branch (UTMB), Galveston, TX
April 1994 – September 1996	Tenured Associate Professor, Department of Internal Medicine, Division of General Internal Medicine and Endocrinology; Director, Metabolic Bone Disease Center, UTMB, Galveston, TX
January 1992 – April 1994	Consultant Physician and Endocrinologist, Chase Farm Hospital, London, United Kingdom
January 1988 – December 1991	Senior Lecturer/Consulting Physician (Associate Professor), Internal Medicine: The Endocrine Unit, Department of Chemical Pathology, Hammersmith Hospital Royal Postgraduate Medical School (HH-RPMS), University of London, London, United Kingdom

ALUMNI ORGANIZATIONS

- Peradeniya Medical School, Sri Lanka (PEMSAA) (life membership)
- University of London, United Kingdom (life membership)
- Rutgers University, New Jersey (life membership)
- Johns Hopkins School of Medicine, Baltimore, MD (life membership)

CLINICAL TRAINING

Internship:

April 1976–Oct. 1976	House Physician, General Internal Medicine , Teaching Hospital, Kandy, Sri Lanka (Dr. N. Amarasekera)
Oct. 1975–April 1976	House Surgeon, Gynecology and Obstetrics , Teaching Hospital, Kandy, Sri Lanka (Professors K. de Silva and M. Gunaratna)

Residency:

Oct. 1976–Oct. 1977	Resident Medical Officer (Resident) , Senior House Officer, General Medicine, General Hospital, Ratnapura, Sri Lanka (Dr. S.Y.D. Herath)
Oct. 1977–April 1978	Resident Medical Officer (Flight Lieutenant) , Sri Lanka Air Force Hospital, Katunayaka, Colombo, Sri Lanka (Air Commodore C.E. Puvimanasinghe); Squadron Leader, 1978

Senior Resident:

May 1978–Dec. 1980	Honorary Medical Registrar (Senior Resident) , Professorial Medical Unit, Teaching Hospital, Kandy, Sri Lanka (Professor T. Varugunam, Professor N. Senanayaka)
--------------------	---

Fellowship (Geriatric Medicine & Rehabilitation):

March 1981–April 1983	Registrar in Acute Medicine in the Elderly, Rehabilitation, and General Medicine (Fellowship/Senior Resident) , Ladywell and Hope (Teaching) Hospitals, Manchester, United Kingdom (Professor Roy Fox, Dr. George Whittingham, Dr. Mahendra Gonsalkorale)
-----------------------	--

Fellowship (Medicine, Endocrinology and Metabolism, and Chemical Pathology):

April 1983–Dec. 1986	Registrar in Chemical Pathology (Endocrinology Unit) , Hammersmith Hospital and Royal Postgraduate Medical School, London, United Kingdom (Professor I. MacIntyre and Professor Donald Moss; (Endocrinology, Professor Graham Joplin)
----------------------	--

Training in General Medicine, Geriatrics, and Endocrinology

Registrar (Equivalent to Senior Resident/Fellow in the US System):

Professorial Medical Unit, Teaching Hospital, Kandy, Sri Lanka (Professor T. Varugunam)

General Medicine, Diabetes, and Endocrinology (Professor T. Varugunam, 2 years)

General Medicine and Neurology (Professor N. Senanayaka, 6 months)

General Medicine, Rheumatology and Cardiology (Dr. Jonathan Reeve and Dr. Michael Gumpel), Northwick Park Hospital & Clinical Research Center, Harrow, Middlesex, United Kingdom (3 months)

General Medicine and Care of the Elderly (Professor R. Fox, Dr. G. Whittingham, and Dr. M. Gonsalkorale), Hope and Ladywell Hospitals, Manchester, United Kingdom (2 years)

Endocrinology and Metabolism (Chemical Pathology), Hammersmith Hospital, London, United Kingdom (Professors I. MacIntyre, D. Moss, and G. Joplin, 4 years)

Endocrine Surgery/Medicine joint clinics (Dr. J. Lynn, endocrine surgeon, overlapping 2 years)

Senior Registrar (Equivalent to an Assistant Professor in the US System):

Endocrinology and Metabolism (Professor I. MacIntyre and Professor G. Joplin), 16 months

General Medicine, Endocrinology and Diabetes (Dr. J. Tooke), Exeter General Hospital, United Kingdom, 1 month; Medicine-Care of the Elderly (Dr. S. Bilawaski), Whittington Hospital, London, United Kingdom, 2 months

Medicine & Geriatrics (Dr. D. Miller), Exeter General Hospital, Exeter, United Kingdom, 1 month

General Medicine and Rehabilitation, West Wales General Hospital, United Kingdom, 1 month

Consultant Physician (Similar to Professor in the US System) General Medicine and Endocrinology:

Endocrinology and Metabolism (Metabolic Bone Diseases), Hammersmith Hospital, London, United Kingdom (4 years)

Endocrinology and Metabolism (Metabolic Bone Diseases), Clementine Churchill Hospital (AMI), Middlesex, United Kingdom (4 years simultaneous with the above)

Metabolic Medicine joint clinical work, Royal Marsden Hospital, Fulham, United Kingdom (18 months simultaneous with work at Hammersmith Hospital)

General Medicine, Endocrinology, and Diabetes: King Faisal and Armed Forces Hospitals Southern Region, Kingdom of Saudi Arabia; the work included setting up a new Endocrine and Diabetic Center for the southern region of the country (2 months)

General Medicine, Endocrinology, and Diabetes, Chase Farm Hospital, Enfield, London, United Kingdom (10 months)

Clinical Experience

Inpatient

1978–83 Care of acute/emergency medical admissions via primary care referrals and through accident and emergency departments, and inpatient services as the duty medical registrar at teaching hospitals, Peradeniya, Sri Lanka; Hope, Ladywell and Salford Royal Hospitals in Manchester, United Kingdom. Areas covered included investigation and management of metabolic, neurological, and endocrine disorders (including diabetes, thyroid disorders, and sub-fertility) at Teaching Hospital Peradeniya, Sri Lanka; Teaching Hospital, Kandy, Sri Lanka; Hope Hospital, Manchester, United Kingdom; and Nuclear Medicine Unit at the University of Peradeniya. Care of elderly patients and experience in rehabilitation medicine at Hope Salford Royal and Ladywell Hospitals, in Manchester, United Kingdom.

1983–91 Investigation and management of various metabolic and endocrine disorders at the Hammersmith Hospital, London (major tertiary referral center for national and international consultations). Regular consultations for endocrine and metabolic disorders at the Hammersmith Hospital and Royal Marsden Cancer Hospital, London,

United Kingdom. Private patient consultations for endocrine disorders at the Hammersmith Hospital and at the Clementine Churchill Hospital, Harrow, United Kingdom. Member of the Hammersmith Hospital Nutritional Advisory Group. Disorders covered included all aspects of general endocrinology, including diabetes, pituitary disorders, metabolic bone diseases, Paget's disease, osteoporosis, hypercalcemia (due to various causes including malignancy), and all other disorders of calcium metabolism.

1992–94 Consultant in General Internal Medicine, Diabetes and Endocrinology.

1995–2001 Professor of General Medicine, and Endocrinology
Consultant in Endocrinology, Metabolism & Nutrition

2001– August 2013: Professor of Medicine; Endocrinology, Metabolism and Nutrition, UMDNJ, NJ

Outpatient

1978–88 Experience as a registrar/senior registrar: General Medicine and Diabetes (Teaching Hospitals, Kandy and Peradeniya, Sri Lanka; Northwick Park Hospital, Harrow, United Kingdom; Hope Hospital, Manchester, United Kingdom); Infertility Clinic (Teaching Hospital, Kandy, Sri Lanka); Rheumatology (Northwick Park Hospital, Harrow, United Kingdom); Neurology (Teaching Hospital, Peradeniya, Sri Lanka); Thyroid Clinic (Nuclear Medicine Unit, Peradeniya, Sri Lanka); Pain Clinic (Hope Hospital, Manchester, United Kingdom); Geriatric Medicine and Rehabilitation (Hope and Ladywell Hospitals, Manchester, United Kingdom); General Endocrinology (Teaching Hospital, Peradeniya, Sri Lanka; Hope Hospital, Manchester, United Kingdom; Hammersmith Hospital, London, United Kingdom); Endocrine Surgery, Calcium and Osteoporosis Clinics (Hammersmith Hospital, London, United Kingdom)

1988–91 Consultant in Charge: Metabolic Bone Disease Clinics, Hammersmith Hospital (Head, Biochemical Endocrinology Unit), Royal Postgraduate Medical School, London, United Kingdom (inpatients and outpatients)

1992–94 Consultant in Endocrinology & Diabetes: Director of the Diabetes Center, Enfield District General Hospital, North London, United Kingdom

1994–01 Physician in Charge: Regional Osteoporosis Center (Metabolic Bone Disease Clinics), University of Texas Medical Branch at Galveston (inpatients and outpatients) and the Director, Biochemical Endocrinology Unit

2001– Director, Regional Osteoporosis Center (Metabolic Bone Disease Clinics)
Aug. 2013: Endocrinology Metabolism & Nutrition, Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital, New Brunswick, New Jersey

CLINICAL AND BOARD CERTIFICATIONS

- Royal College of Surgeons (UK), Member, MRCS (London), 1981
- Royal College of Physicians (UK), Member, MRCP (UK), 1982
- University of London (UK), PhD (Biochemistry and Molecular Biology), 1988
- Royal College of Pathologists (UK), Member, MRCPATH (UK), 1993
- Royal College of Physicians (UK), Fellow, FRCP (London), 1995
- Board Eligible (ABIM), Internal Medicine, since 1996
- University of Peradeniya, Sri Lanka, Doctor of Science (Medicine), 2001
- Ceylon College of Physicians, Fellow, FCCP, 2006
- American College of Diabetes, Fellow, FACD 2007
- American College of Physicians, Fellow, FACP, 2008
- American Board of Physician Executives (Vanguard member), 2008
- American College of Endocrinology, FACE, 2009
- Fellow of the Royal College of Pathologists, FRCPath, 2008
- Master of the American College of Diabetes Specialists, MACDS, 2009

- Certified Research Contract professional, CRCP, 2011

ACCREDITATIONS

- Accredited specialist in Internal Medicine & Endocrinology (Royal College of Physicians), 1982
- Accredited in Chemical Pathology/Laboratory Medicine (Royal College of Pathologists, UK), 1993
- American Board of Internal Medicine (board eligible), 1996

MANAGEMENT TRAINING

2007	Leadership development conference (AACE), Phoenix, AZ
2004–2006	Executive MBA program, Rutgers Business School, Newark, NJ
1999	Clinical Research Skills Workshop—Clinical Investigators (Pfizer), Galveston, TX
1999	Leadership Training Workshop, University of Texas Medical Branch, Galveston
1998–2000	Johns Hopkins University, graduate certificate course, Business in Medicine diploma, Baltimore, MD
1991	Management Skills Workshop, Oxford, United Kingdom
1991	Young Consultants Symposium, Business and Management, Chester, United Kingdom
1991	Managing Diagnostic Pathology Services, Royal College of Pathologists, London, United Kingdom
1988	Resource Management for Medical Staff, The Nuffield Institute for Health Services Studies, Leeds, United Kingdom
1986	Management Course for Pathologists, London, United Kingdom

ADMINISTRATION / LABORATORY MANAGEMENT EXPERIENCE

2004–2006	Executive MBA program (Leadership and Marketing—social business); Rutgers School of Business, Newark, NJ
2001–2008	Chief of Endocrinology, Metabolism & Nutrition, Robert Wood Johnson Medical School (RWJMS) and Robert Wood Johnson University Hospital (RWJUH), New Brunswick, NJ
2001–2013	Director, Osteoporosis Center, Uni. of Medicine and Dentistry of New Jersey
2001–2013	Laboratory research is focused on metabolic bone diseases; aging and oxidative stress; basic cardiovascular cell-biology including molecular biology and biochemistry, and immunoassays at the RWJMS, New Brunswick, NJ
1998–2000	Business in Medicine diploma (modules included Healthcare, Management, Accounting and Leadership), Johns Hopkins School of Business Administration, Baltimore, MD
1994–2001	Research related to metabolic bone diseases and basic cardiovascular (peptides, receptors, and their genes) in my laboratories via externally funded research laboratory at the University of Texas Medical Branch, Galveston
1985–1991	Trained and supervised junior physicians and scientists in clinical biochemistry, endocrinology, and hormone assays For 5 years, I was responsible for running the routine clinical laboratory and the special investigation sections, including supraregional assay services for the calcium-regulating hormones (e.g., parathyroid hormone, vitamin D, and

- 1989–1991 calcitonin) at the Department of Chemical Pathology, Hammersmith Hospital, London, United Kingdom
- 1978–1980 Director, Biochemical Endocrinology Unit at the Royal Postgraduate Medical School, London, United Kingdom. Various research grants awarded to me during this period funded the research activities of this unit
- and
1983–1986 Provided clinical service including emergency cover and be on-call, Clinical Biochemistry/Chemical Pathology at the University of Peradeniya, Sri Lanka (1979–1980) and Hammersmith Hospital, London, United Kingdom (1983–91). Duties included communicating laboratory results interpretation to clinicians; carrying out special laboratory investigations, procedures, and tests; taking care of the chemical pathology laboratory (all analytical biochemical procedures); and supervising all grades of biochemists, technicians, and junior medical staff.

Pharmaceutical Industry-Related Experience: Consultant (current or previous)

- Amgen Pharmaceuticals
- Eli Lilly Pharmaceuticals
- Novartis Pharmaceuticals
- Procter and Gamble (NFP)
- Aventis Pharmaceuticals (NFP)
- Apotex, Inc
- Teva Pharmaceuticals
- Wyeth-Ayerst Pharmaceuticals
- AstraZeneca Pharmaceuticals
- Bayer Pharmaceuticals

Publications and Research Work Related to Pharmaceuticals

Experience in Phase 2, Phase 3, and Phase 4 clinical studies

- Comparison of the effectiveness of calcitonin and percutaneously administered estrogen in the prevention of postmenopausal osteoporosis (sponsored by Ciba-Geigy of Basel, Switzerland, and Besins Iscovesco of Paris, France) (Lancet, Apr 23; 1(8591): 900–902, 1985); Osteoporosis 1987: Proceedings of the International Symposium on Osteoporosis, Viborg: Norhaven, A/S, pp. 528–532, 1987; Recent Research on Gynecological Endocrinology, pp. 239–244, 1988 and pp. 314–316, 1988
- Evaluation of bioavailability of nasal calcitonin, salmon calcitonin, Sandoz (Switzerland), which developed into the currently marketed drug Miacalcin, 1985–1988
- Evaluation of bioavailability of nasal calcitonin, Elcatonin, Toyo Jozo, Japan, 1988/1989
- Evaluation of therapeutic potentials of human calcitonin (Cibacalcin) for osteoporosis and Paget's disease of bone, Ciba-Geigy, Basel, Switzerland, 1985–1989
- Evaluation of hypocalcemic actions of amylin in humans (J Bone Miner Res, 7:1113–1116, 1992)
- Use of pamidronate in patients with Paget's disease of bone refractory to conventional therapy (Calcif Tissue Int., 53: 237–241, 1993)
- Anti-hypertensive effects of oral calcium supplementation in patients with mild hypertension (Am J Hypertens., 6: 996–1002, 1993)
- Investigation of optimal dose and frequency of administration of pamidronate in patients with hypercalcemia of malignancy (Clin Endocrinol, 41: 591–595, 1994)
- Evaluation of combined therapy with estrogen and etidronate in prevention of early postmenopausal osteoporosis (Am Med J, 99: 36–44, 1995; Menopause Digest, 4: 13–15, 1996)
- Four-year randomized controlled clinical study to evaluate the efficacy of combined treatment of estrogen and a bisphosphonate etidronate in established postmenopausal osteoporosis (Am Med J, 104: 219–226, 1998)

- IMPACT Study, multicenter prospective study to assess physician's reinforcement on patient's compliance in postmenopausal women treated with risedronate, Aventis, 1999/2000
- Zoledronic acid ZOL446 study: The use of zoledronic acid in hip fracture prevention in older men and women (CZOL446H2310), Novartis-DCRI/Duke University, 2002/2004
- Zoledronic acid ZOL446: Study of BMD and biomarker changes following administration of Zoledronic acid in postmenopausal women, CZOL446H2315, Novartis, 2004/2005
- The use of transdermal nitroglycerin therapy for prevention of early postmenopausal bone loss: The NOVEL clinical study, J Clin Endocrinol Metab, 94(9): 3356–3364, 2009

HONORS, AWARDS, AND OTHER PROFESSIONAL ACTIVITIES

2013	Jefferson Science Fellow; finalist; United States, state department
2011 - Present	Vice-chair, Scientific Advisory Board, Int. Society for Clinical Densitometry
2011 - 2015	Board of Directors, American Association for Clinical Endocrinologists
2011 - Present	Board of Directors, Turner Foundation
2008 - 2011	Board of director, International Society for Clinical Densitometry
2009	Master of the American College of Diabetes Specialists (MACDS)
2009	International Osteoporosis Foundation Prize, Sydney, Australia
2008 - 2014	Board of Directors, American Association for Clinical Endocrinologists, New Jersey
2009	Jefferson Science Fellow; finalist; United States, state department
2008	Fellowship, Royal College of Pathologists
2008 - 2013	Board of Directors, Samadhi Foundation
2007	First prize, annual open National Business Plan Competition, Rutgers Business School, Rutgers University
2007	NIH Director's Council of Public Representatives (COPR), Associate
2007	Dr. Oscar S. Gluck ISCD 2007 Humanitarian Award for "outstanding service to those in need"
2006–2008	Chair, Interagency Council on Osteoporosis, State of New Jersey
2005	Lifetime Achievement Award, Sri Lanka Foundation, Los Angeles, CA
2005	McNulty Scholarship, Rutgers School of Business, Newark, NJ
2000–2014	National Institutes of Health, reviewer
2002–2014	Member, Inter-agency Council on Osteoporosis, state of New Jersey
2007–2011	State of New Jersey appointed Co-chair (2007/2009) and Chair (2009/11), of the Inter-agency Council on Osteoporosis (ICO), state of New Jersey
2003–2012	Member, The Cancer Institute of New Jersey, New Brunswick, NJ
2001	Glenn Foundation Award for Endocrinology; 82nd Annual Meeting American Endocrine Society, Denver, CO
2001–2005	Board member, New York and New Jersey Osteoporosis Board
2000	The best clinical paper in University of Texas Medical Branch, Galveston (outside peer-reviewed award)
2000	Graduate certificate course, "Business in Medicine" diploma, Johns Hopkins University, Baltimore, MD
1999-2000	Consultant, External Advisory Panel (Anabolic Steroids), Drug Enforcement Administration (DEA), Washington, DC

1999	Special Recognition Award for innovation, from the South Asian Chamber of Commerce for Research and Development
1998–2001	Board member, Texas Osteoporosis Board
1998–2001	Associate member, Active Scientific Staff, Shriners Burns Institute
1997	Glenn Foundation Award for Endocrinology; 79th Annual Meeting of the American Endocrine Society, Minneapolis, MN
1995, 1997, 1999, 2009	Plenary Awards—annual meetings of American Society for Bone and Mineral Research (ASBMR)
1996	Fellowship of Sealy Center for Aging at UTMB in recognition of scientific contributions to aging
1998	Fellowship, Royal College of Physicians, London, United Kingdom
1992–1994	Consultant to the International Atomic Energy Authority (IAEA), Life Sciences Division, Vienna, Austria
1993	Member of the Royal College of Physicians, London, in recognition of contributions to clinical science
1993	Fellow of the International Neuropeptide Society, in recognition of original scientific contributions to Neuroscience
1993	Dr. Boy Frame Award for Clinical Excellence in the Field of Bone and Mineral Metabolism, 8th Annual Meeting of Adult Bone & Mineral Working Group, American Society for Bone & Mineral Research, Tampa, FL
1991–1993	Examiner, Membership of the Royal College of Physicians (MRCP Part II)
1991–2001	External and internal examiner for MD and PhD degrees
1991–1994	External examiner (WHO consultant for MD Pathology [equivalent to MRCPPath; part II]), Postgraduate Institute of Medicine
1990	Samuel Leonard Simpson Fellowship in Endocrinology
1989	Gilliland Traveling Fellowship in Medicine
1988, 1991–92	Royal Society United Kingdom, study tour prize
1986–94, 1998	American Endocrine Society travel grants
1987, 1989	Guarantors of Brain Award
1989, 1996	The Clinical Endocrinology Trust Fellowship
1987	ICI Pharmaceuticals study tour grant
1987	MRCPPath (Part II) dissertation, grade A+
1973, 1975	Best medical student research project awards
1974	Distinction in pharmacology
1972	Distinction in biochemistry

POST-DOCTORAL FELLOWS AND OTHER SCIENTISTS TRAINED

1988–1990	Christopher Davis, PhD	1998–2000	Kumar Kaluarchchi, PhD
1988–1990	Fuguang Zhang, MS	1998–2001	Adrian Recinos III, PhD
1989–1991	Poshitha Premaratna, PhD	1999–2001	Sankar Surendran, PhD
1990–1991	Ahmed Ahmed, MD	1999–2001	Chandrashekar Thota, PhD
1994–1995	Wan-lin Lu, PhD	2002–2004	Viaa Valasakaki, MS
1991–1992	Ranjan Gunasekera, MD, PhD	2002–2003	Gurpreet Singh, MD
1995–1996	Chin Xu, MS	2002–2003	Neela Sirinivas, MD, MPH
1996–1998	Maria Chapa, MS	2002–2004	Ann Marie Van Hoven, MD
1997–1998	Vijay Shankar, MD, PhD	2002–2004	Simon Agrawala, MD
1998–1998	Harshani Gunasena, PhD	2001–2005	Chandana Herath, PhD
1998–1999	Fuguang Zhang, MS	2003–2005	Azze Farooki, MD

2004–2006	Sheri Gillis-Funderburk, MD	2006–2008	Svetlana Fomin, MD
2004–2006	Gretchen Perilli, MD	2001–2008	Gayathri Kulkarani, PhD
2004–2008	Jaya Ghoush, MSc	2004–2008	Jaya Ghosh, MS
2004–2006	Dishini de Silva, BSc (Eng.)	2002–2008	Julia Grimes, DO, MPH
2006–2008	Diane Fresca, MD	2007–2009	Sefton Vergamo, MD
2006–2008	Amy Toscano-Zukor, MD	2008–2009	Esther Ash, MD
2006–2007	Xingbin Wang, MD, PhD	2006–2013	Anoja Warusawithana, BS
2006–2007	Masako Ueda, MD	2008–2012	Carola Springer, MS

STUDENTS IN TRAINING

1995	Levoir Lewis, Sunishka Wimalawansa	2004	Radshika Marya
1996	Jessica Yu, Sunishka Wimalawansa, Shyma Muthali, Nalaka Senaratra, Dinushka Wimalawansa	2005	Diane Morris
1997	Tanvi Kamdar, Anuja Mudali, Andrea Augustus	2006	Alyson McGhan
1998	Kim Jenkins, Dinushka Wimalawansa, Sunishka Wimalawansa,	2007	Eleaine Nau
1999	Jenifeer Buchli, Steven Tabor, Laura Davies	2008	Annie Zeb, Dharshan Shaa
2000	Samantha Megha, James Taylor	2009	Mahjabeen Ismail, Chaaya Maija
2003	Julie Gowaski	2010	Kevin Bonila, Adam, Koryean, EJ Nicolas
		2011	Lisa Cannarella, Christopher Caravanos Lina Forero, Sheri Jones
		2012	Sheri Jones, Ajay Singh, Randy Jackson, Shyam Sridhar

Director, Elective Training Program – Endocrinology and Metabolism, RWJMS

2002–2009

Assistant Fellowship Program Director – Endocrinology and Metabolism

2002–2008

PAST TEACHING ACTIVITIES

A. Undergraduate

- 1978-80 Clinical Biochemistry, Medical, Dental and Veterinary undergraduates at Medical School, Peradeniya, Sri Lanka (lectures, tutorials, and practicals); ward teaching and tutorials (General Medicine and Metabolic Medicine), 4th and 5th year medical students, Teaching Hospitals, Kandy and Peradeniya, Sri Lanka
- 1982-83 Regular ward teaching (General Medicine) for fourth and final year medical students, University of Manchester, United Kingdom
General Medicine Teaching for MRCP examination candidate for medical staff at the Ladywell, Salford Royal and Hope Hospitals, Manchester, United Kingdom
- 1983-92 Lectures and case demonstrations for the Chemical Pathology Module, Diploma in Clinical Pathology, and MSc courses in Clinical Biochemistry, Royal Postgraduate Medical School, University of London, United Kingdom
Membership Teaching (MRCP and MRCPPath Examinations) for technical staff and junior medical staff, Hammersmith Hospital, London, United Kingdom
- 1992-94 Clinical teaching and ward tutorials: medical students at the University of London, United Kingdom
- 1994-01 Clinical teaching in General Medicine for Medical and Pharmacy Students, Residents, and Fellowship Training in Metabolic Bone Diseases (Endocrine) at UTMB, Galveston
- 2001-Now UMDNJ–Robert Wood Johnson Medical School

B. Postgraduate Teaching

- 1979-80 University of Peradeniya, MSc course in clinical biochemistry, and MD (Medicine and Pathology)
- 1979-80 Institute of Child Health, London, and Royal Postgraduate Medical School, London (Diploma and MSc Courses)
- 1988-91 Recognized Teacher: Royal Postgraduate Medical School, University of London
- 1994-2001 Taught postgraduate courses at UTMB, and at the Graduate School of Pharmacology
- 2001-Now Teaching postgraduate courses at Rutgers, UMDNJ and Graduate School of Physiology; Nutrition, Cell Biology, Molecular Medicine, and Pharmacology
- 2003-Now Minority Affairs Committee mentoring undergraduate and graduate students (American Endocrine Society)

UNIVERSITY OF TEXAS CLINICAL AND EDUCATIONAL ACTIVITIES

Clinical Activities at UTMB (1994–1999):

- General medicine wards (3 months/year) (1995–2000)
- Hypertension consults (2 months/year; 1994–1997)
- Metabolic bone disease consults (throughout the year) (1994–2000)
- Metabolic bone disease outpatient clinic (twice a week throughout the year) (1994–2000)
- Member, Pharmacy and Therapeutic Committee (1997–2000)

Teaching Responsibilities at University of Texas Medical Branch at Galveston

- Undergraduate Teaching
 - Endocrinology and Hypertension Consults Service
 - General Medicine wards inpatient teaching
 - Lectures to medical students and house officers (residents)
 - Mentor program for medical students (summer research programs)
 - Introduction to Clinical Medicine (ICM); student training and evaluations
 - Introduction to Patient Evaluation (IPE); Interactive Learning Track (ILT)
 - Integrated Curriculum Evaluation Exercise (ICEE)
- Postgraduate teaching: seminars and symposia; update lectures
- Resident teaching (inpatient and outpatient)
 - General Medicine, Hypertension, Metabolic Bone Diseases
- Regular teaching activities: Graduate School of Pharmacology
Medical School: Endocrinology and Dermatology courses
- Regular UT-Med Group Practice CME presentations to community physicians and internal medicine house staff
- Presentation of scientific research data and discussions (once a week)
- Annual summer undergraduate student science program
- Volunteer, UTMB Medical Explorer Post (Annually)
- Training of junior high and high school students and high school science teachers during summer science camps at UTMB
- Graduate students and post-doctoral teaching
- Participation in medical students' research programs
- Judge, National Student Research Forum; Galveston County Science Fair (Annually)

Robert Wood Johnson Medical School Activities/Committees

- Career Development Committee (Dept. APT), Department of Medicine (2002–2010)

- Fundraising committee, Department of Medicine (2002–2005)
- Elective Director, Endocrinology (2002–2009)
- UMDNJ Committee for the GCRC project application (2002/2005)
- Strategic Planning Executive Committee, Department of Medicine (2003/2005)
- Co-Chair, Departmental Resource Development Committee (2003–2005)
- Member, GI Neuro-endocrine Tumor Board (2007-2013)
- Summer Clinical Internship Program (2008)
- Pediatric Scientific Oversight Committee (2008–2013)

Provision of Continuing Medical Education Programs (and CME Directorships)

- FLARE Workshop, The American Endocrine Society, New Orleans, LA, 2014
- Two CME presentations: Optimizing management of high risk osteoporosis evolving strategies, mechanisms and treatment paradigms (May–June, 2013), CME provider–University of Massachusetts, School of Medicine:
 - Strengths and limitations of established therapies for osteoprotection (San Francisco, CA)
 - New therapeutic paradigms focused on injectable therapies in patients at high risk of fracture (Chicago, IL).
- Two CME presentations: Optimizing management of high risk osteoporosis evolving strategies, mechanisms and treatment paradigms (April–May, 2012), CME provider–University of Massachusetts, School of Medicine:
 - New therapeutic paradigms focused on injectable therapies in patients at high risk of fractures: From mechanism of actions to landmark trials on fracture prevention (Chicago, IL).
 - Scientific foundations and pathophysiology of osteoporosis: Fundamentals of bone remodeling and novel mechanisms to inhibit bone resorption (Princeton, NJ).
- New approaches in treating type II diabetes; Women’s Christian Association Hospital, Jamestown, NY (CME provided by Buffalo University (May, 2012)
- Fundamentals of nutrition and healthy living for professionals: ways to control obesity epidemic; Raritan Bay Medical center, New Jersey (May 2012)
- Series of three CME presentations: New Frontiers in the Science and Medicine of Osteoporosis Management (April–May, 2011), CME–University of Massachusetts, School of Medicine:
 - Scientific foundation and pathophysiology of osteoporosis: fundamentals of bone remodeling and novel mechanisms to inhibit bone resorption: Focus on Rank Ligand (San Francisco, CA)
 - Capture the fracture: Evidence and FRAX-based guidance on risk stratification for fracture in postmenopausal women (Princeton, NJ)
 - Strength and limitation of established therapies for osteoprotection: Balancing efficacy against issues of compliance, tolerability, and regimen adherence with bisphosphonates (New York, NY)
- South Asian Total Health Initiative (SATHI) and Center for Health Families and Cultural Diversity (CHFCD):
 - Integrative healing, alternative medicine, and spirituality: meditation, spirituality, and health (Princeton, NJ)

- CME Program Chair, 1st Annual Symposium on Endocrinology for Primary Care Physicians, “All You Want to Know About Treatment of Common Endocrine Disorders in Ambulatory Patients,” NJ-American Association for Clinical Endocrinologists, UMDNJ–RWJMS, New Brunswick, NJ, 2010 (CME Director)
 - All you want to know about vitamin D (New Brunswick, NJ)
 - Prevention of medical complications associated with obesity (New Brunswick, NJ)
- Series of three CME presentations: New Frontiers and Real World Challenges in the Management of Osteoporosis (April–May 2010), CME–University of Massachusetts, School of Medicine:
 - Focus on bisphosphonate therapy, extended dosing intervals, and post-fracture prevention (Los Angeles, CA)
 - Bone mineral density testing in the primary care setting: Interpretation and pitfalls
 - Best-use strategies at the front lines of practice (Chicago, IL).
- Osteoporosis 2009; Seeking Answers for Clinical Practice, 31st Annual Meeting of ASBMR, Denver, CO, 2009 (CME Director)
- Evaluation and Management of Osteoporosis Encountered in Adults with Developmental Disabilities, UMDNJ–Center for Continuing and Outreach Education, CME Co-Activity Director CCOE and the IFCD 2009 (CME Director)
- Evaluation and Management of Osteoporosis Encountered in Children and Adults with Developmental Disabilities, UMDNJ–Center for Continuing and Outreach Education (CCOE) and the Developmental Disabilities Nurses Association (DDNA); 2008 (Speaker and CME Activity Director)
- Ethics in Endocrinology Research, Faculty Member, International Congress of Endocrinology and The Endocrine Society, Rio De Genera, Brazil, 2009.
- Osteoporosis in the 21st Century: Implications for Clinicians and Researchers, American Academy of CME, 2008 (CME Activity Director/Guest Editor)
- American Academy of Developmental Medicine and Dentistry (AADMD), Developmental Disabilities Nurses Association (DDNA), 2008 (CME Activity Director/Guest Editor)
- EP Global Communications, Inc., and Vemics, Inc., The Basic Biochemistry and Pathophysiology of Osteoporosis as Seen in the General Population and in Adults with Developmental Disabilities (Co-sponsor: UMDNJ–Center for Continuing and Outreach Education and American Academy of Developmental Medicine and Dentistry, 2007 [CME Activity Director])
- Liberty Communications Network/Medical Crossfire®; Osteo-Opportunities: Steps Along the Path of Treatment, 2006
- Medical Crossfire: Monograph on osteoporosis: “Diagnosis and treatment of bone building,” 2005 (CME Activity Director)
- Medical Crossfire: The ORAG Meta-Analysis, 2004/2005 (CME Activity Director)
- Fracture prevention and osteoporosis: Building on current efforts to promote bone health, 2003
- Prevention and treatment of osteoporosis: Call to action, RWJMS–UMDNJ, 2002
- Therapeutic advances in the management of osteoporosis, CME symposia, Houston, TX, 2001
- Update on osteoporosis, Southern Texas Medical Association, Corpus Christi, TX, 2000
- Osteoporosis update, CME symposia, UTMB, Galveston, TX, 1999

Other Teaching Activities

- American College of Physicians, Summer Clinical Internship Program (2010/2011)

- UMDNJ–Summer Clinical Internship Program (2008-Present)
- American Endocrine Society, Minority Affairs Committee, related teaching (2006–Present)
- American Endocrine Society International Trainee Workshops (2007–2010)
- UMDNJ medical student and graduate student teaching (2001–2012)
- Teaching in medical ethics courses (ethics in medicine and in clinical research) (2007–2010)

Past Research Experience

In 1973 and 1975, awarded the best medical student projects, which led to two scientific publications. During my 2½ years as a lecturer (Assistant Professor) in Clinical Biochemistry and Medical Registrar at the Medical School, Peradeniya, and Teaching Hospital, Kandy, Sri Lanka, a prospective study carried out on weight gain during pregnancy and maternal nutrition and its relationship to fetal viability, toward a Master's degree in Medical Sciences.

For my PhD thesis, I studied the family of peptides encoded in the calcitonin gene, including the hormone calcitonin and its carboxy-terminal flanking peptide, katalcalcin, and a potent vasodilator, calcitonin gene-related peptide (CGRP). Identification and characterization of specific binding sites/CGRP receptors by autoradiography and *in vitro* membrane receptor-binding assays in human and several other species. Studies were done to identify stimuli that affect the release of these peptides using a multichannel superfusion chamber system. CGRP in plasma and cerebrospinal fluid was characterized using various chromatographic systems, including reverse-phase HPLC, sizing and ion-exchange HPLC, conventional gel-permeation and ion-exchange chromatography, and TLC. Using these techniques, CGRPs and tachykinins were isolated and purified for the first time from normal human tissues (spinal cord) in 1996. For the first time, β -human CGRP was isolated and purified to homogeneity (1.9×10^7 fold purification) from the human spinal cord and fully characterized and sequenced by fast atom bombardment mass spectrometry with Professor H.R. Morris, FRS, at the Imperial College, London, United Kingdom. The first partial identification of the putative γ -CGRP peptide obtained from normal neural tissues (human spinal cord and DRGs obtained from cadavers) occurred in 1977.

Polyadenylated α - and β -CGRP mRNAs isolated from dorsal root ganglia from human cadavers were characterized using several molecular biological techniques, with a view to understanding the differential expression of CGRP genes. Similar work was done to study the expression of messenger RNA for PTH-related peptide (PTHrP) and amylin in human fetal and adult endocrine tissues.

Other research activities include the development of novel immunoassays for calcium regulating hormones and cardioactive peptides (e.g., amplified enzyme immunoassays [two-site assays], enzyme-receptor assays, radioimmunoassays, and radio-receptor assays).

Journal Reviewer

- | | |
|--|---|
| - <i>Bone</i> | - <i>Biochemical Pharmacology</i> |
| - <i>Biochemical Pharmacology</i> | - <i>Journal of Clinical Endocrinology and Metabolism</i> |
| - <i>Calcified Tissue International</i> | - <i>Journal of Applied Physiology</i> |
| - <i>Clinical Therapeutics</i> | - <i>Journal of Bone and Mineral Research</i> |
| - <i>Endocrine</i> | - <i>Osteoporosis International</i> |
| - <i>Endocrinology</i> | - <i>Journal of Clinical Densitometry</i> |
| - <i>Experimental Biology and Medicine</i> | - <i>Journal of Bone and Mineral Metabolism</i> |
| - <i>Expert Opinion journals</i> | - <i>Neuro-Signals</i> |
| - <i>Hypertension</i> | - <i>Peptides</i> |
| - <i>Journal of Endocrinology</i> | - <i>Pharmacological Review</i> |
| - <i>Journal of Hypertension</i> | - <i>Physiological Reviews</i> |
| - <i>Journal of Vascular Research</i> | |

Editorial Boards:Previous:

Journal of Clinical Densitometry (2005–2007)
 Journal of Musculoskeletal Interactions (2006–2008)
 Journal of Chinese Clinical Medicine (2009–2012)

Current:

Vitamins & Minerals (2012, cont.)
 Biosensors & Bioelectronics (2013, cont.)
 Research and Reports in Endocrine Disorders (2013, cont.)
 Endocrinology & Metabolism (2014, cont.)
 Journal of Journal of Diabetes, Metabolic Disorders & Control (2014, cont.)
 Biosensors & Bio electronics (2014, cont.)
 MOJ Clinical & Medical Case Reports (2015, cont.)
 Current Research in Diabetes & Obesity Journal (2015, cont.)
 Achieves of Clinical Nephrology (2015-cont.)
 International Journal of Environment & Agricultural Research (2015 – cont.)
 International Journal of Nutritional Sciences (2015, cont.)
 Journal of Archives of Clinical Nephrology (2015 – cont.)
 International Journal of Environmental and Agricultural Research (2015 – cont.)
 SciRes Literature, Diabetes and Metabolism (2015 – cont.)
 Gavin Journal of Diabetes & Metabolic disorders (2015-cont.)
 Journal of Clinical & Medical Sciences (2016-cont.)
 Metabolic Syndrome, Prediabetes & Diabetes (2016-cont.)
 International Journal of Nephrology and Reno-Vascular Disease (2016-cont.)

Research Areas (Past and Present)**1. Peptide receptor purification and cloning of receptor genes:**

Isolated, purified, and characterized calcitonin gene-related peptide (CGRP), amylin, and neuropeptide Y (NPY-Y₂) receptors. Raising monoclonal antibodies against CGRP- and NPY-Y₂ receptor proteins using these highly purified proteins. Construction of porcine and human brain cDNA libraries for screening with radio-labeled oligonucleotides and monoclonal antibodies in a eukaryotic expression cloning system.

2. Development of receptor-based agonists and antagonists:

Synthesized series of peptide analogues based on the specific CGRP and NPY-Y₂ peptide-binding domain of the receptor, and have screened for their biological activities. Small molecular, non-peptide mimetics were developed using combinatorial chemistry and screened with highly specific assays based on a partially purified receptors and *in vivo* systems.

3. Development of novel assays and raising antibodies:

Developed in-house EIA (ELISA) (e.g., for CGRP and CT) and receptor-based assays, radio-receptor assays for CGRP and NPY. In addition to radioimmunoassay, we also developed two-site enzyme immunoassay for PTHrP, CGRP, NPY, and receptor-based highly specific amplified immunoassays for CGRP and NPY. Experience in raising

monoclonal and polyclonal antibodies and various cell culture and molecular biological techniques.

4. *Metabolic bone diseases and hypercalcemia of malignancy:*

Optimized intravenously administered pamidronate therapy for treatment of hypercalcemia of malignancy and patients with Paget's disease of bone refractory to conventional therapy. Demonstrated pancreatic peptide, amylin's effect on calcium homeostasis and controlling osteoclastic activity *in vitro* and *in vivo* in animals and in humans. Development and synthesis of many peptide analogues, including calcitonin-amylin hybrid molecules with higher specific activity and higher potency.

5. *Calcitonin and percutaneous hormone replacement therapy for osteoporosis:*

Participated in the initial development and assessment of the efficacy of nasally administered modified eel calcitonin (Turbocalcin) and salmon calcitonin (Miacalcin) in the mid-1980s. These compounds tested in phase two studies in postmenopausal women and patients with Paget's disease and hypercalcemia of malignancy. Published a book and several articles on the subject of hypercalcemia of malignancy and possess extensive experience in investigations and management of metabolic bone diseases.

6. *Experience with "intravenous" administration of bisphosphonates:*

I have used intravenously administered pamidronate extensively in my patients (e.g., treated more than 400 patients with Paget's, more than 500 patients with hypercalcemia of malignancy, and more than 3,000 patients with osteoporosis).

7. *Role of nitric oxide in bone metabolism:*

Studied the role of nitric oxide in bone metabolism. Demonstrated the efficacy of nitric oxide donor therapy, nitroglycerine and nitrates in prevention of estrogen deficient (Bone, 18: 301–304, 1996) as well as in corticosteroid-induced osteoporosis (Bone, 21: 275–280, 1997).

Demonstrated for the first time that the beneficial effects of estrogen in bone are in part mediated via nitric oxide/cGMP pathway (Wimalawansa et al, J Bone Miner Res, 1996).

Carried out the first randomized controlled study (a proof of concept pilot study) comparing the efficacy of percutaneous nitroglycerin ointment vs. hormone replacement therapy in prevention of bone loss in women (Wimalawansa, J Bone Miner Res, 15: 2240–2244, 2000).

Conducted a single-center National Institutes of Health-funded randomized, double-blind clinical trial (NOVEL clinical study) to assess the efficacy of nitroglycerin (Phase 3 study with IND from FDA to Wimalawansa) in prevention of early postmenopausal bone loss.

Wimalawansa et al, Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab, 94(9): 3356–3364, 2009.

8. *Role of vitamin E (Dl- α -tocopherol) in bone metabolism:*

Carried out pioneering work on vitamin E and bone and described these data in 1999 (J Bone Miner Res).

9. *New strategy to treat pregnancy-induced hypertension (prevention of pre-eclamptic toxemia and preterm delivery):*

In studies done in collaboration with Dr. Yallampalli (OB/GYN) using an animal model of pre-eclampsia and preterm delivery using CGRP, nitric oxide, and a progestogen, we were able to minimize the complications associated with this relatively common disorder in an animal model of pre-eclampsia. We have also demonstrated the positive interactions between these compounds and sex steroidal regulation of the CGRP receptor-effectors system.

10. *Effect of microgravity on the hormones and skeletal system:*

Using animal models that simulate weightlessness (i.e., microgravity and space flight), we demonstrated the relationship of the endocrine system to musculoskeletal losses in

microgravity. Demonstrated a marked suppression of blood sex-steroid hormone levels during exposure to simulated weightlessness and the partial reversal of musculoskeletal losses with the replacement of these hormones (e.g., testosterone or estrogen).

11. Secondary and tertiary peptide structure prediction and crystallography (Structural Chemistry):

Experiments conducted to demonstrate the secondary and tertiary structures of the family of peptides comprising CGRP, amylin, and calcitonin with circular dichroism, multi-dimensional NMR spectroscopy, and knowledge-based computer modeling.

12. Prevention of re-stenosis following coronary angioplasty:

Designing and evaluating new methods of prevention of coronary artery spasm, re-stenosis following angioplasty, and coronary stenting using animal models (rabbit and pig) (1994–1997). Development of novel coated intracoronary stents with biological material to prevent stent occlusion (1996).

13. Development of once-a-week therapy with bisphosphonate for treatment of osteoporosis:

Original concept of infrequent use of oral bisphosphonates was developed and applied to practice in 1995. Two-year interim comparative data from once-daily vs. once-a-week therapy was presented at the ASBMR, and the 4-year data were subsequently presented at ASBMR and American Endocrine Society meetings in 2001.

14. Development of new concepts of using calcitonin gene-related peptide for female sexual arousal disorders and treatment of congestive cardiac failure in humans:

Wimalawansa developed the original concept in 1999, and the VasoGenix Company applied USPTO in 2002.

15. Molecular biology and gene therapy:

Preliminary studies were conducted in rabbits and pigs using CGRP gene as well as CGRP receptor genes (1996–1998).

16. Solid-phase peptide synthesis:

Have synthesized more than 200 peptides since the late 1980s using solid-phase peptide synthesis, including α - and β -human CGRP, calcitonin, human amylin, and amylin amide, PTH (1-34), PTHrP (1-34) (1-36), tachykinin, NPY and fragments, and several analogues of these peptides. Large quantities (i.e., 500 mg each) of CGRP and NPY peptides were synthesized and distributed to many other scientists across the world. Purified synthetic peptides were used in specific affinity columns during the mass scale purification of these two receptors from brain tissues.

17. Ovarian failure and menopause:

In addition to demonstration of dose-response curve with estradiol, we reported the minimum effective doses of 17β -estradiol (using plasma levels of 17β -estradiol as a marker) for the maintenance of the skeleton (Recent Research in Gynecological Endocrinology, 2: 314, 1988), and the relationship of plasma 17β -estradiol levels to changes in bone mineral density. Comparative study conducted to evaluate the effects of percutaneously administered 17β -estradiol and human calcitonin in the prevention of early postmenopausal bone loss (Lancet, i: 800, 1988). Two, 4-year prospective, controlled, randomized clinical studies were done to assess the effect of bisphosphonate and its combination with estrogen in prevention of bone loss in early postmenopausal women (Am J Med, 99: 36, 1995) and in patients with established postmenopausal osteoporosis (Am J Med, 104: 219–226, 1998). These two were the first set of clinical studies demonstrating the beneficial effects of combined therapy in osteoporosis.

18. Induction of sleep:

Isolated and partially characterized the chemical factors liberated from the male sex organs that are highly potent in the induction of sleep ("fatigue factor"). The aim was to isolate this factor to homogeneity, with a view of developing a novel therapeutic agent based on this structure for use for insomnia and conscious sedation.

19. Purification of water for human consumption:

We are developing a novel, highly cost-effective method of purification of water (i.e., to remove heavy metals, fluoride, and agrochemicals) that is applicable globally. In addition, it is a highly cost-effective method for point-of-care water testing for key contaminants.

Invited Presentations

Invited to speak at more than 180 national and international conferences and 48 medicine grand round presentations.

In addition, since 1995, have given about 10 to 15 presentations yearly in local communities, church groups, and for primary care physicians in Texas and New Jersey.

Membership in Scientific Societies (current and previous)

American Endocrine Society	International Society for Neuroendocrinology
American College of Physicians	International Society for Clinical Densitometry
American Soc. for Bone & Mineral Research	College of Acupuncture (Sri Lanka)
American Asso. for Advancement of Science	Royal College of Physicians (United Kingdom)
American Association of Physician Executives	Life Member, College of Physicians (Sri Lanka)
American Medical Association	Life member, American Association of Physicians of Indian Origin (AAPI)
American Association for Clinical Endocrinologists	Royal College of Pathologists (United Kingdom)
American Society for Gene Therapy	Sri Lanka Medical Association
International Neuropeptide Society	Royal College of Surgeons (Eng.)
Fellow, Royal College of Physicians (Lon.)	New York Academy of Sciences
International Bone and Mineral Society	Society for Endocrinology
International Society for Gynecological Endocrinology	Life Member, Sri Lanka Medical Association of North America

Ad Hoc or Regular Grant Reviewer

- National Aeronautics and Space Administration, Life Sciences, Washington DC
- Medical Research Council, New Zealand
- University Grant's Commission, Hong Kong
- The Wellcome Trust/Foundation, United Kingdom
- Jockey Club, Hong Kong
- Medical Research Council, Hong Kong
- Medical Research Council, United Kingdom
- External Reviewer, VA Merit Review Boards, United States
- National Institutes of Health, United States

EXTRACURRICULAR ACTIVITIES***Ananda College, Colombo (1962–1970):***

College honors for field hockey, soccer, basketball, badminton, and cadetting
 Leader of the All Island "Millers Cup" winning rifle-shooting team
 Member of the Sri Lankan National Schools' teams for hockey and soccer

University of Sri Lanka, Peradeniya (1971–1975):***Best All-Round Sportsman, University of Sri Lanka, Peradeniya, 1974***

University full honors for field hockey, soccer, athletics, basketball, gymnastics, and badminton

Black belt in Karate (1974)

Member of the Sri Lankan youth teams (under 23) in field hockey and soccer

Member of the Kandy district and the Sri Lanka field hockey team

Expeditions and outdoor activities:

Founder President, Sri Lanka University Explorers' Club (1973–1975)

Founder President, Sri Lanka Explorers' Club (1975–1980)

Founding member of both the University and Sri Lanka Explorers' clubs (have organized and undertaken more than 250 expeditions, including one in the Himalayas in India)

Activities include hiking, mountaineering, and rock-climbing, camping, cycling, canoeing, and orienteering

Director, National Orienteering Program (1994–1998)

Co-director, Outward Bound Trust and Training Program, National Council YMCA (1977–1980)

Member, Sri Lanka National Advisory Council for Students' Adventure Clubs (Ministry of Education, Sri Lanka, 1979–1980)

Initiated more than 150 “nature clubs” and “explorer clubs” in more than 100 high schools across Sri Lanka (1973–1980).

Military Service:

Sri Lanka Air Force: Flight Lieutenant (1977); retired Squadron Leader (1980)

Cardio-Pulmonary Resuscitation (CPR):

Healthcare Provider Certificate from the American Heart Association (renewed, 2015)

Founder and member of the Board of Directors (2001–2006) VasoGenix Pharmaceuticals

Founder, CG Therapeutics, 2007

CHARITABLE AND VOLUNTEER WORK

- *Co-Founder, Chairman of the Board of Directors and Vice-President of Medical Affairs, International Foundation for Chronic Disabilities (IFCD), 2008–Present*
- *Chair, Wimalawansa Education Trust Fund (WETF) for Needy Children, 1999–Present*
- *Chair, Wimalawansa Foundation, 2007–Present*
- *Founder President, International Foundation for Revitalization, Empowerment, Education and Development (I-FREED); a non-governmental charitable organization (President 2000–2006)*
- *Founder President, Hela Bodhu Padanama, North America, 2005–Present*
- *Member, National Advisory Council on South Asian Affairs (NACSAA), an independent, charitable, US-based public policy interest group, 2005–Present*
- *Council Member, NJ State Interagency Osteoporosis Council (IOC), 2002–Present*
- *Chairman, NJ State Interagency Osteoporosis Council (IOC), 2007/08 (Co-Chair, 2005/6)*
- *Council member, Ananda College OBA, 2007–Present*
- *Council member and Chair of the CME Committee, Sri Lanka Medical Association of North America (SLMANA), 2006–Present*
- *Member, Board of Directors, Samadhi Foundation, 2007–2013*
- *Member, Board of Directors, Turner Foundation, 2011–Present*
- ***Editorial Board Member, a number of scientific journals***

COMMITTEE MEMBERSHIPS IN NATIONAL AND INTERNATIONAL SCIENTIFIC ORGANIZATIONS

- *American Association of Clinical Endocrinologists (AACE):*
 - Board of Directors, national AACE (2010-Present)
 - Board of Directors, New Jersey–AACE (2008-Present)
 - Member, Academic Endocrinologists Committee (2006-Present)
 - Member, Legislative Committee (2010-2012)
 - Member, Clinical Research Committee (2009-2012)
 - Member, Abstract Review Committee (2006-Present)
 - Member, Annual Scientific Congress organization Committee (2011-2013)
 - Member, Health Care Disparity Committee (2011-2013)
 - Member, osteoporosis and bone disease scientific committee (2012-Present)
 - Member, adrenal disease scientific committee (2012-2013)
 - Member, International Committee (2014-Present)
- *International Society for Clinical Densitometry (ISCD):*
 - Member, Scientific Advisory Committee (2012-present)
 - Member, Public Policy Steering Committee (2005-2011)
 - Member, Grants, Review, and Education Committee
 - Member, State Legislative/Insurance sub-committee (2005-2010)
 - Board of Director (2007-2010)
- *American Society for Bone and Mineral Research (ASBMR):*
 - Member, Industry Relations Task Force (2009-2010)
 - Member, Calcium and Vitamin D Task Force (2009-2010)
 - Member, Glucocorticoid-induced osteoporosis Task Force (2009-2010)
 - Member, Industry Relations Task Force (2010-Present)
 - Member, Abstract Review Committee (2006-Present)
 - Member, Glucocorticoid-Induced Osteoporosis Task Force (2009-2010)
 - Member, Professional Practice Committee (2007–2010)
- *American College of Endocrinologists (ACE):*
 - Member, Empower Committee (2007–2010)
- *American College of Physicians (ACP):*
 - Member, Cultural Diversity Committee (2008–Present)
- *American Society of Nutrition (ASN):*
 - Member, Medical Nutrition Council (MNC) (2009–Present)
 - Member, Education Task Force (2009–Present)
 - Member, Membership Committee (2010–Present)
- *American Medical Association (AMA):*
 - Member, Internal & External Relationships Committee (2009-Present);
 - International Medical Graduate Section (2009-Present)
 - Member, Leadership Development Committee (2008–Present)
- *American Endocrine Society*
 - Member, Minority Affairs Committee and a member, Faculty Mentoring Group (2008-2013)
 - Faculty member, FLAR training program (2014)
- *DeVry University, New Jersey*

- Member, Industry Advisory Committee (2009–Present)
- International Foundation for Chronic Disabilities (IFCD) 2007 – cont.
 - Founder President Membership development committee
 - Vice-President, Medical Affairs
- American Academy of Developmental Medicine and Dentistry
 - Membership development committee

Publications: https://www.researchgate.net/profile/Sunil_Wimalawansa/publications/

BIBLIOGRAPHY

Peer-Reviewed Publications

1. **Wimalawansa, S.J.** Use of papaya in the treatment of chronic infected ulcers. *Ceylon Medical Journal*, 27: 59–61, 1981.
2. Senanayaka, N., **Wimalawansa, S.J.** Periodic paralysis complicating malaria. *Postgraduate Medical Journal*, 57: 273–274, 1981.
3. **Wimalawansa, S.J.**, Herath, K.B., Wikramanayake, T.W., Piyasena, R.D. Total body water and its relation to body fat. *Ceylon Medical Journal*, 29: 82–86, 1981.
4. **Wimalawansa, S.J.** Relationship of maternal parity to outcome of pregnancy. *Ceylon Medical Journal*, 30: 49–53, 1982.
5. Herath, K.B., **Wimalawansa, S.J.**, Wikramanayake, T.W., Piyasena, R.D. Estimation of total body water and water turnover rates in Sri Lanka using tritiated water. *Journal of National Science Council*, 51: 371–378, 1982.
6. Self, C.H., **Wimalawansa, S.J.**, Johannsson, A., Bates, D., Girgis, S.I., MacIntyre, I. A new sensitive and fast peptide immunoassay based on enzyme amplification: used in the determination of CGRP and the demonstration of its presence in the thyroid. *Peptides*, 6: 627–630, 1985.
7. Girgis, S.I., Macdonald, D.W.R., Stevenson, J.C., Bevis, P.J.R., **Wimalawansa, S.J.**, Lynch, C., Self, C.H., Morris, H.R., MacIntyre, I. Calcitonin gene-related peptide: potent vasodilator and major product of the calcitonin gene. *Lancet*, ii: 14–16, 1985.
8. Zaidi, M., Bevis, P.J.R., Abeyasekera, G., Girgis, S.I., **Wimalawansa, S.J.**, Morris, H.R., MacIntyre I. The origin of circulating calcitonin gene-related peptide in rat. *Journal of Endocrinology*, 110: 185–190, 1986.
9. **Wimalawansa S.J.**, Wikramanayake T.W. The ratio: birth weight to maternal weight, as an index of maturity of neonate. *Ceylon Journal of Medical Sciences*, 30: 39–44, 1987.
10. **Wimalawansa S.J.**, Emson P.C., MacIntyre I. Regional distribution of calcitonin gene-related peptide and its specific binding sites in the rat, with particular reference to the nervous system. *Neuroendocrinology*, 46: 131–136, 1987.
11. **Wimalawansa S.J.**, MacIntyre I. The presence of calcitonin gene-related peptide in the human cerebrospinal fluid. *Brain*, 110: 1647–1655, 1987.

12. **Wimalawansa S.J.**, Wikramanayake T.W. Factors affecting weight gain during pregnancy and the growth of the infant. *Ceylon Journal of Medical Sciences*, 30: 21–28, 1987.
13. **Wimalawansa S.J.**, MacIntyre I. Heterogeneity of plasma calcitonin gene-related peptide: partial characterization of immunoreactive forms. *Peptides*, 9: 407–410, 1988.
14. MacIntyre I., Stevenson J.C., Whitehead M.I., **Wimalawansa S.J.**, Banks L.M., Healy M.J.R. Calcitonin for prevention of postmenopausal bone loss. *Lancet*, i: 900–901, 1988.
15. **Wimalawansa S.J.**, MacIntyre I. Calcitonin gene-related peptide and its specific binding sites in the cardiovascular system of the rat. *International Journal of Cardiology*, 20: 29–37, 1988.
16. Seth R., Motte P., Kehely A., **Wimalawansa S.J.**, Self C., Bellet D., Bohuon C., MacIntyre I. A sensitive and specific enzyme-immunometric assay for human calcitonin using monoclonal antibodies. *Journal of Endocrinology*, 119: 351–357, 1988.
17. Macintyre, I., Whitehead, M.I., Banks, L.M., Stevenson, J.C., **Wimalawansa, S.J.**, Healy, M.J.R. Calcitonin for prevention of postmenopausal bone loss. *Obstetrical and Gynecological Survey*, 43 (10), 619-620, 1988.
18. **Wimalawansa S.J.** Sensitive and specific radio-receptor assay for calcitonin gene-related peptide. *Journal of Neuroendocrinology*, 1:15–19, 1989.
19. Seth S., Motte P., Kehely A., **Wimalawansa S.J.**, Self C.H., Bohuon C., Bellet D., MacIntyre I. The development of a two-site enzyme immunometric assay (EIA) for calcitonin and its application in the measurement of the hormone in normal subjects, MTC patients and postmenopausal women. *Hormone and Metabolic Research*, 21: 3–5, 1989.
20. **Wimalawansa S.J.**, Morris H.R., MacIntyre I. Both α - and β -calcitonin gene-related peptides are present in plasma, cerebrospinal fluid and spinal cord in man. *Journal of Molecular Endocrinology*, 3: 247–252, 1989.
21. Datta H.K., Zaidi M., **Wimalawansa S.J.**, Ghatei M.A., Beacham J.L., Bloom S.R., MacIntyre I. *In vivo* and *in vitro* effects of amylin-amide on calcium metabolism in the rat and rabbit. *Biochemical and Biophysical Research Communications*, 162: 876–881, 1989.
22. Ghatei M.A., Datta H., Watt D.B., **Wimalawansa S.J.**, Zaidi M., MacIntyre I., Bloom S.R. Amylin and amylin-amide lacks an acute effect on blood glucose and insulin. *Journal of Endocrinology*, 124: R9–R11, 1990.
23. **Wimalawansa S.J.**, Morris H.R., Etienne A., Blench I., Panico M., MacIntyre I. Isolation, purification and characterization of beta-hCGRP from human spinal cord. *Biochemical and Biophysical Research Communications*, 167: 993–1000, 1990.
24. Zaidi M., Datta H.K., Bevis P.J.R., **Wimalawansa S.J.**, MacIntyre I. Amylin amide: a bone conserving peptide from pancreas. *Experimental Physiology*, 75: 529–536, 1990.
25. Brain S.D., **Wimalawansa S.J.**, MacIntyre I., Williams T.J. The demonstration of vasodilatory activity of pancreatic amylin in the rabbit. *American Journal of Pathology*, 136: 487–490, 1990.
26. Brain S.D., MacIntyre I., **Wimalawansa S.J.**, Williams T.J. Amylin amide, which is structurally similar to calcitonin gene-related peptide (CGRP), stimulates increased blood flow *in vivo*. *European Journal of Pharmacology*, 183: 221, 1990.

27. Datta H.K., Rafter P.W., **Wimalawansa S.J.**, Chen Z.P., MacIntyre I. CGRP and amylin-amide display a proliferative effect on human umbilical endothelial cells and osteoblast-like osteosarcoma cell-line. *Biochemical Society Transactions*, 18: 1276, 1990.
28. Hothersall J.S., Muirhead R.P., **Wimalawansa S.J.** The effect of amylin and calcitonin gene-related peptide on insulin-stimulated glucose transport in the diaphragm. *Biochemical and Biophysical Research Communications*, 169: 451–454, 1990.
29. **Wimalawansa S.J.** Effects of *in vivo* stimulation on molecular forms of circulatory calcitonin and calcitonin gene-related peptide in man. *Molecular and Cellular Endocrinology*, 71:13–19, 1990.
30. Harrison M., James N., Broadley K., Bloom S.R., Armour R., **Wimalawansa S.J.**, Heath D., Waxman J. Somatostatin analogue treatment for malignant hypercalcemia. *British Medical Journal*, 300: 1312–1313, 1990.
31. Davis J.P., Archer D.J., Fisher C., **Wimalawansa S.J.**, Baldwin D. Multiple recurrent giant cell lesions associated with high circulatory parathyroid hormone-related peptide in a young adult. *British Journal of Oral and Maxillofacial Surgery*, 29: 102–105, 1991.
32. **Wimalawansa S.J.** Circadian variation of plasma calcitonin gene-related peptide in man. *Journal of Neuroendocrinology*, 3: 319–322, 1991.
33. Chance W.T., Balasubramaniam A., Zhang F.S., **Wimalawansa S.J.**, Fischer J.E. Anorexia following the intra-hypothalamic administration of amylin. *Brain Research*, 539:352–354, 1991.
34. **Wimalawansa S.J.** Does the treatment of osteoporosis with estrogens improve skin fragility? *Journal of Tissue Viability*, 1: 22–25, 1991.
35. **Wimalawansa S.J.** Isolation, purification and biochemical characterization of calcitonin gene-related peptide receptors. Proceedings of the First International Symposium on Calcitonin Gene-Related Peptide, Graz, Austria, 1991. *Annals of the New York Academy of Sciences*, 657: 70–87, 1991.
36. **Wimalawansa S.J.** Age-related increase of calcitonin gene-related peptide in rat thyroid and circulation. *Peptides*, 12(5): 1143–1147, 1991.
37. Zaidi, M., Moonga, B. S., Bevis, P. J., Alam, A. S., Legon, S., **Wimalawansa, S.**, MacIntyre, I., Breimer, L. H. Expression and function of the calcitonin gene products. *Vitamins and Hormones*, 46: 87-164, 1991.
38. **Wimalawansa S.J.**, Gunasekera R.D., Datta H.K. Hypocalcaemic actions of amylin-amide in man. *Journal of Bone and Mineral Research*, 7(9): 1113–1116, 1992.
39. Krootila K., Oksala O., von Dickhoff K., **Wimalawansa S.J.**, Uusitalo H. Ocular irritative response to YAG laser capsulotomy in rabbits: Release of calcitonin gene-related peptide and effects of methysergide. *Current Eye Research*, 11: 307–314, 1992.
40. **Wimalawansa, S.J.** Isolation, purification, and biochemical characterization of calcitonin gene-related peptide receptors. *Annals of New York Academy of Sciences*, 657: 70-87, 1992.
41. **Wimalawansa S.J.** Age-related changes of tissue content of immunoreactive calcitonin gene-related peptide. *Aging–Clinical and Experimental Research*, 4(3): 211–217, 1992.

42. Giuliani S., **Wimalawansa S.J.**, Maggie C.A. Involvement of multiple receptors in the biological effects of calcitonin gene-related peptide and amylin in rat and guinea pig preparations. *British Journal of Pharmacology*, 107: 510–514, 1992.
43. **Wimalawansa S.J.** Long- and short-term side effects and safety of calcitonin in man: A prospective study. *Calcified Tissue International*, 52(2): 90–93, 1993.
44. **Wimalawansa S.J.** CGRP radioreceptor assay: A new diagnostic test for medullary thyroid carcinoma. *Journal of Bone and Mineral Research*, 8(4): 467–473, 1993.
45. **Wimalawansa S.J.**, El-Kholy A.A. A comparative study of distribution and biochemical characterization of brain CGRP receptors in five different species. *Neuroscience*, 54(2): 513–519, 1993.
46. **Wimalawansa S.J.** Therapeutic options in prevention and treatment of osteoporosis. *Experiments in Clin Endocrinology (Life Science Advances)*, 12:1–27, 1993.
47. **Wimalawansa S.J.** Effects of neonatal capsaicin therapy on plasma contents and tissue levels of immunoreactive-CGRP. *Peptides*, 14(2): 247–252, 1993.
48. **Wimalawansa S.J.**, Gunasekera R.D., Zhang F. Isolation, purification and characterization of calcitonin gene-related peptide receptor. *Peptides*, 14(4): 691–699, 1993.
49. **Wimalawansa S.J.**, Banks, L. M. Therapeutic success in severe iatrogenic osteoporosis in a young woman. *Journal of Royal Society of Medicine*, 86(2): 117-8, 1993.
50. **Wimalawansa S.J.** Sexually transmitted diseases in the age of AIDS. *Ceylon Medical Journal*, 38(1):12-14, 1993.
51. **Wimalawansa S.J.** Hypercalcaemia of malignancy: etiology, pathophysiology, and management. *Reviews on Endocrine-Related Cancer*, 45: 5–24, 1993.
52. **Wimalawansa S.J.**, Gunasekera R.D. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. *Calcified Tissue International*, 53(4): 237–241, 1993.
53. **Wimalawansa S.J.** An anti-hypertensive effect of oral calcium supplementation is mediated through the potent vasodilator CGRP. *American Journal of Hypertension*, 6(11): 996–1002, 1993.
54. **Wimalawansa S.J.** Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. *Cancer*, 73(8): 2223–2230, 1994.
55. **Wimalawansa S.J.** Dramatic response to plicamycin in a patient with severe Paget's disease refractory to calcitonin and pamidronate. *Seminars in Arthritis Rheumatism*, 23(4):267-8, 1994.
56. **Wimalawansa S.J.** Optimal frequency of administration of pamidronate in patients with hypercalcemia of malignancy. *Clinical Endocrinology*, 41: 591–595, 1994.
57. **Wimalawansa S.J.**, Gunasekera, R.D. The effectiveness of pamidronate in patients with Paget's disease of bone refractory to conventional therapy. *Seminars in Arthritis and Rheumatism*, 23 (1):1–2, 1994.
58. **Wimalawansa S.J.**, Baily F. Validation, role in peri-operative assessment, and clinical applications of an immune-radiometric assay for human calcitonin. *Peptides*, 16(2): 307–312, 1995.

59. Bryer-Ash M., Follett L., Hodges N., **Wimalawansa S.J.** Amylin-mediated reduction in insulin sensitivity corresponds to reduced insulin receptor kinase activity in the rat *in vivo*. *Metabolism*, 44(6): 705–711, 1995.
60. **Wimalawansa S.J.** Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. *American Journal of Medicine*, 99: 36–42, 1995.
61. **Wimalawansa S.J.**, Supowit S.C., DiPette D.J. Mechanisms of the antihypertensive effects of dietary calcium and role of calcitonin gene-related peptide in hypertension. *Canadian Journal of Physiology and Pharmacology*, 73: 981–985, 1995.
62. Bouali S.M, **Wimalawansa S.J.**, Jolicoeur F.B. *In vivo* central actions of rat amylin. *Regulatory Peptide*, 56(2): 167–174, 1995.
63. **Wimalawansa S.J.** Purification, and biochemical characterization of neuropeptide Y-Y2 receptors. *Journal of Biological Chemistry*, 270(31): 18523–18530, 1995.
64. Skofitsch G., **Wimalawansa S.J.**, Jacobowitz D.M., Gubisch W. Comparative immuno-histochemical distribution of amylin-like immunoreactivity in the rat central nervous system. *Canadian Journal of Physiology and Pharmacology*, 73: 945–956, 1995.
65. D'Este L., **Wimalawansa S.J.**, Renda T.G. Amylin-immunoreactivity is co-stored in a serotonin cell subpopulation of the vertebrate stomach and duodenum. *Archives of Histology and Cytology*, 58: 537–547, 1995.
66. **Wimalawansa S.J.**, DeMarco G., Gangula P., Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss [<http://www.ncbi.nlm.nih.gov/pubmed/8726385>]. *Bone*, 18(4): 301–304, 1996.
67. Yallampalli C., Dong Y.-L., **Wimalawansa S.J.** Calcitonin gene-related peptide reverses the hypertension and significantly decreases the fetal mortality in pre-eclampsia rats induced by N^G-nitro-L-arginine methyl ester. *Human Reproduction*, 11(4): 895–899, 1996.
68. **Wimalawansa S.J.** Calcitonin gene-related peptide: Molecular genetics, physiology, pathology and therapeutic potentials. *Endocrine Reviews*, 17(5); 533–585, 1996.
69. Gangula P.R.R., Supowit S.C., **Wimalawansa S.J.**, Zhao H., Hallman D.M., DiPette D.J., Yallampalli C. Calcitonin gene-related peptide is depressor in NG-nitro-L-arginine methyl ester-induced hypertension during pregnancy. *Hypertension*, 29(2): 248–253, 1997.
70. **Wimalawansa S.J.** Calcitonin gene-related peptide, calcitonin and amylin: A peptide super family. *Critical Reviews in Neurobiology*, 11(4), 167–239, 1997.
71. Cooper C., Li H., **Wimalawansa S.J.** Cancer-associated hypercalcemia and parathyroid hormone-related peptide: a new peptide with diverse roles. *Regulatory Peptide Letters*, 7:33–38, 1997.
72. Gangula P.R.R., **Wimalawansa S.J.**, Yallampalli C. Progesterone up-regulates vasodilator effects of calcitonin gene-related peptide in N^G-nitro-L-arginine methyl ester-induced hypertension. *American Journal of Obstetrics and Gynecology*, 176(4), 894–900, 1997.
73. **Wimalawansa S.J.**, Chapa M.T., Yallampalli C., Zhang R., Simmons D.J. Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats [<http://www.ncbi.nlm.nih.gov/pubmed/9276093>]. *Bone*, 21: 275–280, 1997.

74. **Wimalawansa S.J.** Combined therapies with calcitonin and corticosteroids, or bisphosphonate for treatment of hypercalcaemia of malignancy. *Journal of Bone and Mineral Metabolism*, 15: 160–164, 1997.
75. **Wimalawansa S.J.**, Simmons D.J. Prevention of corticosteroid-induced bone loss with alendronate. *Proceedings of the Society of Experimental Biology and Medicine*, 217: 162–167, 1997.
76. **Wimalawansa S.J.**, Cooper C.W. Calcitonin and osteoporosis. *Regulatory Peptide Letters*, 7: 39–42, 1997.
77. **Wimalawansa S.J.** Four-year randomized controlled trial of hormone replacement therapy and bisphosphonate alone or in combination in women with postmenopausal osteoporosis. *American Journal of Medicine*, 104: 219–226, 1998.
78. Yallampalli C., **Wimalawansa S.J.** Calcitonin gene-related peptide is a mediator of vascular adaptation during hypertension in pregnancy. *Trends in Endocrinology and Metabolism*, 9(3): 113–117, 1998.
79. Morara S., **Wimalawansa S.J.**, Rosina A. Monoclonal antibodies reveal expression of the CGRP receptor in Purkinje cells, inter-neurons and astrocytes of rat cerebellar cortex. *Neuroreport*, 9: 3755–3759, 1998.
80. **Wimalawansa S.J.**, Yallampalli C. Pre-eclamptic toxemia: Potential new therapy based on animal studies. *Ceylon Medical Journal*, 43: 138–144, 1998.
81. Dong Y.-L., Gangula P.R., Fang L, **Wimalawansa S.J.**, Yallampalli C. Uterine relaxation responses to calcitonin gene-related peptide and calcitonin gene-related peptide receptor decreased during labor in rats. *American Journal of Obstetrics and Gynecology*, 179: 497–506, 1998.
82. Wimalawansa S.M., Chapa M.T., Wei Jingna N., Westlund Karin N., Quast M.J., **Wimalawansa S.J.** Reversal of weightlessness-induced musculoskeletal losses with androgens: Quantitation by MRI. *Journal of Applied Physiology*, 86: 1841–1846, 1999.
83. Gangula P.R.R., Zhao H., Supowit S., **Wimalawansa S.J.**, DiPette D., Yallampalli C. Pregnancy and steroid hormones enhance the vasodilatory response to calcitonin gene-related peptide (CGRP) in rats. *American Journal of Physiology*, 176: H284–H288, 1999.
84. Ye Z., **Wimalawansa S.J.**, Westlund KN. Receptor for calcitonin gene-related peptide: Localization in the dorsal and ventral spinal cord. *Neurosciences*, 92(4): 1389–1397, 1999.
85. Yallampalli, C., Gangula, P.R.R., Kondapaka, S., Fang, L., **Wimalawansa, S.J.** Regulation of calcitonin gene-related peptide receptors in the rat uterus during pregnancy and labor and by progesterone. *Biology of Reproduction*, 61: 1023–1030, 1999.
86. Wimalawansa S.M., **Wimalawansa S.J.** Simulated weightlessness-induced attenuation of testosterone production may be responsible for bone loss. *Endocrine*, 10(3): 253–260, 1999.
87. Dong Y.-L., Fang L., Kondapaka S., Gangula P.R., **Wimalawansa S.J.**, Yallampalli C. Involvement of calcitonin gene-related peptide in the modulation of human endometrial contractions during pregnancy. *Journal of Clinical Investigation*, 104: 559–565, 1999.
88. **Wimalawansa S.J.** Restoration of ovariectomy-induced bone loss by nitroglycerin. *Calcified Tissue International*, 66: 56–60, 2000.

89. Gangula P.R.R., Zhao H., **Wimalawansa S.J.**, Supowit S.C., DiPette D.J., Westlund K.N., Gagel R., Yallampalli C. Increased blood pressure in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice. *Hypertension*, 35: 470–475, 2000.
90. Wimalawansa S.M., Chapa T., Fang L., Yallampalli C., Simmons D., **Wimalawansa S.J.** Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. *Journal of Bone and Mineral Research*, 15(6): 1119–1125, 2000.
91. Gangula P.R., **Wimalawansa S.J.**, Yallampalli C. Pregnancy and sex-steroid hormones enhance circulating calcitonin gene-related peptide concentrations in rats. *Human Reproduction*, 15(4): 949–953, 2000.
92. **Wimalawansa S.J.** Prevention and treatment of osteoporosis: Efficacy of combined therapies of hormone replacement therapy with anti-resorptive agents. *Journal of Clinical Densitometry*, 3(2): 1–15, 2000.
93. Gangula P.R.R., Lanlua P., **Wimalawansa S.J.**, Supowit S., DiPette D., Yallampalli C. Regulation of calcitonin gene-related peptide expression in dorsal root ganglia of rats by female sex steroid hormones. *Biology of Reproduction*, 62: 1033–1039, 2000.
94. Wimalawansa S.M., **Wimalawansa S.J.** A novel pharmacological approach to prevention of musculoskeletal losses associated with simulated microgravity. *Journal of Musculoskeletal and Neuronal Interactions*, 1(1): 35–41, 2000.
95. **Wimalawansa S.J.** Nitroglycerin therapy is as effective as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: A human pilot clinical study. *Journal of Bone and Mineral Research*, 15: 2240–2244, 2000.
96. **Wimalawansa S.J.** Use of the combination of HRT and a bisphosphonate for prevention and treatment of osteoporosis. *Journal of Musculoskeletal and Neuronal Interactions*, 1(3): 2000.
97. D'Este L., Casini A., **Wimalawansa S.J.**, Renda T.G. Immunohistochemical localization of amylin in rat brainstem. *Peptides*, 21(11): 1743–1749, 2000.
98. Wimalawansa S.M., Shankar V.S., Simmons D.J., **Wimalawansa S.J.** The mechanism of bone resorption by cyclosporine: Involvement of the NO/cGMP pathway. *Journal of Musculoskeletal and Neuronal Interactions*, 1(2): 141–143, 2000.
99. Morara S., Rosina A., Provini L., Forloni G., Anna Caretti A., **Wimalawansa S.J.** Calcitonin gene-related peptide receptor expression in the neurons and glia of the developing rat cerebellum: an auto-radiographical and immunohistochemical analysis. *Neuroscience*, 100(2): 381–391, 2000.
100. Zhang L., Hoff A.O., **Wimalawansa S.J.**, Cote G., Gagel R., Westlund K.N. Arthritic calcitonin/alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. *Pain*, 89: 265–273, 2001.
101. Halhali A., **Wimalawansa S.J.**, Berentsen V., Avila E., Thota C., Larrea F. Calcitonin gene- and parathyroid hormone-related peptides in preeclampsia: Effects of magnesium sulfate. *Obstetrics and Gynecology*, 97: 893–897, 2001.
102. Gangula P.R., Zhao H., **Wimalawansa S.J.**, Supowit S.C., DiPette D.J., Yallampalli C. Pregnancy and steroid hormones enhance the systemic and regional hemodynamic effects of calcitonin gene-related peptide in rats. *Biology of Reproduction*, 64: 1776–1783, 2001.

103. D'Este L., **Wimalawansa S.J.**, Renda T.G. Distribution of amylin-immunoreactive neurons in the monkey hypothalamus and their relationships with the histaminergic system. *Archives of Histology and Cytology*, 64(3): 295–303, 2001.
104. Classey J.D., Lasalandra M.P., Knight Y.K., **Wimalawansa S.J.**, Goadsby P.J. Immunohistochemical comparison of CGRP and substance P (peptides and receptors) and NMDAR1 and GLUR1 receptor distribution in the cat trigeminocervical complex. Cephalalgia (Blackwell Science Ltd.), *Pharmacology*, 21: 351–367, 2001.
105. Gunaratne G., Rajapakse C.S., Bassler K., Mohanty K.K., **Wimalawansa S.J.** Model for bone strength and osteoporotic fractures [<http://www.ncbi.nlm.nih.gov/pubmed/11863854>]. *Physical Review Letters*, 88(6): 068101, 2002.
106. Yallampalli C., Chauhan M., Kondapaka S., **Wimalawansa S.J.** Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity. *Trends in Endocrinology and Metabolism*, 13(6): 263–269, 2002.
107. Lanlua P., Bukoski R.D., **Wimalawansa S.J.**, Yallampalli C. Effects of pregnancy and female sex-steroid hormones on calcitonin gene-related peptide content of mesenteric artery in rat. *Biology of Reproduction*, 67: 1430–1434, 2002.
108. Gangula P.R.R., **Wimalawansa S.J.**, Yallampalli C. Sex hormones enhance hypotensive effects of calcitonin gene-related peptide in aged female rats. *Biology of Reproduction*, 67: 1881–1887, 2002.
109. Gangula P.R.R., Dong Y.-L., **Wimalawansa S.J.**, Yallampalli C. Infusion of pregnant rats with calcitonin gene-related peptide (CGRP)₈₋₃₇, a CGRP receptor antagonist, increases blood pressure and fetal mortality and decreases fetal growth. *Biology of Reproduction*, 67: 624–629, 2002.
110. Chauhan M., Thota C.S., Kondapaka S.B., **Wimalawansa S.J.**, Yallampalli C. CGRP receptor heterogeneity: a role for receptor component protein? *Trends in Endocrinology*, 14(1): 4–6, 2002.
111. Dong Y.-L., Vegiraju S., Gangula P.R., Kondapaka S.B., **Wimalawansa S.J.**, Yallampalli C. Expression and regulation of calcitonin gene-related peptide receptor in the rat placenta. *Biology of Reproduction*, 67: 1321–1326, 2002.
112. Gunaratne G.H., Mohanty K., **Wimalawansa S.J.** A model of trabecular bone and an application to osteoporosis. *Physica Acta*, 315: 98–104, 2002.
113. Witlin A.G., Li Z.-Y., **Wimalawansa S.J.**, Grady J., Grafe M.R., Yallampalli C. Placental and fetal growth and development in late rat gestation is dependent on adrenomedullin. *Biology of Reproduction*, 67: 1025–1031, 2002.
114. Witlin A.G., Gangula P.R.R., **Wimalawansa S.J.**, Grafe M., Grady J.J., Yallampalli C. Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation. *Hypertension in Pregnancy*, 22: 9–24, 2003.
115. Rajapakse C.S., Thomsen J.S., Ortiz J.E., **Wimalawansa S.J.**, Ebbesen E.N., Mosekilde L., Gunaratne G.H. An expression relating breaking stress and density of trabecular bone. *Physical Review Letters*, 8: 1-21, 2003.

116. Dong Y.-L., **Wimalawansa S.J.**, Yallampalli C. Effects of steroid hormones on calcitonin gene-related peptide receptors in cultures human myometrium. *American Journal of Obstetrics and Gynecology*, 188: 466–472, 2003.
117. Chauhan M., Thota C.S., Kondapaka S., **Wimalawansa S.J.**, Yallampalli C. Evidence for the existence of a new receptor for CGRP, which is not CRLR. *Peptides*, 24: 65–71, 2003
118. Advani S., **Wimalawansa S.J.** Bones and nutrition: Common sense supplementation for osteoporosis. *Current Women's Health Reports*, 3(3): 187–192, 2003.
119. Witlin A.G., Gangula P.R.R., **Wimalawansa S.J.**, Grafe M., Grady J.J., Yallampalli C. Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation. *Hypertension in Pregnancy*, 22(1): 9–24, 2003.
120. Fristad I., Vandevska-Radunovic V., Fjeld K., **Wimalawansa S.J.**, Kvinnsland H. NK1-, NK2-, NK3- and CGRP-1-receptors identified in rat oral soft tissues, in bone, and dental hard tissue cells. *Cell and Tissue Research*, 311(3): 383–391, 2003.
121. Qing X., **Wimalawansa S.J.**, Keith I.M. Specific N-terminal CGRP fragments mitigate chronic hypoxic pulmonary hypertension in rats. *Regulatory Peptides*, 110: 93–99, 2003.
122. Gangula P.R.R., Thota C., **Wimalawansa S.J.**, Bukoski R.D., Yallampalli C. Mechanisms involved in calcitonin gene-related peptide-induced relaxation in pregnant rat uterine artery. *Biology of Reproduction*, 69(5): 1635–1641, 2003.
123. Grimes J.P., **Wimalawansa S.J.** Breast-feeding and postmenopausal osteoporosis. *Current Women's Health Reports*, 3(3): 193–198, 2003.
124. Vandevska-Radunovic V., Fristad I., **Wimalawansa S.J.**, Kvinnsland I.H. CGRP-1 and NK-1 receptors in postnatal, developing rat dental tissues. *European Journal of Oral Sciences*, 111(6): 497–502, 2003.
125. Rajapakse, C.S., Thomsen J.S., Espinoza-Ortiz J.S., **Wimalawansa S.J.**, Ebbesen E.N., Mosekilde L., Gunaratne G.H. An expression relating breaking stress and density of trabecular bone [10.1016/j.jbiomech.2003.12.001; <http://www.ncbi.nlm.nih.gov/pubmed/15212930>]. *Journal of Biomechanics*, 37(8): 1241–1249, 2004.
126. Yallampalli C., Kondapaka S.B., Lanlua P., **Wimalawansa S.J.**, Gangula P.R. Female sex steroid hormones and pregnancy regulate receptors for calcitonin gene-related peptide (CGRP) in rat mesenteric arteries, but not in aorta. *Biology of Reproduction*, 70: 1055–1062, 2004.
127. Gangula P.R.R., Kondapaka S.B., Lanlua P., **Wimalawansa S.J.**, Yallampalli C. Female sex steroid hormones and pregnancy regulate receptors for calcitonin gene-related peptide in rat mesenteric arteries, but not in aorta. *Biology of Reproduction*, 70: 1055–1062, 2004.
128. Chauhan M., Gangula, P.R., **Wimalawansa, S.J.**, Yallampalli C. Studies on the effects of the N-terminal domain antibodies of calcitonin receptor-like receptor and receptor activity-modifying protein 1 on calcitonin gene-related peptide-induced vaso-relaxation in rat uterine artery. *Biology of Reproduction*, 70: 1658–1663, 2004.
129. Penchalaneni J., **Wimalawansa S.J.**, Yallampalli C. Adrenomedullin antagonist treatment during early gestation in rats causes fetoplacental growth restriction through apoptosis. *Biology of Reproduction*, 71: 1475–1483, 2004.

130. Gangula, P.R.R., Lanlua, P., Bukoski, R.D., **Wimalawansa, S.J.**, Yallampalli, C. Mesenteric arterial relaxation to calcitonin gene-related peptide is increased during pregnancy and by sex-steroid hormones. *Biology of Reproduction*, 71: 1739–1745, 2004.
131. Rajapakse C.S., Ortiz J.E., **Wimalawansa S.J.**, Ebbesen E.N., Thomsen J.S., Mosekilde L., Gunaratne G.H. A mathematical model to study properties of trabecular bone. *Journal of Biomechanics*, 2005.
132. Klein G.L., **Wimalawansa S.J.**, Kulkarni G., Sherrard D.J., Sanford A.P., Herndon D.N. The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: A double-blind, randomized, controlled study. *Osteoporosis International*, 16; 631–635, 2005.
133. Liebschner M.A.K., Mueller R., **Wimalawansa S.J.**, Rajapakse C.S., Gunaratne G.H. Testing two predictions for fracture load using computer models of trabecular bone [10.1529/biophysj.104.057539; <http://www.ncbi.nlm.nih.gov/pubmed/15879468>]. *Biophysical Journal*, 89(2): 759–767, 2005.
134. Margolis R.N., **Wimalawansa S.J.** Novel targets and therapeutics for bone loss. Skeletal development and remodeling in health, disease and aging. Skeletal development and remodeling in health, disease and aging. *Annals of the New York Academy of Sciences*, 1068; 402–409, 2006.
135. **Wimalawansa S.J.** Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans [<http://www.ncbi.nlm.nih.gov/pubmed/18056048>; 10.1196/annals.1402.066]. *Annals of the New York Academy of Sciences*, 1117: 283–297, 2007.
136. **Wimalawansa S.J.** Nitric oxide: New evidence for novel therapeutic indications [10.1517/14656566.9.11.1935; <http://www.ncbi.nlm.nih.gov/pubmed/18627331>]. *Expert Opinion on Pharmacotherapy*, 9(11):1935–1954, 2008.
137. **Wimalawansa S.J.** Insight into bisphosphonate-associated osteomyelitis of the jaw: Pathophysiology, mechanisms and clinical management. *Expert Opinion on Drug Safety*, 7(4): 491–512, 2008.
138. **Wimalawansa, S.J.** Nitric oxide: Novel therapy for osteoporosis [10.1517/14656560802197162; <http://www.ncbi.nlm.nih.gov/pubmed/19006476>]. *Expert Opinion on Pharmacotherapy*, 9(17): 3025–3044, 2008.
139. **Wimalawansa S.J.** Bisphosphonate-associated osteomyelitis of the jaw: Guidelines for practicing clinicians. *Endocrine Practice*, 14: 1150–1168, 2008.
140. **Wimalawansa S.J.** Effects of fruits and vegetables on skeletal health. *FAV-Health – 2007*; [Eds. B Patil, P Murano, M.J. Amiot-Carlin], *Acta Horticulturae*, 420-431; 2009.
141. **Wimalawansa, S.J.**, Grimes, J.P., Wilson, A., Hoover, D.R. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone Loss [doi: 10.1210/jc.2008-2225; <http://www.ncbi.nlm.nih.gov/pubmed/19549739>]. *Journal of Clinical Endocrinology & Metabolism*, 94(9): 3356–3364, 2009.
142. **Wimalawansa, S.J.** Nitric oxide and bone [doi: 1749-6632.2009.05230.x; <http://www.ncbi.nlm.nih.gov/pubmed/20392265>]. *Annals of the New York Academy of Sciences*, NY, 1192: 391–403, 2010.

143. **Wimalawansa, S.J.** Vitamin D in the new millennium [doi 10.1007/s11914-011-0094-8; <http://www.ncbi.nlm.nih.gov/pubmed/22249582>]. *Current Osteoporosis Research* Current Osteoporosis Research, 10(1):4-15, 2012.
144. **Wimalawansa, S.J.** Vitamin D: What clinicians would like to know. *Sri Lanka Journal of Diabetes, Endocrinology and Metabolism*; 2: 73-88, 2012
145. **Wimalawansa, S.J.** Vitamin D: An essential component for skeletal health. In, Skeletal Biology and Medicine II: Bone and cartilage homeostasis and bone disease, *Annals of the New York Academy of Sciences, NY, 2012*, 1240(1): E1-12, 2012; doi: 10.1111/j.1749-6632.2011.06374.x
146. **Wimalawansa, S.J.** Visceral adiposity and cardio-metabolic risks: Epidemic of Abdominal Obesity in North America. *Research and Reports in Endocrine Disorders*, 3: 17-30, 2013.
147. **Wimalawansa, S.J.** Food fortification programs to alleviate micronutrient deficiencies. *J. Food Process Technol.*, 4(8): 257-267, 2013; doi:10.4172/2157-7110.1000257
148. **Wimalawansa, S.J.** Thermogenesis based interventions for treatment for obesity and type 2 diabetes mellitus. *Expert Reviews of Endocrinology & Metabolism*, 8(3), 275–288, 2013.
149. **Wimalawansa, S.J.** Post-traumatic stress disorder: An under-diagnosed and under-treated entity. *Comprehensive Research Journal of Medicine and Medical Science*, 1(1): 1-12, 2013.
150. **Wimalawansa, S.J.** Purification of contaminated water with reverse osmosis: Effective solution of providing clean water for human needs in developing countries. [http://www.ijetae.com/files/Volume3Issue12/IJETAE_1213_14.pdf], *International Journal of Emerging Technology and Advanced Engineering*, 3(12), 75-89, 2013.
151. **Wimalawansa, S.J.** Pathophysiology of obesity: Focused, cause-driven approach to control the epidemic. *Global Advanced Research Journal of Pharmacy and Pharmacology*, 2(1): 2-12, 2013.
152. **Wimalawansa S.J.** Causes and risk factors for posttraumatic stress disorder: The importance of right diagnosis and treatment. *Asian Journal of Medical Sciences*, 5(2): 1-13, 2014.
153. **Wimalawansa S.J.** Controlling obesity and its complications by elimination of causes and adopting healthy habits: “cause-driven” approach. *Advances in Medical Sciences*, 3(1): 1-15, 2014.
154. Wimalawansa, S.A. and **Wimalawansa, S.J.** Changing agricultural practices in dry zonal areas and escalating incidences of chronic kidney disease of multi-factorial origin. *Wudpecker Journal of Agriculture and Environment*, 3(5), 110-124, 2014.
155. **Wimalawansa, S.J.** Mechanisms of developing post-traumatic stress disorder: New targets for drug development. *CNS & Neurological Disorders & Drug Targets*, 13(5): 807-816, 2014.
156. **Wimalawansa, S.J.** Escalating Chronic Kidney Diseases of Multi-factorial Origin in Sri Lanka: Causes, Solutions, and Recommendations. *Environmental Health and Preventive Medicine*, DOI 10.1007/s12199-014-0395-5. 19(6), 375-394, 2014. <http://www.ncbi.nlm.nih.gov/pubmed/26462963>
157. **Wimalawansa, S.J.** Stigma of obesity: A major barrier to overcome. *Journal of Clinical and Translational Endocrinology* [DOI: 10.1016/j.jcte.2014.06.001]. 1(3); 73-76, 2014.

158. Wyne, K.L. and **Wimalawansa, S.J.** Screening and diagnosis of chronic kidney disease of multi-factorial origin. Proceedings of the 5th International conference of sustainable build environment; "Prevention of CKDmfo from Sri Lanka." Kandy, Sri Lanka [ICSBE/14/237]; 234-243, 2014.
159. Wimalawansa, S.A. and **Wimalawansa, S.J.** Agrochemical-related environmental pollution: Effects on human health. Global Journal of Biology, Agriculture & Health Sciences, 3(3): 72-83, 2014. <http://www.gifre.org/admin/papers/gjbahs/72-83-Pollution-vol-3-3-gjbahs.pdf>
160. Grant, W.B., **Wimalawansa, S.J.**, Holick, M.F., Cannell, J.J., Pludowski, P., Lappe, J.M., Pittaway, M., May, P. Emphasizing the Health Benefits of Vitamin D for Those with Neurodevelopmental Disorders and Intellectual Disabilities, <http://www.mdpi.com/2072-6643/7/3/1538>, doi:10.3390/nu7031538, Nutrients 2015, 7(3), 1538-1564.
161. **Wimalawansa S.J.** Escalating chronic kidney diseases of multi-factorial origin (CKDmfo) in Sri Lanka: Causes, solutions, and recommendations—update and responses. Environmental Health and Preventive Medicine, DOI 10.1007/s12199-015-0447-5; <http://link.springer.com/article/10.1007/s12199-014-0395-5> ; 20(1): 152–157, 2015.
162. Wimalawansa, S.A. and **Wimalawansa, S.J.** Clean water, healthy environment, and preservation of watersheds: Correct, enforceable policies are essential. Journal of Hydrology, 1(1): 3-15, 2015. <http://www.jacobspublishers.com/index.php/journal-of-hydrology-articles-in-press>
163. **Wimalawansa, S.J.** Obesity and type 2 diabetes: Preventing complications. Editorial, DOI:10.15406/jdmdc.2015.02.00047 <http://medcraveonline.com/JDMDC/JDMDC-02-00047.pdf> Journal of Diabetes, Metabolic Disorders & Control, 2(4): 47-50, 2015.
164. **Wimalawansa, S.J.** The role of ions, heavy metals, fluoride, and agrochemicals: Critical evaluation of potential aetiological factors of chronic kidney disease of multifactorial origin (CKDmfo/CKDu) and Recommendations for Its Eradication. Environ Geochem Health; DOI 10.1007/s10653-015-9768-y; PMID: 26462963; 38 (3): 639-678, 2015. <http://www.ncbi.nlm.nih.gov/pubmed/26462963> <http://link.springer.com/article/10.1007/s10653-015-9768-y>
165. Wimalawansa, S.A. and **Wimalawansa, S.J.** Protection of watersheds and control of fertilisers to prevent phosphate eutrophication of reservoirs in Sri Lanka. Internat. Journal of Research in Environmental Science, 1: 2s, 1-19, 2015. <https://www.arcjournals.org/pdfs/ijres/v1-i2/1.pdf>
166. **Wimalawansa S.J.** In the era of budgetary constraints, cost-effective management of metabolic syndrome, type 2 diabetes, and obesity is essential. Current Research in Diabetes & Obesity J. 1(1); 1-5, 2015. <http://juniperpublishers.com/crdoj/pdf/CRDOJ.MS.ID.555554.pdf>
167. Grant, W.B., **Wimalawansa, S.J.** Holick, M.F. Vitamin D supplements and reasonable solar UVB should be recommended to prevent escalating incidence of chronic diseases. doi: <http://dx.doi.org/10.1136/bmj.h321>, <http://www.mdpi.com/2072-6643/7/3/1538> BMJ, 2015; 350, h321, 2015. <http://www.bmj.com/content/350/bmj.h321/rr-1>
168. **Wimalawansa, S.J.** Agrochemicals and chronic kidney disease of multifactorial origin: An Environmentally induced occupational exposure disease. doi <http://dx.doi.org/10.16966/2380-5498.111>, (IJNKF) International Journal of Nephrology and Kidney Failure, 1(3): 1-11, 2015. <https://www.sciforschenonline.org/journals/nephrology-kidney/IJNKF-1-111.php>

169. Weeraratne, C.S. and **Wimalawansa, S.J.** A Major irrigation project (Accelerated Mahaweli Programme) and the chronic kidney disease of multifactorial origin in Sri Lanka. *International Journal of Environmental & Agriculture Research (IJOEAR)*, 1(6), 16-27, 2015.
<http://ijoeear.com/Paper-October-2015/IJOEAR-OCT-2015-11.pdf>
170. Wimalawansa, S.A. and **Wimalawansa, S.J.** Chronic kidney disease of multifactorial origin (CKDmfo/CKDu): Escalating incidence and long-term survival estimates. *Journal of Urology and Nephrology Research. J. J. Nephro Urol.*, 2(4): 1-15, 2015.
171. **Wimalawansa S.J.** Preventing long-term complications of obesity, type 2 diabetes, and metabolic syndrome: Common sense approach. *Endocrinol & Metab Syndr.*, 4(4): 1-6, 2015. doi:10.4172/2161-1017.1000206. <http://www.omicsonline.org/open-access/preventing-longterm-complications-of-obesity-type-2-diabetes-andmetabolic-syndrome-2161-1017-1000206.pdf>
172. Smith, G. and **Wimalawansa, S.J.** Reconciling the irreconcilable: Micronutrients in clinical nutrition and public health. <http://dx.doi.org/10.4172/2376-1318.1000e136>, *Vitamins and Minerals*, 4: 1, 1-4, 2015.
http://www.academia.edu/11797603/Reconciling_the_Irreconcilable_Micronutrients_in_Clinical_Nutrition_and_Public_Health
173. **Wimalawansa S.J.** Strategic framework for managing non-communicable diseases: Preventing chronic kidney disease of multi-factorial origin (CKDmfo / CKDu) as an example. *Chronic Dis. Int.*, 2(2): 1-8, 2015.
174. **Wimalawansa, S.J.** Effect of water hardness on non-communicable diseases, including chronic kidney disease of multifactorial origin (CKDmfo/CKDuo). *J. Environmental Science & Health*, 10.15436/2378-6841.16.029, 2 (1), 1-11, 2016.
175. **Wimalawansa S.J.** Vitamin D deficiency is surrogate marker for visceral fat content, metabolic syndrome, and future metabolic complications. DOI: 10.15406/jdmdc.2016.03.00059. *J Diabetes Metab Disord Control*, 3(1): 1-10, 2016.
176. Smith, G., **Wimalawansa S.J.**, Laillou, A, Sophonneary, P., Un, S., Rathavuth Hong, R., Poirot, E., Kuong, K., Chamnan, C., De los Reyes, F., Wieringa, F.T. High Prevalence of Vitamin D deficiencies in Cambodia: A Common Deficiency in a Sunny Country. *Nutrients* 2016, 8, 290; doi:10.3390/nu8050290 <http://www.mdpi.com/2072-6643/8/5/290/html>
177. Naser, K.A. and **Wimalawansa, S.J.** Diabetes Diet: Is Glycemic Index Still Relevant in Medical Nutrition Therapy? *SLR- Diabetes Metab. (E-Pub)*. 1(1): 1-4, 2015.
178. **Wimalawansa, S.J.** Endocrinological mechanisms of depressive disorders and ill health, doi.org/10.1586/17446651.2016.1127755, *Expert Review of Endocrinology and Metabolism*, (1), 9-11, 2016.
179. **Wimalawansa, S.J.** Vitamin D adequacy and improvements of comorbidities in persons with intellectual developmental disabilities. *J. Childhood & Developmental Disorders*, 2(3): 22-33, 2016.
180. **Wimalawansa S.J.** Optimum duration and safety of long-term use of potent anti-resorptive medications in osteoporosis. [E-Pub, June 2016]. DOI: 10.1080/17446651.2016.1202111; *Expert Review of Endocrinology & Metabolism*, 11:4, 329-348, 2016; <http://www.tandfonline.com/doi/pdf/10.1080/17446651.2016.1202111?needAccess=true>

181. Wimalawansa, S.A. and **Wimalawansa, S.J.** Environmentally induced, occupational diseases with emphasis on chronic kidney disease of multifactorial origin affecting tropical countries. *Annals of Occupational & Environ Med*, 28(33), 1-13, 2016. DOI: 10.1186/s40557-016-0119-y; <https://aoemj.biomedcentral.com/articles/10.1186/s40557-016-0119-y>
182. **Wimalawansa, S.J.** Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. *J. Steroid Biochem. Mol. Biol.*, (in press).
183. **Wimalawansa, S.J.** Extra-Skeletal benefits, Endocrine Functions, and Toxicity of Vitamin D (e-Pub; 8.23.2016), *J. Endocrinology and Diabetes*, 3(1): 1-5, 2016. <http://www.symbiosisonlinepublishing.com/endocrinology-diabetes/endocrinology-diabetes52.pdf>
184. Camacho, PM, Petak, SM, Binkley, NC, Harris, T, Kleerekoper, M, Lewiecki, M, Miller, P, Narula, HS, Pessah-Pollack, R, Tangpricha, V, **Wimalawansa, SJ**, Watts, N. American association of clinical endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis, *Endocrine Practice* (E-Pub; 19.18.2016).
185. **Wimalawansa, S.J.** Vitamin D: Biology, Physiology, and Pathology, Editorial Garvin J. *Diabetes, Metabolic Disorders*, (in press).
186. **wimalawansa, S.J.** Non-musculoskeletal Benefits of Vitamin D. *J. Steroid Biochem. Mol. Biol.*, (in press).

PROCEEDINGS:

1. **Wimalawansa S.J.**, Piyasena R.D. Increased activity of the thyroid gland in premature canities. *Proceedings of the Ceylon Association for the Advancement of Science*, 1975.
2. **Wimalawansa S.J.** Subcutaneous fat and its relationship to health. *Proceedings of the Sri Lanka Association for the Advancement of Science*, 1978.
3. de Silva L.V.K., **Wimalawansa S.J.**, Dissanayaka S., Karalliadde S.K., Wikramanayake T.W. The relationship between birth weight and maternal weight. *Proceedings of the Sri Lanka Association for the Advancement of Science*, 1979.
4. Karalliadde S., **Wimalawansa S.J.**, Dissanayaka S., de Silva L.V.K., Wikramanayake T.W. Secretary immunoglobulin A in vitamin A deficient children. *Proceedings of the Sri Lanka Association for the Advancement of Science*, 1979.
5. **Wimalawansa S.J.**, Pathirana C., Wikramanayake T.W. Weight gain during pregnancy in rural Sri Lankan women. *Proceedings of the Kandy Society of Medicine*, 1979.
6. **Wimalawansa S.J.**, Perera P.A.J. A comparative study of socio-economic status and health of inhabitants in a remote village, Meemure, and in an urban village, Uda-Peradeniya. *Proceedings of the Kandy Society of Medicine*, 1979.
7. **Wimalawansa S.J.** Sociological and nutritional assessment of an under-developed remote village in Sri Lanka. Four-year prospective project. The National Science Council, Sri Lanka, 1980.
8. **Wimalawansa S.J.**, Piyasena R. Relationship between premature graying and premature balding to thyroidal activity. *Proceedings of the Kandy Society of Medicine*, 1980.
9. **Wimalawansa S.J.** Relationship of parity to weight gain during pregnancy. *Proceedings of the Kandy Society of Medicine*, 1980.
10. **Wimalawansa S.J.**, Kehely A., Banks L.M., Stevenson J.C., Endacott J., Whitehead M.I., MacIntyre I. The effect of percutaneous oestradiol and low dose human calcitonin on postmenopausal bone loss. In: *Osteoporosis 1987, Proceedings of the International*

- Symposium* (Eds., Christiansen C., Johansen J.S., Riis B.J.), Viborg: Norhaven A/S, pp. 528–532, 1987.
11. **Wimalawansa S.J.** The value of CGRP radioreceptor assay for the detection of medullary thyroid carcinoma. *CRC Medullary Thyroid Group Newsletter*, Multiple Endocrine Neoplasia, type 2, 1988.
 12. **Wimalawansa S.J.**, Stevenson J.C., Kehely A., Banks L.M., MacIntyre I. Prevention of post-menopausal bone loss with small doses of calcitonin and percutaneous oestrogen. In: *Recent Research on Gynecological Endocrinology* (Vol. 2) (Eds., Genazzani C.A.R., Petraglia F., Volpe A., Facchinetti F.I.), pp. 239–244, 1988.
 13. **Wimalawansa S.J.** Osteoporosis: a preventable disease. *Bone*, 5:4, 1988.
 14. **Wimalawansa S.J.**, MacIntyre, I. Can we determine the lowest dose of oestradiol still active on bone? In: *Recent Research on Gynecological Endocrinology* (Vol. 2) (Eds., Genazzani C.A.R., Petraglia F., Volpe A., Facchinetti F.I.), pp.314–316, 1988.
 15. **Wimalawansa S.J.** Isolation, purification, characterization, and raising monoclonal antibodies for CGRP receptor. Proceedings of the International Symposium on Calcitonin Gene–Related Peptide, Graz, Austria, 1991. *Regulatory Peptides*, 34(2): 77, 1991.
 16. **Wimalawansa S.J.** Use of plasma 17 β -oestradiol as a guideline for parenteral administration of oestrogen for the prevention and treatment of osteoporosis. In: *Osteoporosis 1990* (Eds., Christiansen, C., Overgaard, K.), Vol. 3, 1917–1922, 1991.
 17. **Wimalawansa S.J.** Therapeutic uses of calcitonin. Ciba-Geigy Hand Book, 1991.
 18. **Wimalawansa S.J.**, Banks, L. Human calcitonin is effective in arresting the progression of spinal cord compression in patients with spinal Paget's disease. *Seminars in Arthritis and Rheumatism*, 1994.
 19. **Wimalawansa S.J.**, Dramatic response to plicamycin in a patient with severe Paget's disease refractory to calcitonin and pamidronate. *Seminars in Arthritis and Rheumatism*, 23(4): 267, 1994.
 20. Emilio J., Roldán A., **Wimalawansa S.J.**, Gunasekera R.D. Oral pamidronate in refractory Paget's disease. *Calcified Tissue International*, 55(3), 240, 1994.
 21. **Wimalawansa S.J.**, Combined therapy with estrogen and etidronate on bone mineral density in the hip and vertebrae: four-year randomized study. *Menopause Digest*, 4:13–15, 1996.
 22. **Wimalawansa S.J.**, Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study. *Osteoporosis Update*, 9:11, 1996.
 23. **Wimalawansa S.J.**, Iatrogenic osteoporosis: A case report. *Regulatory Peptide Letters*, 7: 40A, 1997.
 24. Shankar V.S., Yang S., Yang Y., Chapa M.T., Simmons D.J., **Wimalawansa S.J.** Cyclosporine A induces dentin resorption via nitric oxide-cGMP pathway in osteoblast-osteoclast co-cultures. In: *Calcium Metabolism: Comparative Endocrinology* (Eds., Danks J., Dacke C., Flik, Gay C.), BioScientifica Ltd., Bradley Stoke, Bristol, United Kingdom, 1999.
 25. **Wimalawansa S.J.** Prevention of oophorectomy-induced bone loss with nitric oxide donor, nitroglycerin: A human pilot clinical study. *Bone Research Update* (in Japanese), 2001.
 26. Wimalawansa S.M., Chapa T., Fang L., Yallampalli C., Simmons D., **Wimalawansa S.J.** Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. *Bone Research Update* (in Japanese), 2001.
 27. **Wimalawansa S.J.**, A substantial body of evidence. *OsteoUpdate*, 4–5, 2001.

28. **Wimalawansa S.J.**, (Guest Editor). Fracture prevention and osteoporosis. Liberty Communication Network/Medical Crossfire, 2003.
29. **Wimalawansa S.J.**, (Guest Editor). The ORAG meta-analyses. Liberty Communication Network/Medical Crossfire, 4(21): 2003.
30. **Wimalawansa S.J.**, Calcitonin: Overview. *Encyclopedia of Endocrine Diseases*, Academic Press, Elsevier Science (Ed., Luciano Martini), 2004.
31. **Wimalawansa S.J.**, (CME, Director and Guest Editor). Osteoporosis: From bone biology to prevention and treatment strategies. Embryon Communication Company, Somerville, NY, 2004.
32. **Wimalawansa S.J.**, (CME, Director and Guest Editor). The FACT study. Liberty Communication Network/Medical Crossfire, 2005.
33. **Wimalawansa S.J.**, (CME Activity Director, Guest Editor). Medical Crossfire: Monograph on osteoporosis. *Diagnosis and Treatment of Bone Building*, 2005.
34. **Wimalawansa S.J.**, (CME, Guest Editor). Osteo-Opportunities: Steps Along the Path of Treatment. Liberty Communications Network/Medical Crossfire, 2006.
35. **Wimalawansa S.J.**, (CME Activity Director/Guest Editor). Osteoporosis in the 21st Century: Implications for Clinicians and Researchers. American Academy of CME, 2008.
36. **Wimalawansa S.J.**, Evaluation and Management of Osteoporosis Encountered in Adults and Children with Developmental Disabilities. UMDNJ–Center for Continuing and Outreach Education (CCOE); American Academy of Developmental Medicine and Dentistry (AADMD); Developmental Disabilities Nurses Association (DDNA) (CME Activity Director/Guest Editor), 2008.
37. May R.L., Chahal H., **Wimalawansa, S.J.**, Bone health program. *Healthy Times*, 20(2): 5–7, 2009.
38. **Wimalawansa, S.J.** Water, Health, and Policies. Proceedings of the 50th Anniversary Academic Conference, University of Sri Jayewardenepura, pp 27–30, 2009.
39. **Wimalawansa S.J.**, Food, vitamin D deficiency, and chronic human health conditions. 9th Int. Conference, Functional Food Components in Health and Diseases, 32-33, 2011.
40. **Wimalawansa, S.J.**, Update on osteoporosis. Felicitation volume; Prof Illangasekera.
41. **Wimalawansa, S.J.**, Optimal intakes of vitamin D for persons with intellectual developmental disabilities: Sunlight Isn't enough, almost everyone needs vitamin D supplements. Exceptional Parenting Magazine (Eparent.com), 38-40, Nov. 2014.
<https://www.questia.com/magazine/1G1-390188533/optimal-intakes-of-vitamin-d-for-persons-with-intellectual>
42. **Wimalawansa, S.J.**, Individualized Approaches to Improve Obesity Management. Sri Lankan Scientist [ISSN-2420-7306], 1 (2): 11-13, 2015.
43. **Wimalawansa, S.J.**, Chronic kidney disease of multifactorial origin in Sri Lanka. Sri Lankan Scientist [ISSN-2420-7306], 1 (2): 20-21, 2015.
44. **Wimalawansa, S.J.**, Losing Weight to Reduce Obesity Associated Complications. Sri Lanka Scientist, 2016.
45. **Wimalawansa, S.J.** Environmental pollution-associated chronic kidney disease of multifactorial origin in Sri Lanka (CKDmfo). Proceedings of the 5th Int. Conference on Sustainable Built Environment-2014, Kandy, Sri Lanka. *Climate Change, Community-Environment and Ecosystem, and Environmental Pollution, and Chronic Kidney Disease* [ICSBE/14/244]; 244-520, 2014.

46. **Wimalawansa, S.J.** Optimal intakes of vitamin D for persons with intellectual developmental disabilities: Sunlight Isn't enough, almost everyone needs vitamin D supplements. *Exceptional Parenting Magazine* (Eparent.com), 38-40, Nov. 2014
<https://www.questia.com/magazine/1G1-390188533/optimal-intakes-of-vitamin-d-for-persons-with-intellectual>
47. **Wimalawansa, S.J.**, Metabolic Syndrome and Associated Complications. Sri Lanka Scientist, 2016.

PUBLICATIONS (Book Chapters)

1. **Wimalawansa S.J.**, MacIntyre, I. Parathyroid hormone, PTH-related peptide, calcitonin and calcitonin gene-related peptide. In: *Macmillan Directory-Genetically Engineered Human Therapeutic Drugs* (Eds., Copsey, D.N., Delnatte, S.Y.J.), Pantech Partners, 1988.
2. McEwan J., Legon S., **Wimalawansa S.J.**, Zaidi M., Dollery C., MacIntyre I. Calcitonin gene-related peptide: a review of its biology and relevance to the cardiovascular system. In: *Endocrine Mechanisms in Hypertension* (Vol. 2) (Eds., Laragh J. H., Brenner B., Kaplan N.), pp. 287–306, 1989.
3. **Wimalawansa S.J.** Calcitonin: Molecular biology, physiology, pathophysiology and its therapeutic uses. In: *Advances in Bone Regulatory Factors: Morphology, Biochemistry, Physiology and Pharmacology* (Eds., Pecile A., Bernard B.), Plenum Press, pp. 121–160, 1989.
4. Zaidi M., Moonga B.S., **Wimalawansa S.J.**, Bevis P.J., Legon S., Alam A.S., MacIntyre I., Breimer L.H. Expression and function of calcitonin gene products. In: *Vitamins and Hormones: Advances in Research and Applications* (Vol.46) (Eds., Aurbach G.D., McCormick D.B.), California, Academic Press, 87–164, 1991.
5. **Wimalawansa S.J.** Calcitonin. In: *Therapeutic Drugs: A Clinical Pharmacopeia* (Eds., Dollery C.T.), C18–C22, Churchill Livingstone, United Kingdom, 1991.
6. **Wimalawansa S.J.**, MacIntyre, I. Calcitonin and calcitonin gene-related peptide receptors. In: *Receptor Data for Biological Experiments: A Guide to Drug Selectivity* (Eds., Doods H.N., van Meel J.C.A.), Ellis Horwood Ltd., Sussex, England, pp. 138–144, 1991.
7. **Wimalawansa S.J.** Calciferol. In: *Therapeutic Drugs: A Clinical Pharmacopeia* (Eds., Dollery C.T.), C13–C17, Churchill Livingstone, United Kingdom, 1991.
8. **Wimalawansa S.J.** Use of synthetic peptides in specific affinity chromatography for purification of specific peptide receptors. In: *Innovation and Perspectives in Solid Phase Synthesis (Peptides, Polypeptides and Oligonucleotides)*, (Ed., Epton R.), Intercept Ltd., Andover, United Kingdom, pp. 111–119, 1991.
9. DiPette D., **Wimalawansa S.J.** Cardiovascular Actions of Calcitonin Gene-Related Peptide. In: *Calcium Regulating Hormones and Cardiovascular Function* (Eds., Crass J. III, Avioli L.V.), Chapter 10; 239–252, 1995.
10. D'Este L., Vaccaro R., **Wimalawansa S.J.**, Maeda T., Renda T.G. Amylin-immuno-reactivity in monkey hypothalamus. *Calcitonin Gene-Related Peptide '98* (Eds., Poyner D., Marshall I., Brain S.D.), Biology Intelligent unit 10; R.G. Landes Co., Austin, Texas, pp 187–188, 1999.
11. Yallampalli C., **Wimalawansa S.J.** Calcitonin gene-related peptide and pregnancy. *The CGRP Family: Calcitonin Gene-Related Peptide, Amylin, and Adrenomedullin* (Eds., Poyner D., Marshall I., Brain S.D.), RG Landes Co., Austin, Texas, pp 229–238, 2000.
12. **Wimalawansa S.J.** Osteoporosis: A preventable and treatable disease; an overview. The Nutrition Society publication (Felicitation volume), (Eds., Wikramanayake T.W., Rajapakse L.), JF and I Printers Ltd, 64–130, 2000.

13. **Wimalawansa S.J.** Calcium and blood pressure. *Clinical Calcium*, 2004.
14. **Wimalawansa S.J.** Skeletal effects of nitric oxide: A novel agent for osteoporosis. In: *Principles of Bone Biology*, 3rd ed. (Eds., Bilezikian J., Raize L., Martin T.J.), pp. 1275–1311, 2008.
15. **Wimalawansa S.J.** Calcitonin: History, Physiology, Pathophysiology and Therapeutic Applications In: *Osteoporosis in Men*, Chapter 53; 653-666. 2nd ed. (Eds., Orwoll E., Bilezikian J., Vanderschueren D.), 2010.

PUBLICATIONS (Medical Books)

1. **Wimalawansa S.J.** *Handbook on Comprehensive Management of Diabetes*. Armed Forces Hospitals, Saudi Arabia, 1993
2. **Wimalawansa S.J.** *Hypercalcaemia of Malignancy: Etiology, Pathogenesis and Clinical Management* (Medical Intelligence Unit, Monograph), Springer, NY and R.G. Landes Co., Medical Publishers, Austin, Texas, 1995 [ISBN: 1-57059-286-1].
3. **Wimalawansa S.J.** *Osteoporosis: Time to Act* (handbook for the primary care physicians) (in completion)
4. **Wimalawansa S.J.** *Vitamin D: Everything you need to know*. Karu Sons, Homagama, Sri Lanka, (Ed. 1.0, 2011/Ed. 1.1, 2012), [ISBN: 978-955-9098-94-2].
5. Update on Vitamin D. (Ed.) **Sunil J. Wimalawansa**, Springer (In preparation)
6. **Wimalawansa S.J.** Water and environmental pollution: Prevention of chronic kidney disease of multi-factorial origin in Sri Lanka (in process; Karu Sons, Homagama, Sri Lanka).

Published, several non-medical books

MANUSCRIPTS SUBMITTED:

1. **Wimalawansa, S.J.**, Wimalawansa, SM. Neurohormonal defect in posttraumatic disorders–PTSD is an endocrine disorder (in review; *Frontiers in Neuroscience*).
2. **Wimalawansa, S.J.** Vitamin D needs in the elderly. *International Journal of Diabetes & Endocrinology*.
3. **Wimalawansa, S.J.** Persons with Intellectual, Developmental Disabilities: Vitamin D requirements. *Journal of Developmental Disabilities*.
4. **Wimalawansa, S.J.** Low Bone Mass in Patients with Turner Syndrome: To treat or not to treat with anti-osteoporosis agents. *European Journal of Endocrinology*.
5. Haq, A., **Wimalawansa, S.J.**, Pludowski, P., Anouti, F.A. Clinical practice guidelines for vitamin D in the United Arab Emirates. *J. Steroid Biochem. Mol. Biol.*, (in review).
6. **Wimalawansa, S.J.** D and Cardiovascular Diseases, *J. Steroid Biochem. Mol. Biol.* (in review).

MANUSCRIPTS IN PREPARATION

1. Wimalawansa D.R., Senaratna N.A., Wimalawansa S.M., Yallampalli C., **Wimalawansa S.J.** Enhancement of bone mineral density following combined therapy with the nitric oxide donor, nitroglycerin, and bisphosphonates.
2. Wimalawansa S.M., Quast M., **Wimalawansa S.J.** DXA is more sensitive than MRI in determining changes of bone mineral content in rats: an interventional study.
3. **Wimalawansa S.J.** Prevention of corticosteroid-induced bone loss in humans with pre-stabilization of the skeleton with bisphosphonate. *Journal of Bone and Mineral Research*.
4. **Wimalawansa S.J.** Experience of treating more than 2,000 patients with intravenous bisphosphonates in treatment of established osteoporosis.

5. **Wimalawansa S.J.** Practical and cost-effective alendronate dosage regimen, which improves patient compliance, while maintaining its efficacy.
6. Grimes J.P., Cosgrove N.M., Wilson A.C., Warusawithana A., Marrero L., Rojo G., Guerard C., Salters S., **Wimalawansa S.J.** Recruit and retain: strategies to maximize recruitment and the retention of postmenopausal women in an osteoporosis trial.
7. Kaluarachchi K., Gorenstein D., **Wimalawansa S.J.** Three-dimensional structure determination of human CGRP (8-37) in 50 percent aqueous trifluoroethanol by 2D NMR.
8. Surendran S., Chandrasekhar T., Wimalawansa S.M., Wimalawansa D.R., Recinos A., **Wimalawansa S.J.** Alpha tocopherol (vitamin E) prevents ovariectomy-induced bone loss.
9. Work place bullying and post-traumatic stress disorders.
10. Osteoporosis and chronic disease management. Are we abandoning our elders? Medical Economics Journal.

PATENTS:

1. **Wimalawansa S.J.** A method for counteracting vasospasms, ischemia, renal failure and treating male impotence using calcitonin gene-related peptide (CGRP). US patent #5,958,877, 1999.
2. Yallampalli C., **Wimalawansa S.J.** Treatment or prevention of preeclampsia, eclampsia, and prevention of preterm labor with calcitonin gene-related peptide (CGRP), CGRP analogue, a progestational agent, a nitric oxide (NO) synthase substrate or a donor, and cyclooxygenase inhibitor. US patent #5,910,482.
3. **Wimalawansa S.J.**, Yallampalli, C. New treatment of osteoporosis: Treatment of osteoporosis and other metabolic bone disorders with nitric oxide substrate and/or donor. US patent #5,898,038.
4. **Wimalawansa S.J.**, Yallampalli C. Treatment of osteoporosis and other metabolic bone disorders with combinations of nitric oxide substrate and/or donor, with bisphosphonates or other compounds. US patent # 6,133,320.
5. Southard J., Yewey G., Rosenthal G.J., **Wimalawansa S.J.** Compositions and methods for treating female sexual arousal disorders using calcitonin gene-related peptide. US patent #10/756,157.
6. **Wimalawansa S.J.** Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates (US-0097468 pending/abandoned).
7. Southard J., **Wimalawansa S.J.**, Yewey G. Method of treating heart failure, myocardial ischemia and renal insufficiency using calcitonin gene-related peptide. US patent #10/756,490.

PRESENTATIONS AND VARIED PUBLICATIONS:

A. INVITED PRESENTATIONS

1. Physiological and pharmacological studies on peptides derived from CT/CGRP gene. Department of Internal Medicine, University of Texas, Houston, Texas, United States of America, 1986.
2. Pathophysiology of Paget's disease and its management. Calcitonin and Metabolic Bone Diseases, London, United Kingdom, 1987.
3. Prevention of postmenopausal osteoporosis with calcitonin and estrogen. Peptide Workshop, London, United Kingdom, 1987.
4. Can we determine the lowest dose of estradiol still active on bone? International Congress of Gynecological Endocrinology, Cranes Montana, Switzerland, 1988.
5. Pathophysiology and management of osteoporosis. Departments of Radiology and Pharmacology, Kyushu University Medical School, Fukuoka, Japan, 1988.
6. Metabolic bone diseases: Therapeutic options. Department of Medicine, University of Tokyo, Japan, 1988.
7. Assessment and prevention of postmenopausal osteoporosis. Departments of Medicine and Radiology, University of Saitama Medical School, Saitama, Japan, 1988.
8. Does calcitonin gene-related peptide and/or its analogues have a therapeutic role in cardiovascular disorders in man? Departments of Medicine and Cardiology, University of Saitama Medical School, Saitama, Japan, 1988.
9. Peptide and steroid receptors, and their second messenger systems. Medical School Peradeniya, Peradeniya, Sri Lanka, 1988.
10. Osteoporosis: can we prevent? Kandy Society of Medicine, Kandy, Sri Lanka, 1988.
11. Gynecological problems in old age. National Symposium on Aging, Instituto Ostetrico Ginecologico, Milan, Italy, 1988.
12. Prevention and treatment of postmenopausal osteoporosis. Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, 1988.
13. Isolation and characterization of receptor for calcitonin gene-related peptide. British Heart Foundation Symposium on Receptors, London, United Kingdom, 1989.
14. Role of calcitonin in bone formation and resorption. Advances in bone regulatory factors. NATO Advanced Study Institute, Sicily, Italy, 1989.
15. Disorders of calcium metabolism in children. The Institute of Child Health, University College and Middlesex School of Medicine, London, United Kingdom, 1989.
16. Hypercalcaemia: Calcium-lowering agents in clinical practice. Therapeutic Update, Royal Postgraduate Medical School, London, United Kingdom, 1989.
17. The role of calcitonin in prevention and treatment of osteoporosis. Department of Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada, 1989.
18. Calcitonin, CGRP and amylin peptide "super family." Vancouver General Hospital, Vancouver, British Columbia, Canada, 1989.
19. Prevention and treatment of osteoporosis in men and women. King Edward VII Hospital, Midhurst, West Sussex, United Kingdom, 1990.

20. Molecular biology, pathophysiology and physiological roles of calcitonin. First International Symposium on Bone Metabolism, Platja d'Aro, Spain, 1990.
21. Predictive value of plasma 17β -oestradiol levels for the prevention and treatment of osteoporosis. Third International Conference of Osteoporosis, Copenhagen, Denmark, 1990.
22. Biological activity of calcitonin and its role in the treatment of osteoporosis. "Treatment of osteoporosis: Update and new alternatives," Spanish Society of Bone and Mineral Research. Seville, Spain, 1990.
23. Clinical management of hypercalcaemia of malignancy. Symposium on Hypercalcaemia of Malignancy, London, United Kingdom, 1990.
24. Review of amylin and calcitonin gene peptide family. University of Cincinnati, Cincinnati, Ohio, 1990.
25. Biological actions of calcitonin gene peptide products. Vancouver General Hospital, Vancouver, British Columbia, Canada, 1990.
26. Osteoporosis: Do we need to treat? Sri Lanka Postgraduate Medical Institute, Colombo, Sri Lanka, 1990.
27. Radioreceptor assay for CGRP: A novel assay for the diagnosis and follow up of MTC in conjunction with calcitonin immunoassay. First European Congress of Medullary Thyroid Carcinoma, Paris, France, 1990.
28. Isolation, purification and characterization of natural, bioactive molecules. Celltech, Slough, United Kingdom, 1991.
29. Use of synthetic peptides in specific-affinity chromatography during purification of polypeptide receptors. Second International Symposium of Solid-Phase Peptide Synthesis, Canterbury, United Kingdom, 1991.
30. Isolation, purification, characterization and raising monoclonal antibodies for calcitonin gene-related peptide receptors. First International Symposium on Calcitonin Gene-related Peptide, Graz, Austria, 1991.
31. Pathophysiology of metabolic bone disorders. University of Texas Medical Branch at Galveston, 1992.
32. Calcitonin gene-related peptide and its receptors: Molecular genetics, structure, and functions. University of Texas Medical Branch at Galveston, 1992.
33. Etiology, Pathophysiology, and Prevention and Treatment of Osteoporosis. First International Medical Congress, South East Asia, Kandy, Sri Lanka, 1992.
34. Pituitary disorders and their clinical management. Sri Lanka Medical Association, Colombo, Sri Lanka, 1992.
35. Review of physiology and pharmacology of calcitonin gene-related peptide. SmithKline Beecham, King of Prussia, Pennsylvania, 1992.
36. Diagnosis and clinical management of pituitary adenoma. King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 1993.
37. Hypertension, obesity and insulin resistance: Syndrome X. Sri Lanka Medical Association, Colombo, Sri Lanka, 1993.
38. Pathophysiology and management of diabetes complications. King Fahad General Hospital, Jeddha, Saudi Arabia, 1993.
39. Management of common metabolic bone disorders in man. North London Postgraduate Medical Institute, Enfield, London, United Kingdom, 1994.

40. Overview of calcitonin gene-related peptide. CNR, University of Milano, Milan, Italy, 1994.
41. Calcitonin gene-related peptide receptors: characterization, species distribution, and sub-types. Second International Symposium on CGRP, Montreal, Quebec, Canada, 1994.
42. Clinical management of osteoporosis in year 2000 (a series of eight lectures). Hospitals in Galveston County and South Texas, 1995–1996.
43. Counter measures for prevention of musculo-skeletal losses after exposure to microgravity. Annual meeting of the UTHSC and NASA Space Biomedical Institute Conference, Webster, Texas, 1996.
44. New therapy for pre-eclamptic toxemia. 45th Annual Session of the Ceylon College of Physicians, Colombo, Sri Lanka, 1997.
45. Recent advances in osteoporosis. Diagnostic Clinic, Houston, Texas, 1999.
46. The role of nitric oxide in health and disease. 45th Annual Session of the Ceylon College of Physicians, Ceylon, Sri Lanka, 1997.
47. Role of nitric oxide in general health and skeletal integrity. University of Saitama, Saitama, Japan, 1997.
48. Clinical uses of peptides derived from the calcitonin gene family. University of Osaka Faculty of Medicine, Osaka, Japan, 1997.
49. Isolation, purification and characterization of peptide receptors. University of Osaka, Faculty of Health Sciences, Osaka, Japan, 1997.
50. Prevention and treatment of osteoporosis. University of Osaka, Faculty of Medicine, Osaka, Japan, 1997.
51. Physiology and pathophysiology of osteoporosis. Sri Lanka Medical Association, Colombo, Sri Lanka, 1997.
52. Isolation, purification and cloning of NPY-Y2 receptor. Kobe University School of Medicine, Kobe, Japan, 1997.
53. Clinical utility of calcitonin with special reference to amylin-calcitonin hybrid molecules. Tsumura Co., Tokyo, Japan, 1997.
54. Update on management of osteoporosis, University of Ruhuna, Galle, Sri Lanka, 1997.
55. Management of osteoporosis in year 2000. University of Sri Jayewardenepura, Maharagama, Sri Lanka, 1997.
56. Review of biological effects and therapeutic potentials of calcitonin gene-related peptide. Chinese University of Hong Kong, Hong Kong, 1997.
57. Nitric oxide in health and disease. Hong Kong Pharmacological Society, Hong Kong, 1997.
58. Physiology and therapeutic potentials of calcitonin gene-related peptide. Hong Kong Pharmacological Society, Hong Kong, 1997.
59. Nitric oxide in health and disease. Plenary Lecture at the 30th Annual Session of the Ceylon College of Physicians, Colombo, Sri Lanka, 1997.
60. Skeletal effects of nitric oxide donor therapy *in vivo*. Sun Valley Bone Biology Workshop, Sun Valley, Idaho, 1997.
61. Clinical management of pituitary tumors. Sultan Qaboos University College of Medicine, Sultanate of Oman, 1997.
62. Nitric oxide: Physiology and pathophysiology. Sultan Qaboos University College of Medicine, Sultanate of Oman, 1997.

63. Pathophysiology and clinical management of osteoporosis, Dean's Lecture. Sultan Qaboos University College of Medicine, Sultanate of Oman, 1997.
64. Calcitonin gene-related peptide receptors: Potential therapeutic applications. Sultan Qaboos University College of Medicine, Sultanate of Oman, 1997.
65. Role of nitric oxide on bone metabolism: State of the art. Argentinean Society of Osteology and Mineral Metabolism, Buenos Aires, 1998.
66. Recent advances in management of osteoporosis. Sri Lanka Medical Association of North America, New York, 1998.
67. Physiology and pharmacology of prevention of musculoskeletal losses in simulated microgravity. International Workshop on Musculoskeletal Interactions, Athens, Greece, 1999.
68. Nitric oxide in health and disease. Diagnostic Clinic, Houston, Texas, 1999.
69. *In vivo* effects of nitric oxide donor therapy in humans. Annual Meeting of the Australian and New Zealand Society for Bone and Mineral Research, Cairns, Australia, 1999.
70. Nitric oxide: Surgeons perspective. Annual Meeting of the College of Surgeons in Sri Lanka, Colombo, 1999.
71. Blood pressure and cardiovascular tone: Role of CGRP family of peptides. Fourth International Meeting on CGRP, Copenhagen, Denmark, 2001.
72. Diagnosis of osteoporosis and monitoring its therapy: Use of bone density tests and biochemical markers, and their interpretations. Prevention and Treatment of Osteoporosis: Call to Action, University of Medicine and Dentistry of New Jersey, 2002.
73. Lectures (series of seven) on osteoporosis and metabolic bone diseases given in academic institutions and major hospitals in India (Chennai, Bangalore, New Delhi, Hyderabad, Bombay), December 2002.
74. Advances in the treatment of osteoporosis: Current doctrine and future directions. Update in Internal Medicine, Atlantic City, New Jersey, 2002.
75. Prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Management for Primary Care Physicians, New Brunswick, New Jersey, 2002.
76. Nitric oxide actions in health and disease. Geriatric research, Education and Clinical Center, Bronx VA, New York, 2003.
77. Update on osteoporosis: what is new and what is on the way? Janssen Pharmaceuticals, Trenton, New Jersey, 2003.
78. Women's health issues with special emphasis on menopause and bone. School of Osteopathic Medicine, Stratford, New Jersey, 2003.
79. Mini Medical School–Bone Health: Robert Wood Johnson Medical School, New Brunswick, New Jersey, 2003.
80. Lectures (series of 10) on metabolic bone diseases, osteoporosis, cardiovascular diseases and lipids given in Japan (Saitama, Oita, Kobe, Osaka, Tokyo, Niigata), 2003.
81. Effects of terrorism, war, and peace on the health care delivery in South-East Asia with special reference to Sri Lanka. South Asian Peace Workshop, Atlanta, Georgia, 2003.
82. Postmenopausal osteoporosis. Update, Sixth Annual International Medical Congress, Peradeniya, Sri Lanka, 2004.
83. Diabetes, metabolic syndrome and coronary artery disease: over lapping diseases. Sri Lanka Medical Association, 2004.

84. Metabolic syndrome: What you should know? St. Alban's Day Medical Seminar, New Brunswick, New Jersey, 2004.
85. Role of nitric oxide in skeletal integrity. Rutgers School of Nutrition Sciences, New Brunswick, New Jersey, 2004.
86. Use of intravenous pamidronate in postmenopausal osteoporosis. New York-Downtown Bone Club, New York, 2005.
87. Calcium metabolism, osteoporosis and skeletal health. Molecular Medicine Course, UMDNJ–Rutgers University postgraduate program, 2005.
88. Bone mineral density: pros and cons. Third International Conference on Bone and Mineral Research and Fifth International Osteoporosis Symposium, Xian, China, 2005.
89. Diagnosis and management of secondary causes of osteoporosis. Third International Conference on Bone and Mineral Research and Fifth International Osteoporosis Symposium, Xian, China, 2005.
90. Novel methods of administration of bisphosphonates for patients with osteoporosis. Penn State College of Medicine, Pennsylvania Osteoporosis Society, 2006.
91. Nitric oxide: From bench to the clinic. Penn State College of Medicine, Hershey Medical Center, Hershey, Pennsylvania, 2006.
92. Nitric oxide in health and disease. Sri Lanka College of Physicians, 2006.
93. Optimization of the measurements of bone mineral density. Urology Associates of North Jersey, Livingston, New Jersey, 2006.
94. Update of management of osteoporosis. New Delhi, India, 2006.
95. Critically interpreting bone mineral density reports. New Delhi, India, 2006.
96. Are the medications the answer to osteoporosis? New Delhi, India, 2006.
97. Importance of micro-architecture and bone quality on fractures. New Delhi, India, 2006.
98. Post fracture care. The College of Surgeons of Sri Lanka, Annual Scientific Sessions, 2006.
99. Insight into osteoporosis for orthopedic surgeons. The College of Surgeons of Sri Lanka, Annual Scientific Sessions, 2006.
100. New developments in the management of pre-eclamptic toxemia: Lessons learned from animal models. Sri Lanka College of Obstetrics & Gynecologists, 2006.
101. Cardiovascular diseases & metabolic syndrome: risk reduction. Princeton, New Jersey, 2006.
102. Epidemic of obesity, diabetes and metabolic syndrome: What can we do to prevent? Sri Lanka Endocrine Society, 2006.
103. AACE National Course on Clinical Research Teaching Program, New York, 2007.
104. Obesity and metabolic syndrome: What is behind the recent diabetes epidemic? Update in Internal Medicine, Princeton, New Jersey, 2007.
105. New modalities of treating osteoporosis in developmentally disabled patients. Hunterdon Development Center, Clinton, New Jersey, 2007.
106. Nitric oxide: From the bench to the clinic. Second International Conference on Skeletal Biology and Medicine, New York, 2007.
107. Ethics in medicine. Doctors Association, Colombo South, Sri Lanka, 2008.
108. Half-a-day workshop on advances and management of osteoporosis in the 21st century, Kandy Society of Medicine, Sri Lanka, 2008.

- Osteoporosis epidemic: facts and figures relevant to Asia
 - Pathophysiology and secondary causes of osteoporosis
 - Diagnosis and management of osteoporosis
 - Therapeutic advances and future developments
109. Osteoporosis in developmentally disabled people: how to manage? Developmental Disabilities Nurses Association (DDNA) Annual National Scientific Meeting, Connecticut, 2008.
110. Half-a-day workshop on bone mineral density, interpretation, and osteoporosis testing, Colombo, Sri Lanka, 2008.
- Methodologies of BMD measurements and radiation basics
 - Who should be screened for osteoporosis using DXA?
 - Interpretations of DXA data and report formatting
 - Pitfalls of DXA and cautions for interpretation/reporting
111. Ethical aspects of practice of medicine. Ninth International Medical Congress, Kandy, Sri Lanka, 2008.
112. How to take care of osteoporosis patients with developmental disabilities. Hunterdon Development Center, Clinton, New Jersey, 2008.
113. Update of management of osteoporosis. Medicine Grand Rounds, St. Joseph's Hospital, New Jersey, 2008.
114. Bioethics in Clinical Research, Endocrine Society International course on Bioethics, Rio de Janeiro, Brazil, 2008.
115. Nitric oxide: From bench to the clinic. Animal Biosciences and Endocrinology, Rutgers University, New Jersey, 2008.
116. How to conduct a clinical research program (series of three lectures). Colombo, Sri Lanka, 2008.
117. Ethical aspects of clinical research. University of Tokyo, Japan, 2008.
118. Metabolic syndrome and obesity—link to clinical diseases. Sri Lanka Medical Association Annual Scientific Meeting, Colombo, Sri Lanka, 2009.
119. Metabolic bone diseases. Sri Lankan Endocrine Society First Annual Scientific Session, Colombo, Sri Lanka, 2009.
120. Advances in management of osteoporosis. Sri Lankan Endocrine Society First Annual Scientific Session, Colombo, Sri Lanka, 2009.
121. Workshop on BMD and osteoporosis (three lectures). Galle Medical School, Sri Lanka, 2009.
122. Prevention of diabetes in vulnerable populations. College of General Practitioners, Colombo, Sri Lanka, 2009.
123. Identification and management of male hypogonadism. Galle Medical School, Sri Lanka, 2009.
124. Bisphosphonates: Adverse effects; how long to treat. Ceylon College of Physicians, Colombo, Sri Lanka, 2009.
125. Second messenger systems in human endocrinology. Sri Lankan Endocrine Society First Annual Scientific Session, Colombo, Sri Lanka, 2009.
126. Fractures due to osteoporosis: How significant is this problem in persons with development disabilities? 20th Annual Conference on Medical Care for Persons with Development Disabilities: Promoting Healthy Aging, New Jersey, 2009.

127. Endocrinology of HIV patients. New York University Medical Center, New York, 2009.
128. Water, health and policies. Keynote Speech, 50th Anniversary of the University of Sri Jayewardenepura.
129. Medical complications of diabetes, obesity, and metabolic syndrome. 13th Annual CME program Sri Lanka Medical Association of North America, New York, 2009.
130. Nitrates and Nitroglycerin: Skeletal Health Effects in Cardiac Patients, First International Cardiology Congress, Shanghai, 2009.
131. Effects of internal conflicts on health care delivery and remedies. Pathways to Reconciliation Summit, Amman, Jordan, 2009.
132. Post-war economic development and reconciliation. Pathways to Reconciliation Summit, Amman, Jordan, 2009.
133. Ethical dilemmas in enhancement technology in medicine. Second International Conference on Drug Discovery & Therapy, Dubai, 2010.
134. All you want to know about vitamin D. First CME symposium on Endocrinology for Primary Care Physicians, New Brunswick, New Jersey, 2010.
135. Ways to prevent medical complications of obesity and metabolic syndrome. CME symposium on Endocrinology for Primary Care Physicians, New Brunswick, New Jersey, 2010.
136. Pros and cons of using DXA for making the diagnosis of osteoporosis. CME program (University of Massachusetts, School of Medicine), Princeton, New Jersey, 2010.
137. New Frontiers in Osteoporosis Care: Focus on Bisphosphonate Therapy, Extended Dosing Intervals, and Post-Fracture Prevention. CME program (University of Massachusetts, School of Medicine), Pittsburgh, Pennsylvania, 2010.
138. Prevention of simulated weightlessness-induced musculo-skeletal losses with a combination therapy. International Society for Muscular-Skeletal Interaction, Cologne, Germany, 2010.
139. Skeletal effects of nitric oxide: from the bench to the clinic. Second International Conference on Drug Discovery and Therapy, Dubai, 2010.
140. Bone seeking agents and skeletal necrosis. Radiation Oncology Rounds, Cancer Institute, University of Medicine and Dentistry of New Jersey, Newark, 2010.
141. Combination therapies for prevention of simulated weightlessness-induced musculo-skeletal losses. International Workshop on Muscular-Skeletal and Neuronal Interactions, Cologne, Germany, 2010.
142. New frontiers and real world challenges in osteoporosis. Bone mineral density testing in the primary care setting: Interpretation, pitfalls, and best-use strategies at the front lines of practice. CME program, Princeton, New Jersey, 2010.
143. Case studies in osteoporosis: Applying evidence and guidelines to the front lines of patient management. New frontiers and real world challenges in osteoporosis. CME program, Buffalo, New York, 2010.
144. New Frontiers and Real World Challenges the Management of Osteoporosis. Bone mineral density testing in the primary care setting: Interpretation, pitfalls, and best-use strategies at the front lines of practice. Pittsburgh, Pennsylvania, 2010.
145. All you want to know about treatment of common endocrine disorders in ambulatory patients. "All you want to know about vitamin D." First Annual Symposium on Endocrinology for Primary Care Physicians, NJ-AACE, New Brunswick, New Jersey, 2010.

146. All you want to know about treatment of common endocrine disorders in ambulatory patients. "Prevention of medical complications associated with obesity." First Annual Symposium on Endocrinology for Primary Care Physicians, NJ-AACE, New Brunswick, New Jersey, 2010.
147. Beneficial effects of spirituality and meditation on health. South Asian Total Health Initiative (SATHI) and the Center for Health Families and Cultural Diversity (CHFCD), Princeton, New Jersey, 2010.
148. Preparation of grant budgets for federal funding. MAGI Conference, San Francisco, CA, 2010.
149. New therapeutic advances in osteoporosis. Ceylon College of physicians, Colombo, 2010.
150. Atypical-subtrochanteric fractures: causes and clinical management options. Department of Orthopedic Surgery, Colombo General Teaching Hospital, Sri Lanka, 2010.
151. Drug-induced osteomyelitis of the jaw: Guidelines for clinicians. International Cancer Forum & Translational Research, Chongqing, China, 2010.
152. Health, skeleton, and vitamin D. Symposium on Skeletal Health in Persons with Disabilities. The World Congress of Disabilities, Dallas, Texas, 2010
153. NIH budgets: Grant budgets for federal funding. MAGI Conference, Philadelphia, PA, 2010.
154. Post menopausal osteoporosis - Novel inhibitory mechanisms and new management strategies. Key-note speech, Annual Scientific Congress, Menopause Society, Colombo, Sri Lanka, 2011
155. Budgets preparation for NIH grants. MAGI Conference, Philadelphia, PA, 2011.
156. Diabetes mellitus: family physician's perspective. Primary Care Diabetic Group of Sri Lanka, Colombo, Sri Lanka, 2011
157. Advances in management of type 2 diabetes. Sri Lanka Medical Association quarterly lecture, Colombo, 2011
158. Special considerations in clinical management of osteoporosis. College of General practitioners, Colombo, Sri Lanka, 2011
159. Standing tall against osteoporosis. Somerset country medical association, Somerset, NJ, 2011
160. What is new in the management of Type II Diabetes? Gall medical Association, Galle, Sri Lanka, 2011
161. Relationship of vitamin D deficiency with diabetes. Diabetes Foundation, Hackensack, NJ. 2011.
162. Diet, Lifestyle, and Medical Choices in Promoting Better Health, UMDNJ-RWJMS, 2011
163. Vitamin D: All What You Need to Know. Sri Lankan Medical Association, North America, annual CME scientific session, NY, 2011
164. Lifestyle medicine, American Nutrition Society / FESAB annual meeting, San Diego, 2012.
165. Nitric oxide donor therapy: from bench to the clinic. 50th Anniversary academic celebration, Peradeniya Medical School, Kandy, Sri Lanka, 2012
166. Improvements in healthcare delivery in Asia, via public-private partnership. Key note speech, Annual Academic Sessions, Nutrition Society of Sri Lanka, Colombo, 2012.
167. Optimizing management of high-risk osteoporosis evolving strategies, mechanisms and treatment paradigms: New therapeutic paradigms focused on injectable therapies in patients at high risk of fractures: From mechanism of actions to landmark trials on fracture

- prevention. CMEducation resources, CME–University of Massachusetts School of Medicine, 2012
168. Scientific foundations and pathophysiology of osteoporosis: Fundamentals of bone remodeling and novel mechanisms to inhibit bone resorption. CMEducation resources, CME–University of Massachusetts School of Medicine, 2012
 169. New approaches in treating type II diabetes; Women’s Christian Association Hospital, Jamestown, NY (CME–Buffalo University), 2012
 170. Fundamentals of nutrition and healthy living for professionals: ways to control obesity epidemic; Raritan Bay Medical center, New Jersey, 2012
 171. Dietary, Lifestyle, and Medical Choices in Promoting Health, New Jersey Institute of technology (NJIT), Honors College Colloquium, 2012.
 172. Water, Human Health and Public Policies, Plenary lecture. Annual scientific sessions, Faculty of Medicine, University of Colombo, Sri Lanka, 2012.
 173. Preventative and public health aspects of osteoporosis. International Medical University, School of Public Health, Kuala Lumpur, Malaysia, 2012
 174. Advances in Osteoporosis and BMD testing, Department of Medicine, Hospital Putrajaya, Kuala Lumpur, Malaysia, 2012
 175. Update on osteoporosis. Department of Medicine, School of Medicine, Kuala Lumpur, Malaysia, 2012
 176. Essential lifestyle changes for professionals; how to keep healthy. Hayleys Executive Forum, Colombo, Sri Lanka, 2012.
 177. Management of Type 2 diabetes in general practice, College of General Practice, Colombo, Sri Lanka, 2012
 178. Dietary, Lifestyle, Medical, and Stress-Relief Choices in Promoting Health. The Journal of Federations of American Societies for experimental biology [FASEB Journal]. 2012; 26:377.2.
 179. Obesity and Type 2 diabetes; complications in postmenopausal women. College of Obstetrics and Gynecology, Colombo, Sri Lanka, 2012
 180. Management of osteoporosis in 2012, Endocrine Society, Colombo, Sri Lanka, 2012
 181. Water pollution and health risks: The importance of having countrywide enforceable policies, Rutgers University, 2013.
 182. Vitamin D and cardiovascular diseases. First regional workshop in Vitamin D, Riyadh, The Kingdom of Saudi Arabia, 2013.
 183. Vitamin D: History, chemistry, functions and bioavailability. First regional workshop in Vitamin D, Riyadh, The Kingdom of Saudi Arabia, 2013.
 184. Vitamin D sufficiency and insufficiency: Definitions and consequences. First regional workshop in Vitamin D, Riyadh, The Kingdom of Saudi Arabia, 2013.
 185. Role of vitamin D in patients with developmental disabilities. American Association of Developmental Disability Medicine and Dentistry, Mesa, Arizona, 2013.
 186. Alleviation of micronutrient deficiencies via food fortification to. 2nd International Food Science Conference, Kansas City, MO, 2013.
 187. You are not always young: Diet, lifestyle, and healthy choices for better life. Sri Lanka Foundation Institute, Shippers Academy Colombo, 3, 2013.
 188. Water pollution-associated ill Health: Special emphasis on chronic kidney disease in Sri Lanka; annual Olcott Memorial Oration–2013.

189. FLARE Workshop, Laboratory management skills, The American Endocrine Society, New Orleans, LA, 2014
190. The role of vitamin D in patients with developmental disabilities. Workshop on vitamin D, American Academy of developmental medicine and dentistry, Princeton New Jersey, 2014.
191. The role of vitamin D in the cardiovascular disease. 1st International Symposium on vitamin D, Dubai, UAE, 2014.
192. Vitamin D, type 2 diabetes and metabolic syndrome. 1st International Symposium on vitamin D, Dubai, UAE, 2014.
193. Preventative strategies of chronic kidney disease of multi-factorial origin. 5th International Symposium on Sustainable built Environment. Kandy, Sri Lanka, 2014.
194. Vitamin D and the musculoskeletal system—clinical orthopedics. 1st International Symposium on vitamin D, Dubai, UAE, 2014.
195. Chronic kidney disease of multi-factorial origin: What steps need to be taken to eradicate it? Sri Lanka Association for Advancement of Science, Colombo, Sri Lanka, 2014.
196. Clean water for everyone: what is needed to be done to prevent chronic kidney disease of multi-factorial origin in Sri Lanka (CKDmfo). 5th International Congress of Sustainable Built Environment, Kandy Sri Lanka, 2014.
197. Inaugural annual “Olcott Oration”—2014: Alternative medicine and spirituality as tools for stress management and enhancing individual performance. Dubai, UAE, 2014.
198. Early diagnosis and prevention of chronic kidney disease of multi-factorial origin. Department of Health, Preventive Medicine Strategy Conference, Colombo, Sri Lanka, 2014.
199. Eradication of chronic kidney disease of multifactorial origin (CKDmfo), Agrarian Research Institute, Colombo, Sri Lanka, 2015.
200. Global issues with freshwater: Way to protect this heritage. Water Symposium, Rutgers University, Newark, New Jersey, 2015.
201. Advances of managing patients with osteoporosis. Kandy Society of Medicine, Sri Lanka, 2016.
202. Vitamin D, cardiovascular system and health. Galle Society of Medicine, Karapitiya General Hospital, Sri Lanka, 2016
203. Pitfalls and interpretation of bone mineral density scans and reporting. Teaching Hospital, Kandy, Sri Lanka, 2016.
204. Advances in the management of type 2 diabetes. Endocrine Society of Sri Lanka, Colombo, Sri Lanka, 2016.
205. Clinical practice guidelines for vitamin D, in the United Arab Emirates (Afrozul Haq and Sunil Wimalawansa), 5th International Congress of Vitamin D, Abu Dhabi, U.A.E., 2016
206. Vitamin D, Type 2 Diabetes, and Metabolic Syndrome. 5th International Congress of Vitamin D, Abu Dhabi, U.A.E., 2016
207. Why Physician leaders fail and how to ensure success, American Medical Association, Annual Meeting, Chicago, IL, June 2016.

B. Medicine Grand Round Presentations:

1. New therapeutic options in management of osteoporosis. Royal Postgraduate Medical School, London, United Kingdom, 1989.
2. Metabolic bone disorders: Unusual clinical presentations. Royal Postgraduate Medical School/Hammersmith Hospital, London, United Kingdom, 1991.
3. Osteoporosis: Can we prevent this disease? Postgraduate Medical Institute (North London, United Kingdom), 1994.

4. Osteoporosis, etiology, pathogenesis, and clinical management. Internal Medicine, The University of Texas Medical Branch, Galveston, 1995.
5. Management of osteoporosis. Family Medicine, The University of Texas Medical Branch at Galveston, 1995.
6. New therapeutic options in management of osteoporosis. Diagnostic Clinics, Houston, Texas, 95.
7. Prevention and treatment of osteoporosis. Primary Care Internal Medicine: update on Principles and Practice, Galveston, Texas, 1996.
8. Update on the management of osteoporosis. Family Medicine, The University of Texas Medical Branch at Galveston, 1997.
9. Osteoporosis: pathogenesis and new advances in clinical management. OB/GYN Department, University of Texas Medical Branch, Galveston, 1996 and 1998.
10. Nitric oxide in health and disease. Diagnostic Clinic, Houston, Texas, 1999.
11. Pitfalls in the diagnoses and management of osteoporosis. Internal Medicine, The University of Texas Medical Branch at Galveston, 1999.
12. Advances in the management of osteoporosis in year 2000. The University of Texas Medical Branch, Galveston, 2000.
13. Management of osteoporosis in the new millennium. Robert Wood Johnson Medical School, New Jersey, 2002.
14. Series of nine lectures (and some press interviews to promote osteoporosis diagnosis and treatment) in several academic institutions and major hospitals in India (Chennai, Bangalore, New Delhi, Hyderabad, and Bombay) on different aspects of osteoporosis and metabolic bone diseases, 2002.
15. New advances in osteoporosis (basic and clinical). Veterans Administration Hospitals, East Orange, New Jersey, 2002.
16. Optimal management of osteoporosis. Bayshore Hospital, New Jersey, 2002.
17. Diagnosis of osteoporosis and monitoring its therapy: use of bone density tests and their interpretations, and biochemical markers. Prevention and Treatment of Osteoporosis: Call to Action, 2002.
18. Nitric oxide; good or a bad guy? Mount Sinai Medical School/Bronx VA Medical Center, New York, 2003.
19. Update on metabolic bone disorders. Medical grand rounds at Janssen, Trenton, New Jersey, 2003.
20. Women's health issues, with special reference to menopause and bone. Osteopathic School of Medicine, OB/GYN, Stratford, New Jersey, 2003.
21. Skeleton and your health. Mini Medical School, UMDNJ–RWJMS, New Jersey, 2003.
22. Osteoporosis in the new millennium, UMDNJ–Newark, University Hospital, New Jersey, 2004.
23. Series of 10 lectures on metabolic bone diseases, osteoporosis, cardiovascular diseases and lipids, in Japan (Saitama, Oita, Kobe, Osaka, Tokyo, Niigata), 2004.
24. New advances in osteoporosis. Bayshore Hospital, New Jersey, 2004.
25. Nitric oxide, friend or a foe. Endocrinology Grand Rounds, Columbia University, New York, 2004.
26. What's new in the field of osteoporosis? VA Medical Center, Orange, New Jersey, 2004.

27. Osteoporosis in the new millennium, Toms River Hospital, 2004.
28. New advances in the management of osteoporosis. Essex County Hospital, New Jersey, 2004.
29. What is new in metabolic bone diseases? Bergen Regional Medical Center, New Jersey, 2004.
30. Prevention of fractures: What can we do? Orthopedic Grand Rounds, Robert Wood Johnson Medical School, New Brunswick, New Jersey, 2004.
31. New advances in management of osteoporosis. Robert Wood Johnson University Hospital, Hamilton, New Jersey, 2005.
32. How physicians can help maintain skeletal health. Somerset Hospital, New Jersey, 2005.
33. Advances in management of osteoporosis. OB/GYN, Jersey Shore Medical Center, New Jersey, 2005.
34. New advances in management of osteoporosis. UMDNJ–Bay Shore Hospital, Bay Shore, New Jersey, 2005.
35. How physicians can help maintain their patients' skeletal health. Raritan Bay Medical Center, Raritan, New Jersey, 2005.
36. Updates on maintaining skeletal health in their patients. Union Hospital, Union, New Jersey, 2005.
37. New advances in osteoporosis management. Staten Island University Hospital, 2005.
38. New initiatives in the treatment of osteoporosis, Bronx VA, New York, 2006.
39. Prevention of adult onset diabetes mellitus. Robert Wood Johnson University Hospital, Hamilton, New Jersey, 2007.
40. Osteoporosis in developmentally disabled patients. Hunterdon Development Center, Hunterdon, New Jersey, 2007.
41. New advances in management of osteoporosis. St. Joseph's University Hospital, Paterson, New Jersey, 2008.
42. Endocrinology in HIV patients. Mount Vernon Hospital, New York, 2010.
43. Diagnosis and management of hyperparathyroidism. Bayshore Medical Center, Meridian Healthcare, New Jersey, 2010.
44. New approaches in treating Type II diabetes. Mount Vernon Hospital, New York, NY, 2011.
45. Vitamin D deficiency, Type II diabetes, and metabolic syndrome: Causalities. Teaneck Hospital, New Jersey, 2011
46. New approaches in treating type II diabetes; Women's Christian Association Hospital, Jamestown, NY; CME–Buffalo University, New York, 2012
47. Fundamentals of nutrition and healthy living for professionals: ways to control obesity epidemic in America; Raritan Bay Medical center, New Jersey, 2012
48. Interpreting DXA studies: Avoiding pitfalls and optimizing the use of bone density data in clinical practice. Roxborough Memorial Hospital, Philadelphia, 2013
49. Vitamin D: How it related to common disorders like diabetes. East Orange General Hospital, East Orange, New Jersey, 2013
50. Advances in the management of obesity and over-weight. Robert Wood Johns University Hospital, Rahway, New Jersey, 2013.
51. Ethical issues confronted in general medicine. Robert Packer Hospital, Guthrie health care system, Sayre, Philadelphia, 2014.

52. Novel approaches in treating type 2 diabetes. Phelps Memorial Hospital Center, New York, 2014.
53. Novel cost-effective strategies in treating type 2 diabetes. Care-point Health, Bayonne Health Center, New Jersey, 2014.
54. Advances in the management of postmenopausal osteoporosis. Kurunagala Medical Society, Kurunagala, Sri Lanka, 2014.

C. Newspaper, Web, Television, and Other Articles

- Series of articles in the Lanka Web:
<http://www.lankaweb.com/news/items/category/professor-sunil-j-wimalawansa/>
- Macro-economic articles in Guardian: <http://www.slguardian.org/?cat=1165> ;
SL-Guardian.macroeconomic.artilces-(Sunil.Wimalawansa)
- A candid study and action plan: Economic and social development for Sri Lanka. Published in three parts, in the Sunday editions of the ***Economic Times***, June–July, 2006 (a series of three, half-page, featured, newspaper articles).
- In memoriam of Iain MacIntyre. John T. Potts Jr., Sunil Wimalawansa, T. John Martin. Bone (journal), 2008
- Where is the future growth? India and China, or elsewhere? 2008
- Economic and social development and the peace: What is ahead after the war? Sunday Times, 2009
- Post war, economic and social progress in Sri Lanka: Where to go from here? Sunday Observer, 2009
- World's largest ever hostage taking, and its rescue in the human history: Lessons to learn from combating terrorism. SL-Guardian, April 2009
- Creating economic and social development and overcoming terrorism: All countries, small or large, can learn from each other. Guardian, May 2009
- End of the war: Tips for Global economic development, Sydney-SL, Guardian, June 2009.
- Who is helping internally displaced in Sri Lanka? Washington–Sri Lanka, Guardian, September 2009
- Human Rights and Internally Displaced People (IDPs): An international problem. Washington–Sri Lanka, Guardian, October, 2009
- Post-War, Economic and Social Progress in Sri Lanka: Where to go from here? Sunday Island, November, 2009
- Perfecting Life through Buddhism, Lanka Web, January 2011
- Philosophy of life, Lanka Web, February 2011
- Rituals and practices, Lanka Web, March 1 2011
- Realistic approach to Buddhism, Lanka Web, March 2011
- Eight Key Healthy Habits: Simple Suggestions to Keep Healthy—Arogya Parama Labha site –Lanka Web, April 2011
- Devotional faith. Lanka Web, April 2011
- Time to eliminate rituals, Lanka Web, May 2011
- Buddha Jayanthiya-2600, Lanka Web, June 2011

- Colonel Olcott: Founder of the theosophical society. In, Henry Steel Olcott and the revival of Buddhist education (Eds., C. Gunathilale and A. Seneviratne), pp. 24-28, 2011.
- The way of life, Lanka Web, July 2011
- Key Buddhist practices, Lanka Web, September 2011
- The mind and the body, Lanka Web, November 2011
- Does aggression & destruction necessary to solve problems? Lanka Web, December, 2012
- Wisdom and the mind: Believe in yourself. Lanka Web, January, 2012
- Establishment of Buddha Sasana in Lanka by Arahat Mahinda, Lanka Web, September, 2012
- Establishment of Bhikkuni Sasana in Lanka by Venerable Sanghamitta, Lanka Web, October, 2012
- Escalating Incidence of Post-Traumatic Stress Disorders (PTSD) and Suicides Among Soldiers and Civilians Who are Exposed to War Situations in Sri Lanka, Lanka Web, 2012
- United States financial crisis. SL-Guardian, May, 2013
- The causes for the deepening United States economic crisis. SL-Guardian, June, 2013
- The United States economic crisis: solutions. Series of three articles; SL-Guardian, June, 2013; [SL-Guardian.macroeconomic.artilces-\(Sunil.Wimalawansa\)](http://www.sl-guardian.com/macro-economic-artilces-(Sunil.Wimalawansa))
- Series of radio shows on obesity, type 2 diabetes, osteoporosis, vitamin D and other nutritional deficiencies, and fracture prevention, 2012.
- Independent Television Interview: "Prevention of non-communicable diseases affecting developing countries: Cost-effective approaches", 2012
- Television interview on alleviation of chronic kidney diseases in Sri Lanka, April 2013.
- Knocking the kidney killer; Daily News, November, 2013.
<http://www.dailynews.lk/features/knocking-kidney-killer>
- Chronic kidney disease in Rajarata, worse than tsunami. Sunday Observer, November, 2013, <http://www.sundayobserver.lk/2013/11/24/fea06.asp>
- Series of television interviews on environmental pollution and alleviation of chronic kidney diseases in Sri Lanka, November, 2013.
- Water pollution and chronic kidney disease in Sri Lanka, Daily Mirror, January, 2014
<http://www.dailymirror.lk/opinion/172-opinion/43526-water-pollution-and-chronic-kidney-disease-in-sri-lanka.html>
- Agro-chemicals and Chronic Kidney Disease: What needs to be done. February, 2014
http://www.island.lk/index.php?page_cat=article-details&page=article-details&code_title=98247
- Should glyphosate be banned without scientific evidence? Chronic Kidney Disease of Multi-Factorial Origin (CKDmfo). The Island, March 2014,
http://www.island.lk/index.php?page_cat=article-details&page=article-details&code_title=100405
- Myths and Confusions: CKDmfo: http://www.island.lk/index.php?page_cat=article-details&page=article-details&code_title=125383
- <http://www.rivira.lk/epaper/sunday/2015/04/26/index.html#36/z>
- Comprehensive action plan to eradicate CKDmfo: <http://www.sundaytimes.lk/150503/sunday-times-2/kidney-disease-in-ncp-focus-on-prevention-147418.html>
- <http://www.divaina.com/2015/05/07/news07.html>
- Eradicating CKDmfo from Sri Lanka: <http://www.lankaweb.com/news/items/2015/05/07/ckdmfo-urgent-action-needed-by-the-government/>

- <http://www.sundaytimes.lk/150503/sunday-times-2/kidney-disease-in-ncp-focus-on-prevention-147418.html>

D. Other Non-Medical Publications and Books

- Elephant behavior (English) (1980)
- **Meditation publications:**
 - Basic meditation practices (Sinhela, 2007)
 - Happiness through Meditation [*Samatha* meditation] (2012), ISBN: 978-955-9098-93-5
 - Compassion and the Mind Connection [*Metta* meditation] (2012), ISBN: 978-955-9098-95-9
 - Physical and spiritual connection [*Vipassanā* Meditation] (2012), ISBN: 978-955-9098-96-6
 - Buddhist Meditation Practices for Happiness (English, 2012; 600 pages), ISBN: 978-955-458400-6
 - Meditation and the mind connection (English, 2012)
 - Meditation: Physical and spiritual connection (English, 2012)
- **Buddhist publication** (in preparation; English)
 - Buddhism: The way of life
 - Authentic Buddhist philosophy
 - The Buddhist philosophy and practices
 - Awakening to Dhamma
 - Buddhism and the Modern Society
 - Moving Beyond the Obvious
- **Publications related to the history:**
 - The American who revived Buddhism in Asia: Legacy of Colonel Olcott (English, 2011) ISBN: 978-955-9098-91-1
 - Intertwined histories of Buddhism and Sri Lanka (English, 2011), ISBN: 978-955-9098-90-4

E. Invited, Key, Non-Medical Lectures

- Effects of terrorism on the provision of health care, with special reference to Sri Lanka. School of International Studies, Emory University, Atlanta, Georgia, 2003.
- Health care disparities, with comparisons from US and Sri Lanka. International Forum, Rutgers University, 2004.
- Economic and Social Developments in South-East Asia, New Delhi, India, 2006.
- Health care disparities and practical solutions. Ottawa, Canada, 2006.
- Effects of terrorism on the health care delivery. Ottawa, Canada, 2006.
- One-hundred years of Legacy of Colonel Henry Steel Olcott: What can we learn from this great American? Olcott Centennial Memorial Oration, UMDNJ-Robert Wood Johnson Medical School, New Jersey, 2007.
- Leadership development seminar, Bank of Ceylon/Central Bank, Sri Lanka, 2008.
- Leadership development seminar, Bauer-Novartis Corporation, Sri Lanka, 2008.

- Provision of safe and clean drinking water: Government's responsibility, Colombo, Sri Lanka.
- Alternative energy sources and energy efficiency (speaker and symposium chair), Colombo, Sri Lanka, 2008.
- American Endocrine Society: Symposium on Careers in Administration, 2008.
- Food contamination (local and imported food): Problems and solutions. Ministry of Health and the Department of Health, Sri Lanka, 2008.
- Post-war economic development, Bankers Association and the Sampath Bank, Sri Lanka.
- Water and human health, Water Symposium, Colombo, Sri Lanka, 2009.
- Effects of war on health care. Pathways to Reconciliation Summit, Amman, Jordan, 2009.
- Water, health and policies. Keynote Speech, 50th Anniversary of the University of Sri Jayewardenepura, 2009.
- Philanthropic relief work and the effects of war on health care delivery. International Students' Forum, UMDNJ–RWJMS, Piscataway, New Jersey, 2010.
- 125th anniversary of Ananda College; The originator of Buddhist schools in Sri Lanka: Col. Henry Steel Olcott: Col. Olcott Oration, New Brunswick, New Jersey, 2011.
- Spirituality, meditation, and personal development. Fonterra Headquarters, Sri Lanka, 2011.
- Lifestyle changes for professionals, Heystome forum, Colombo, Sri Lanka, 2012.
- Private-Public Partnerships to improve health care delivery, Nutrition Society annual scientific session, plenary lecture, Sri Lanka, 2012.
- Water pollution and poor sanitation-induced chronic diseases: Special emphasis on chronic kidney disease. Annual Col. Olcott Oration, Ananda College, Colombo, 2013.
- Public-Private Partnerships to eradicate non-communicable diseases. Colombo, Sri Lanka, 2013.
- Exercise and healthy eating for professionals: Pros and cons. CEO's forum, Colombo, 2013.
- Water pollution-induced ill health: special emphasis on chronic kidney disease in Sri Lanka. 2013-Col. Olcott Memorial Oration, Ananda College, Colombo, 2013.
- Updates of chronic kidney disease in Sri Lanka (Symposium), Colombo 7, December 2014. Screening and diagnosis of chronic kidney disease of multi-factorial origin. 5th International conference of sustainable build environment; "Prevention of CKDmfo from Sri Lanka." Kandy, Sri Lanka, 2014.
- Alternative medicine and spirituality as tools for stress management and enhancing individual performance. First annual, Col. Olcott Oration, Dubai, UAE, 2014.
- Development of novel strategies for prevention and eradication of CKDmfo. Agrarian Research Institute, Colombo 7, December 2015.
- Prevention of Chronic Kidney Disease in Sri Lanka (seminar), Dharmvijaya Foundation Colombo 7, December 2014.
- Eradication of chronic kidney disease of multifactorial origin from Sri Lanka, YMA-Colombo, Sri Lanka, 2015.

F. Articles about Dr. Wimalawansa

- Journey to Himalaya: A journey of a medical student. Sunday Silumina (cover page), 1981

- Walking to Himalayas: Warana, March, 1981
- Inventor of papaya as a treatment for chronic ulcers, Sunday Dinamina (cover page), April, 1982
- Dr. Wimalawansa: A clinical scientist who save lives; Women's magazine, 1983
- Heart medicine for bone; a new discovery, UTMB Quarterly magazine, 1999
- Rutgers University, School of Business website, 2006
- North Brunswick man: A master of many professions (Sentinel newspaper, 2005)
- Professor wins highest honor for life-time achievements (Home News Tribune, 2006)
- A Sri Lankan honored for his discoveries and contributions (UMDNJ magazine, 2006)
- Sri Lankan native honored with humanitarian award (India-US Business Journal, 2007)
- Exceptional Old Boy: Professor Sunil Wimalawansa. Ananda College OBA Spring publication, April, 2011

G. Communications to Scientific Societies

1) British Meetings (1982–1994)

I have presented papers regularly at meetings of the following Societies in the United Kingdom:

- Society for Endocrinology
- Neuroendocrinology Group
- Biochemical Society
- Society for the Study of Fertility
- British Oncological Association
- CRC Medullary Thyroid Group
- Bone and Tooth Society
- Royal Society of Medicine
- Physiological Society
- Bayliss and Starling Society
- Association for Clinical Biochemists

2) International and National Meetings

I have actively taken part and delivered scientific presentations at the following meetings:

- International seminar on "Teaching of human reproduction, family planning, and population dynamics," WHO, 1978
- Biomedical Research Methodology; National Science Council/WHO, 1978
- Regional Training Course in "Radioimmunoassay and Related Procedures in Medicine"; International Atomic Energy Authority, 1979
- Workshop on "Human Reproduction and Family Planning"; WHO, 1979
- Training seminar on "Social Science Research Methodology"; NSC/UNESCO, 1980
- 13th Meeting of the International Foundation for Biochemical Endocrinology, Neuroendocrine Molecular Biology; Edinburgh, Scotland, 1985
- First International Congress of Neuroendocrinology; San Francisco, California, 1986
- Second International Workshop on Multiple Endocrine Neoplasia Type II; Cambridge, United Kingdom, 1986
- IX International Conference of Calcium Regulating Hormones and Bone Metabolism; Nice, France, 1986
- Ninth Annual Meeting of the American Society for Bone and Mineral Research; Indianapolis, Indiana, 1987
- 69th Annual Meeting of the American Society for Endocrinology; Indianapolis, Indiana, 1987
- Research Directions in Osteoporosis; National Institutes of Health, Bethesda, MD, 1987
- First European Congress of Endocrinology; Copenhagen, Denmark, 1987
- XII International Congress and VII European Congress of Clinical Chemistry; The Hague, Netherlands, 1987

- Second International Congress of Osteoporosis; Aalborg, Denmark, 1987
- First International Congress of the Society for Gynecological Endocrinology; Crans-Montana, Switzerland, 1988
- 10th Annual Meeting of the American Society for Bone and Mineral Research; New Orleans, Louisiana, 1988
- 70th Annual Meeting of the American Society for Endocrine; New Orleans, Louisiana, 1988
- "Molecular Biology of Hormone Action in Endocrinology and Pharmacology"; Milan, Italy, 1988
- Seventh International Congress of Endocrinology; Kyoto, Japan, 1988
- 11th Annual Meeting of the American Society for Bone and Mineral Research and the International Conference of Calcium Regulating Hormones; Montreal, Quebec, Canada, 1989
- Cyclical Etidronate: A New Dimension in Therapy for Osteoporosis; Paris, France, 1989
- 71st Annual Meeting of the American Society for Endocrinology; Seattle, Washington, 1989
- 13th American Peptide Symposium; La Jolla, California, 1989
- First International Peptide Symposium; Oxford, United Kingdom, 1989
- 72nd Annual Meeting of the American Society for Endocrinology; Atlanta, Georgia, 1990
- 12th Annual Meeting of the American Society for Bone and Mineral Research; Atlanta, Georgia, 1990
- International Conference of Bone Metabolism; Barcelona, Spain, 1990
- Third International Symposium of Osteoporosis; Copenhagen, Denmark, 1990
- Sixth International Congress of Menopause; Bangkok, Thailand, 1990
- First European Congress of Medullary Thyroid Carcinoma; Paris, France, 1990
- 73rd Annual Meeting of the American Society for Endocrinology; Washington, DC, 1991
- First International Symposium on Calcitonin Gene-related Peptide; Graz, Austria, 1991
- Management of patients with pituitary tumors and acromegaly; Washington, DC, 1991
- Third International Symposium on Solid-Phase Synthesis; Canterbury, United Kingdom, 1991
- Technological aspects of protein structure and function, ABI, London, United Kingdom, 1992
- First International Symposium on Paget 's disease of Bone; Manchester, United Kingdom, 1992
- International Congress of Endocrinology; Nice, France, 1992
- First International Medical Congress (South East Asia); Kandy, Sri Lanka, 1992
- 14th Annual Meeting of the American Society for Bone and Mineral Research; Minneapolis, Minnesota, 1992
- "Future Trends in Medicine"; London, United Kingdom, 1992
- The sequence and synthesis of technological change: Option for probing biomolecules; ABI European Seminar, London, United Kingdom, 1993
- AIM-WHO workshop on Telematics for Malaria and Other Tropical Diseases; Brussels, Belgium, 1993
- 15th Annual Meeting of the American Society for Bone and Mineral Research; Tampa, Florida, 1993
- Vasoactive peptides: Roles in health and disease of the cardiovascular system; Newport Beach, California, 1994
- 76th Annual Meeting, American Endocrine Society; Anaheim, California, 1994
- Second International Symposium on Calcitonin Gene-Related Peptide; Montreal, Canada, 1994

- 16th Annual Meeting of the American Society for Bone and Mineral Research, Oklahoma City, Oklahoma, 1994
- 77th Annual Meeting, American Endocrine Society; Tampa, Florida, 1995
- 17th Annual Meeting of the American Society for Bone and Mineral Research; Baltimore, Maryland, 1995
- 15th Joint Meeting, British Endocrine Societies; Dublin, Ireland, 1996
- World Congress on Osteoporosis; Amsterdam, Netherlands, 1996
- Bone and Tooth Society Meeting; Manchester, United Kingdom, 1996
- 10th International Congress of Endocrinology; San Francisco, California, 1996
- 18th Annual Meeting of the American Society for Bone and Mineral Research; Seattle, Washington, 1996
- 79th Annual Meeting, American Endocrine Society; Minneapolis, Minnesota, 1997
- 19th Annual Meeting of the American Society for Bone and Mineral Research; Cincinnati, Ohio, 1997
- First Annual Meeting of the American Society for Gene Therapy; Seattle, Washington, 1998
- 20th Annual Meeting of the American Society for Bone and Mineral Research and Joint Meeting with International Bone and Mineral Society; San Francisco, California, 1998
- Ninth Annual Meeting of the Australian and New Zealand Society; Cairns, Australia, 1999
- 21st Annual Meeting of the American Society for Bone and Mineral Research; St. Louis, Missouri, 1999
- Houston Technology Center, Life Sciences Series Seminars, 2000
- World Congress of Osteoporosis (Third); Chicago, Illinois, 2000
- Festschrift (Iain MacIntyre) Scientific Meeting; Cambridge, United Kingdom, 2000
- Bone and Tooth Society meeting; Cambridge, United Kingdom, 2000
- 22nd Annual Meeting of the American Society for Bone and Mineral Research; Toronto, Canada, 2000
- 23rd Annual Meeting of the American Society for Bone and Mineral Research; Phoenix, Arizona, 2001
- 24th Annual Meeting of the American Society for Bone and Mineral Research; San Antonio, Texas, 2002
- 83rd Annual Meeting, American Endocrine Society; Philadelphia, Pennsylvania, 2003
- National Biotechnology Teacher-Leader Program, BIO-2003; Toronto, Canada, 2003
- 25th Annual Meeting of the American Society for Bone and Mineral Research; Minneapolis, Minnesota, 2003
- 84th Annual Meeting, American Endocrine Society; New Orleans, Louisiana, 2004
- National Biotechnology Teacher-Leader Program, BIO-2004; San Francisco, California, 2004
- 26th Annual Meeting of the American Society for Bone and Mineral Research; Seattle, Washington, 2004
- Skeletal development & remodeling in health and disease, and aging; NYAC, New York, 2005
- 85th Annual Meeting, American Endocrine Society; Toronto, Canada, 2005
- 27th Annual Meeting, the American Society for Bone and Mineral Research; Nashville, TN, 2005
- Pri-Med general medicine update (two meetings in 2006); Princeton, New Jersey, 2006
- Co-morbidities associated with obesity—basic sciences and clinical concerns; Douglass College, Rutgers University, New Brunswick, New Jersey, 2006
- 86th Annual Meeting, American Endocrine Society; Boston, Massachusetts, 2006

- 28th Annual Meeting of the American Society for Bone and Mineral Research; Philadelphia, Pennsylvania, 2006
- Current management of the patient with type 2 diabetes. Joint meeting of ACP and the NJ Diabetes Foundation; Franklin Lakes, New Jersey, 2006
- International Society for Clinical Densitometry; Tampa, Florida, 2007
- Pri-Med general medicine update; Princeton, New Jersey, 2007
- Sixth Minority Quality Leadership Forum; Washington DC, 2007
- Second International Conference on Skeletal Biology & Development; NYAC, New York, 2007
- American Association of Clinical Endocrinologists, Seattle, Washington, 2007
- Pri-Med, CME in General Medicine; New York, 2007
- Pri-Med, CME in General Medicine; Princeton, New Jersey, 2007
- 6th Annual Conference, Update in Internal Medicine; Princeton, New Jersey, 2007
- 88th Annual Meeting, American Endocrine Society; San Francisco, California, 2008
- International Society for Clinical Densitometry, San Francisco, California, 2008
- Sixth International Medical Congress; Kandy, Sri Lanka, 2008
- 30th Annual Meeting of the American Society for Bone and Mineral Research; Montreal, Canada, 2008
- 14th International Endocrinology Congress; Rio de Janeiro, Brazil, 2008
- World Congress of Osteoporosis; Bangkok, Thailand, 2008
- Third International Congress on Skeletal Biology, New York, 2009
- International Society for Clinical Densitometry; Orlando, Florida, 2009
- 89th Annual Meeting, American Endocrine Society; Washington, DC, 2009
- 17th American Association of Clinical Endocrinologists, Annual Meeting; Orlando, Florida, 2009
- 31st Ann. Meeting, American Society for Bone & Mineral Research; Denver, Colorado, 2009
- International Society for Clinical Densitometry; San Francisco CA, 2010
- 90th Annual Meeting, American Endocrine Society; San Diego, CA, 2010
- 19th American Association of Clinical Endocrinologists, Boston, MA, 2010
- 32nd Ann. Meeting, American Society for Bone & Mineral Research; Toronto, Canada, 2010
- MAGI, Clinical Research Symposium; San Francisco, California, 2010
- mHealth Summit, NIH and Gates Foundation joint symposium; Washington DC, 2010
- World Congress of Disability, Dallas, Texas, 2010
- International Osteoporosis Society-Asian Congress, Singapore, 2010
- MAGI, Clinical Research Symposium; San Francisco, Philadelphia, 2011
- International Society for Clinical Densitometry; Miami, FL, 2011
- 91st Annual Meeting, American Endocrine Society; Boston, MA, 2011
- 20th American Association of Clinical Endocrinologists, CA, 2011
- 33rd Annual Meeting, American Society for Bone & Mineral Research; San Diego, CA, 2011
- International Society for Clinical Densitometry; Los Angeles, CA, 2012
- Primed- CME program, Philadelphia 2012
- FASEB – Annual Scientific Meeting, American Nutrition Society, San Diego, 2012.
- 21st American Association of Clinical Endocrinologists, Philadelphia, PA, 2012
- 13th Annual meeting, American Association for Developmental Medicine and Dentistry, Mesa, AZ, 2013

- 93rd Annual American Endocrine Society, annual scientific meeting, San Francisco, CA, 2013
- Primed- CME program, NY 2013
- 22nd American Association of Clinical Endocrinologists, annual scientific meeting, Phoenix, AZ, 2013
- 23rd American Association of Clinical Endocrinologists, annual scientific meeting, Las Vegas, NA, 2014
- 14th Annual meeting, American Association for Developmental Medicine and Dentistry, Princeton, NJ, 2014
- 24th American Association of Clinical Endocrinologists, annual scientific meeting, Nashville, TN, 2015

H. Participation in Workshops and Training Seminars

- Workshop on “Medical Education and Teacher Training”; WHO, 1979
- Regional training course in “Radioimmunoassay and Related Procedures in Medicine”; International Atomic Energy Authority, 1979
- Workshop on “Human Reproduction and Family Planning”; WHO, 1979
- Training seminar on “Social Science Research Methodology”; NSC/UNESCO, 1980
- “General Aviation Medicine” diploma course; Royal Air Force and Royal College of Physicians, Farnborough, United Kingdom, 1982
- Refresher course on Hormone Receptors; Biochemical Society, London, United Kingdom, 1984
- Techniques in Molecular Biology; Royal Postgraduate Medical School, London, United Kingdom, 1985
- Management course for trainees in pathology; London, United Kingdom, 1986
- Advanced course on Preparative HPLC; Leicester, United Kingdom, 1987
- Management of Acute Biochemical Emergencies; Royal College of Pathologists, United Kingdom, 1987
- International Meeting for the Advancement of Basic Research Conditions for Endocrinology; Kyoto, Japan, 1988
- Research Directions in Osteoporosis; National Institutes of Health, Bethesda, Maryland, 1987
- International Symposium on the pathogenesis and treatment of osteoporosis; London, United Kingdom, 1988
- Resource management for medical staff; The Nuffield Institute for Health Services Studies, Leeds, United Kingdom, 1988
- Molecular Biology of Hormone Action in Endocrine and Pharmacology; Milan, Italy, 1988
- Applied Biosystems Teaching Seminars; London, 1989, 1990, 1991, 1992, and 1993
- Update on Chemical Pathology; Royal Society of Medicine, London, United Kingdom, 1991
- Residential Management Skills Workshop, NET-RHA; Oxford, United Kingdom, 1991
- Managing Diagnostic Pathology Services; Royal College of Pathologists, London, United Kingdom, 1991
- Practical techniques in the isolation and structural characterization of proteins; ABI, London, United Kingdom, 1993
- Genetic analysis: from gene to protein, Technology for PCR, DNA and protein analysis; ABI, London, United Kingdom, 1993

- Anabolic hormones in bone: Basic research and therapeutic potential; National Institutes of Health (NIDDK) workshop, Bethesda, MD, 1995
- First Annual International Symposium on Local Cardiovascular Drug Delivery; Cambridge, Massachusetts, 1995
- Gene therapy for acquired diseases; Nashville, Tennessee, 1995
- Testosterone Replacement Therapy; Dublin, Ireland, 1996
- Cardiovascular risks in women: New strategies in hormonal therapies; South Shore Harbor, Texas, 1996
- New horizons in rheumatology; Houston, Texas, 1996
- Biology of Aging Endocrine System; San Francisco, California, 1996
- Seminar in Diabetic Retinopathy; Houston, Texas, 1996
- Advances in management of pituitary adenomas; Endocrine Society Symposium, 1997
- Sun Valley Bone Biology Workshop; Sun Valley, Idaho, 1997
- New therapeutic modalities in treatment of diabetes mellitus; Houston, Texas, 1998
- Coronary thrombosis and atherosclerosis: update on theories, trials and treatment; International Symposium, Galveston, Texas, 1997
- Primary Care Internal Medicine: Update on Principals and Practice; Galveston, Texas, 1998
- Comprehensive review course in Internal Medicine; Baylor College of Medicine, Houston, Texas, 1998
- DNA to Drug Development; Waters/Micro-mass, Houston, Texas, 1998
- 6th Annual Internal Medicine: Update on Principles and Practice; Galveston, Texas, 1999
- International workshop on muscular-skeletal interactions; Athens, Greece, 1999
- 2nd Annual International Symposium on Advances in Cardiology; Galveston, Texas, 1999
- First Primary Care Update, Foundation for Better Health Fair; Houston, Texas, 2000
- Clinical Research Skills Workshop for Clinical Investigators (Pfizer); Galveston, Texas
- Grant writing workshop–FASEB/NIH, 2001
- National Biotechnology Teacher-Leader Program, BIO-2003; Toronto, Canada, 2003
- Management of erectile dysfunctions; RWJMS, New Brunswick, New Jersey, 2003
- Sexual health hospital symposia; New Brunswick, New Jersey, 2003
- Risk Management: Strategies for the 21st Century, Improving Communication Skills; UMDNJ, Woodbridge, New Jersey, 2003
- Vascular biology of diabetes; New York, 2003.
- Complementary Medicine; Newark, New Jersey, 2003.
- National Biotechnology Teacher-Leader Program, BIO-2004; San Francisco, California, 2004
- Risks Reduction in Clinical Care; Woodbridge, New Jersey, 2004
- Management of Erectile Dysfunction; New Jersey, 2004
- New advances in small animal imaging; Rutgers University, New Jersey, 2004
- First South Asian American Health Conference: Developing agenda for action to address health disparity; North Brunswick, New Jersey, 2005
- Health development and remodeling in health, disease and aging; New York Academy of Sciences, New York, 2005
- Third International Conference on Bone and Mineral Research and Fifth International Osteoporosis Symposium; Xian, China, 2005
- Bone quality: What is it and can we measure it? Joint NIAMS–ASBMR Meeting; Bethesda, Maryland, 2005

- Skeletal development and remodeling in health, disease and aging; New York Academy of Sciences, New York, 2005
- Vitamin D, calcium and diseases; Rutgers University, New Jersey, 2005
- East-West Encounter Symposia: Eastern and Western perspectives on spirituality, healing, mind-body issues, and world peace; Rutgers University, New Jersey, 2005
- Multiple choice questions and items writing workshop–National Board of Medical Examiners; UMDNJ–RWJMS, New Brunswick, New Jersey, 2006
- Promotional mix in the pharmaceutical industry; Rutgers University Business School, New Brunswick, New Jersey, 2006
- National Minority Health Foundation's 2006 Annual Leadership Summit on Health Disparities, Summit and Leadership Awards Dinner; Washington DC, 2006
- Update in Internal Medicine; Princeton, New Jersey, 2006
- American Association of Clinical Endocrinologists–Leaders Development Conference; Phoenix, Arizona, 2007
- Update in Internal Medicine; Princeton, New Jersey, 2007
- Targeting bone remodeling for the treatment of osteoporosis, American Society for Bone and Mineral Research and National Institutes of Muscular-Skeletal diseases and Arthritis (NIAMS); Washington DC, 2007
- Update in Internal Medicine; Princeton, New Jersey, 2008
- *In vivo* micro-CT imaging workshop; Sanofi-Aventis, Bridgewater, New Jersey, 2008
- Update in Internal Medicine; Princeton, New Jersey, 2009
- Use of audience-response system in teaching; UMDNJ–RWJMS, 2008
- Avaya, Networking workshop; Manhattan, New York, 2009
- Advance Clinical Research Workshop, American Association of Clinical Endocrinologists; San Francisco, California, 2010
- Obstructive sleep apnea and cardio-metabolic syndrome–Joslin Diabetes Center; Harvard School of Medicine, 2010
- South Asian Total Health Initiative (SATHI) and Center for Health Families and Cultural Diversity (CHFCD); Princeton, New Jersey, 2010
- Risk management in a fast changing regulatory environment, Rutgers Business School Financial Management Conferences, Newark, NJ, 2012
- Future Leaders Advancing Research in Endocrinology (FLARE) Program, The Endocrine Society, U.S.A, Faculty member, New Orleans, LA, 2014
- Patient-Centered Diabetes Care: Putting theory into practice. The American Journal of Managed Care Diabetes Symposium, Princeton, NJ, 2014
- Do no harm: Partnership for drug free new Jersey, RWJUH, NJ, 2014
- Biosimilar: Partnership in medical innovation: delivering value for patients, healthcare and the economy. Rutgers Business School, N.J. 2016.

I. PRESENTATIONS AT MEDICAL / SCIENTIFIC MEETINGS

1. **Wimalawansa S.J.**, Piyasena R.D. Increased activity of the thyroid gland in premature canities. The Ceylon Association for Advancement of Science, 1975.
2. **Wimalawansa S.J.** Subcutaneous fat and its relationship to health. Sri Lanka Association for the Advancement of Science, 1978.

3. de Silva L.V.K., **Wimalawansa S.J.**, Dissanayaka S., Karalliadde S.K., Wikramanayake T.W. The relationship between birth weight and maternal weight. The Sri Lanka Association for Advancement of Science, 1979.
4. Karalliadde S., **Wimalawansa S.J.**, Dissanayaka S., de Silva L.V.K., Wikramanayake T.W. Secretary immunoglobulin A in vitamin A deficient children. The Sri Lanka Association for Advancement of Science, 1979.
5. **Wimalawansa S.J.**, Pathirana C., Wikramanayake T.W. Weight gain during pregnancy in rural Sri Lankan women. The Kandy Society of Medicine, Sri Lanka, 1979.
6. **Wimalawansa S.J.**, Perera P.A.J. A comparative study of socio-economic status and health of inhabitants in a remote village, Meemure, and in an urban village, Uda-Peradeniya. The Kandy Society of Medicine, Sri Lanka, 1979.
7. **Wimalawansa S.J.**, Piyasena R.D. Relationship between premature canities and premature balding to thyroidal activity. The Kandy Society of Medicine, Sri Lanka, 1980.
8. **Wimalawansa S.J.** Relationship of parity to weight gain during pregnancy. The Kandy Society of Medicine, Sri Lanka, 1980.
9. **Wimalawansa S.J.**, Self C.H., Girgis S.I., Emson P.C., Dawbarn D., MacIntyre I. The calcitonin gene peptide family: characterization and regional distributions in the rat. (Abst. 18). 13th meeting of the International Foundation of Biochemical Endocrinology; Neuroendocrine Molecular Biology, Edinburgh, Scotland, 1985.
10. **Wimalawansa S.J.**, Morris H.R., MacIntyre, I. Characterization of calcitonin gene-related peptide receptors in rat nervous system (Abst. 350). First International Congress of Neuroendocrinology, San Francisco, California, 1986.
11. **Wimalawansa S.J.**, MacIntyre I. Characterization of the calcitonin gene-related peptide binding sites in the cardiovascular system in the rat. British Neuroendocrine Group, Leicester, United Kingdom, 1986.
12. Zaidi M., Bevis P.J.R., Diez Guerra J., Lynch C., **Wimalawansa S.J.**, Emson P.C., MacIntyre I. Circulation of neurally derived calcitonin gene-related peptide (Abstract 200). First International Congress of Neuroendocrinology, San Francisco, California, 1986.
13. **Wimalawansa S.J.**, MacIntyre I. Calcitonin gene-related peptide: novel neuro-peptide in the human cerebrospinal fluid (Abst. 68). Society for Endocrinology, London, United Kingdom, 1986.
14. **Wimalawansa S.J.** Interim results of the prevention of osteoporosis, calcitonin pilot study. Peptide Workshop, London, United Kingdom, 1986.
15. **Wimalawansa S.J.**, Seth R., MacIntyre I. Novel non-radioisotopic assay for calcitonin, for diagnosis and management of medullary thyroid carcinoma. CRC Medullary Thyroid Group, CRC, London, United Kingdom, 1987.
16. **Wimalawansa S.J.**, Whitehead M., Banks L., Stevenson J.C., MacIntyre I. The influence of therapy on prevention of postmenopausal bone loss and the predictive value of plasma oestradiol and calcitonin (Abst. 221). Eighth Annual Meeting of the American Society for Bone and Mineral Research, 1987.
17. Seth R., Kehely A., **Wimalawansa S.J.**, Self C.H., Motte P., Bonnay M., Bellet D., MacIntyre I. The development of a two-site enzyme-immunometric assay for calcitonin and its application in the measurement of the hormone in normal subjects, MTC patients and postmenopausal women. Meeting on Multiple Endocrine Neoplasia, Type 2, Heidelberg, West Germany, 1987.

18. **Wimalawansa, S.J.**, Morris, H.R., MacIntyre, I. Demonstration of α - and β -calcitonin gene-related peptide in human spinal cord, CSF and in plasma. First European Congress of Endocrinology, Copenhagen, Denmark, 1987.
19. **Wimalawansa S.J.**, MacIntyre I. A novel radio-receptor assay for calcitonin gene-related peptide (Abst. 167). 69th Annual Meeting of the American Endocrine Society, Indianapolis, Indiana, 1987.
20. **Wimalawansa S.J.**, MacIntyre I. Demonstration of monomeric-CGRP in human cerebrospinal fluid. XII International Congress of Clinical Chemistry, VII European Congress of Clinical Chemistry, The Hague, Netherlands, 1987.
21. **Wimalawansa S.J.**, Morris H.R., Panico M., Girgis S.I., MacIntyre I. Demonstration of the presence of β -calcitonin gene-related peptide from human spinal cord (Abst. 730). 69th Annual Meeting of the American Endocrine Society, Indianapolis, Indiana, 1987.
22. Banks L.M., **Wimalawansa S.J.**, Stevenson J.C., Whitehead M.I., MacIntyre I. QCT and its role in assessing the efficacy of treatment for the prevention of postmenopausal bone loss. VI International Workshop on Bone and Soft Tissue Densitometry, Buxton, United Kingdom, 1987.
23. **Wimalawansa S.J.**, Kehely A., Banks L.M., Stevenson J.C., Whitehead M.I., MacIntyre I. The predictive value of plasma oestradiol levels and the effects of oestradiol and calcitonin on postmenopausal bone loss (Abst. 179). International Symposium on Prophylaxis and Treatment of Osteoporosis, Denmark, 1987.
24. Seth R., Motte P., El-Kholy A., Datta H., Zaidi M., Kehely A., **Wimalawansa S.J.**, Bohuon C., MacIntyre I. Immunoreactive and biologically active calcitonin in medullary carcinoma of the thyroid. 10th Annual Meeting of the American Society for Bone and Mineral Research, New Orleans, Louisiana, 1988.
25. El-Kholy A., **Wimalawansa S.J.**, MacIntyre I. A comparative study on characterization and distribution of calcitonin gene-related peptide binding sites in rat, cow and human brain. 70th Annual Meeting of the American Endocrine Society, New Orleans, Louisiana, 1988.
26. **Wimalawansa S.J.**, Zaidi M., MacIntyre I. Osteoporosis: Etiology, Cell Biology and Prevention. The Royal Society, London, United Kingdom, 1988.
27. Seth R., Kehely A., Motte P., **Wimalawansa S.J.**, MacIntyre I. Calcitonin measurement: Application of a novel enzyme-immunometric assay and its comparison with the conventional radioimmunoassay. Bone and Tooth Society, Oxford, United Kingdom, 1988.
28. **Wimalawansa S.J.**, MacIntyre I. Can we determine the minimal doses of 17β -oestradiol still active on bone? Mini Symposium, First International Congress of Gynecological Endocrinology, Crans-Montana, Switzerland, 1988.
29. **Wimalawansa S.J.**, El-Kholy A.A., MacIntyre I. Characterization of specific binding of ^{125}I -CGRP to cerebellar membranes. Eighth International Congress of Endocrinology, Kyoto, Japan, 1988.
30. **Wimalawansa S.J.**, Kehely A., Banks L.M., Stevenson J.C., Whitehead M.I., MacIntyre, I. Calcitonin and oestradiol in the prevention of postmenopausal bone loss. First Congress of the International Society of Gynecological Endocrinology, Crans-Montana, Switzerland, 1988.
31. Whitehead M.I., Fraser D., MacIntyre I., Stevenson J.C., **Wimalawansa S.J.**, Banks L. How should calcitonin and oestrogen therapy for conservation of postmenopausal bone loss be monitored? World Congress of Obstetrics and Gynecology, Rio de Janeiro, Brazil, 1988.

32. McEwan J., **Wimalawansa S.J.**, MacIntyre I. Amylin amide is the third CGRP and activates adenylyl cyclase (Abstract 845). 71st Annual Meeting of the American Endocrine Society, Seattle, Washington, 1989.
33. **Wimalawansa S.J.**, MacIntyre I. Isolation and purification of calcitonin gene-related peptide receptors using specific affinity chromatography (Abstract 1607). 71st Annual Meeting of the American Endocrine Society, Seattle, Washington, 1989.
34. **Wimalawansa S.J.**, Panico M., Ettienne T., Blench I., Morris H.R., MacIntyre I. Full characterization of β -calcitonin gene-related peptide in man. Bone and Tooth Society, Cardiff, United Kingdom, 1989.
35. **Wimalawansa S.J.** Isolation and purification of calcitonin gene-related peptide receptors. CGRP receptor workshop, Royal Postgraduate Medical School, London, United Kingdom, 1989.
36. **Wimalawansa S.J.**, MacIntyre I. Application of a novel radio-receptor assay for CGRP. Joint American Society for Bone and Mineral Research, and International Conference on Calcium Regulating Hormones (ASBMR-ICCRH) Meeting, Quebec, Canada, 1989.
37. MacIntyre I., **Wimalawansa S.J.** Positive relationship of plasma 17β -oestradiol with prevention of postmenopausal bone loss. Joint ASBMR-ICCRH Meeting, Quebec, Canada, 1989.
38. **Wimalawansa S.J.**, Banks L. Therapeutic success in severe iatrogenic osteoporosis. Fourth Annual Meeting of the Adult Bone and Mineral Working Group, Satellite Workshop, ICCRH/ASBMR, Quebec, Canada, 1989.
39. Mahadevan D., **Wimalawansa S.J.**, MacIntyre I., Banga P., Saldanha J. Proposed secondary and tertiary structures for pancreatic islet amyloid polypeptide and calcitonin gene-related peptide. Insulin Symposium, York, United Kingdom, 1989.
40. **Wimalawansa S.J.** Isolation purification and raising monoclonal antibodies for calcitonin gene-related peptide (CGRP) receptors. Peptides: Physiology, Pathology and Therapeutics. Ninth National Scientific Meeting of the Bayliss and Starling Society, Leicester, United Kingdom, 1989.
41. Datta H.K., Rafter P.W., **Wimalawansa S.J.**, Chen Z.P., MacIntyre I. CGRP and amylin amide display a proliferative effect on human umbilical endothelial cells and osteoblast-like osteosarcoma cell line. Biochemical Society, Aberdeen, United Kingdom, 1990.
42. Datta H.K., Rafter P.W., MacIntyre I., **Wimalawansa S.J.** Amylin amide competes for CGRP binding sites on brain membranes and on osteoblast-like osteosarcoma cells (Abstract S229). 12th Annual Meeting of the American Society for Bone and Mineral Research, Atlanta, Georgia, 1990.
43. **Wimalawansa S.J.** Radioreceptor assay for CGRP: A novel assay for the diagnosis of MTC in conjunction with CT-radioimmunoassay. First European Congress of Medullary Thyroid Carcinoma, Paris, France, 1990.
44. **Wimalawansa S.J.**, Bailey F. Validation of a highly sensitive and specific, novel immunoradiometric assay for calcitonin. First European Congress of Medullary Thyroid Carcinoma, Paris, France, 1990.
45. **Wimalawansa S.J.**, Banks, L.M. Human calcitonin therapy can arrest the progression of spinal cord compression in spinal Paget's disease. Fifth Annual Meeting of the Adult Bone and Mineral Working Group, Atlanta, Georgia, 1990.
46. Davis J.P., Archer D.J., Fisher C., Baldwin D., **Wimalawansa S.J.** Multiple recurrent giant cell lesions associated with high circulatory parathyroid hormone-related peptide in a young

- woman. Annual Sessions of the Royal College of Surgeons, London, United Kingdom, 1990.
47. Zaidi M., Moonga B., Ghatei M., Gilby S., **Wimalawansa S.J.**, Bloom S.R., MacIntyre I., Datta H.K. Amylin: A new bone-conserving hormone from the pancreas: *in vivo* and *in vitro* studies on potency and mode of action. 13th Annual Meeting American Society for Bone and Mineral Research, Indianapolis, Indiana, 1990
 48. **Wimalawansa S.J.** Usefulness of PTH-rp levels during bisphosphonate treatment of cancer-associated hypercalcaemia (Abstract 7). British Oncological Association Meeting, Bath, United Kingdom, 1991.
 49. **Wimalawansa S.J.** Isolation and characterization of calcitonin gene-related peptide receptors and raising monoclonal antibodies. First International Symposium on Calcitonin Gene-related Peptide, Graz, Austria, 1991.
 50. **Wimalawansa S.J.**, MacIntyre I., Datta H.K. Hypocalcaemic efficacy of amylin amide in Paget's disease in man (Abstract 1431). 73rd Annual Meeting American Endocrine Society, Washington DC, 1991.
 51. **Wimalawansa S.J.**, Zhang F. Isolation, purification and raising monoclonal antibodies for neuropeptide Y receptors (Abstract 1040). 73rd Annual Meeting American Endocrine Society, Washington, DC, 1991.
 52. **Wimalawansa S.J.** Dramatic response to mithramycin in a patient with severe Paget's disease refractory to calcitonin and pamidronate. 14th Annual Meeting American Society for Bone and Mineral Research, Minneapolis, Minnesota, 1992.
 53. **Wimalawansa S.J.** Positive relationship of the use of nitroglycerin and HMG-CoA inhibitors to BMD. Peptide Workshop, London, United Kingdom, 1992.
 53. **Wimalawansa S.J.** Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. 14th Annual Meeting American Society for Bone and Mineral Research, Minneapolis, Minnesota, 1992.
 54. **Wimalawansa S.J.** Therapeutic options of prevention and treatment of osteoporosis. First joint meeting of the Asiri Medical Club, Abha, Kingdom of Saudi Arabia, 1992.
 55. **Wimalawansa S.J.** Clinical applications of circulatory levels of PTH-rp in cancer-associated hypercalcaemia. International Congress of Endocrinology, Nice, France, 1992.
 56. Gubisch W., Kresse A., **Wimalawansa S.J.**, Skofitsch G. Comparison between the immunocytochemical distribution of amylin, and calcitonin gene-related peptide in the central nervous system of the rat. Conference of Comparative Endocrinologists, Padova, Italy, 1992.
 57. Gunasekera R.D., **Wimalawansa S.J.** Pamidronate is effective for patients with Paget's disease of bone refractory to conventional therapy. First International Symposium on Paget's Disease of Bone, Manchester, United Kingdom, 1992.
 58. **Wimalawansa S.J.**, Banks L.M. Effects of human calcitonin in arresting the progression of spinal cord compression in patients with spinal Paget's disease. First International Symposium on Paget's Disease of Bone, Manchester, United Kingdom, 1992.
 59. **Wimalawansa S.J.** Dramatic response to mithramycin in a patient with severe Paget's disease refractory to calcitonin and pamidronate. First International Symposium on Paget's Disease of Bone, Manchester, United Kingdom, 1992.
 60. Skofitsch G., **Wimalawansa S.J.**, Kresse A. Amylin binds to a sub-population of CGRP-receptors in the rat brain. Gottingener Neurobiologentagung, Germany, 1992.

61. **Wimalawansa S.J.** Pamidronate therapy in hypercalcaemia of malignancy: Relationship with PTH-rp levels. 75th Annual Meeting, American Endocrine Society, Las Vegas, Nevada, 1993.
62. **Wimalawansa S.J.** Calcitonin gene-related peptide in normal pituitary and in pituitary adenoma. Third International Pituitary Congress, Los Angeles, California, 1993.
63. **Wimalawansa S.J.** Etidronate in combination with HRT eliminates unwanted effects of etidronate on the bone, but increases the bone mass: 4-year prospective study. 15th Annual Meeting of the American Society for Bone and Mineral Research, Tampa, Florida, 1993.
64. **Wimalawansa S.J.**, Archer D.J. Successful treatment of life-threatening multiple giant cell granuloma with pamidronate. Eighth Annual Meeting of the Adult Bone and Mineral Working Group, Tampa, Florida, 1993.
65. **Wimalawansa S.J.**, Zhang F. Isolation, characterization of NPY receptors and raising monoclonal antibodies. Neuropeptide Y Meeting, Cambridge, United Kingdom, 1993.
66. **Wimalawansa S.J.** Is there a place for estrogen therapy for women over 70 years of age? 16th Annual Meeting of the American Society for Bone and Mineral Research, Kansas City, Missouri, 1994.
67. **Wimalawansa S.J.** Expression of calcitonin gene-related peptide in pituitary adenomas. 76th Annual Meeting, American Endocrine Society, Anaheim, California, 1994.
68. **Wimalawansa S.J.** Optimal frequency of administration of pamidronate in patients with hypercalcemia of malignancy. 9th Annual Meeting of the Adult Bone and Mineral Working Group, Kansas City, Missouri, 1994.
69. **Wimalawansa S.J.** Combined medical therapies for hypercalcemia of malignancy. 16th Annual Meeting of the American Society for Bone and Mineral Research, Kansas City, Missouri, 1994.
70. Skofitsch G., **Wimalawansa S.J.**, Gubioch W. Comparative immunochemical distribution of CGRP- and amylin-like immunoreactivity in the central nervous system. Second International Symposium on CGRP, Montreal, Canada, 1994.
71. **Wimalawansa S.J.** Calcitonin gene-related peptide (CGRP) receptors: Characterization, species distribution, and receptor sub-types. Second International Symposium on CGRP, Montreal, Canada, 1994.
72. Skofitsch G., **Wimalawansa S.J.**, Jobstl B. Autoradiographic distribution of amylin, calcitonin and CGRP-binding sites in the rat central nervous system. Second International Symposium on CGRP, Montreal, Canada, 1994.
73. **Wimalawansa S.J.**, Supowit S.C., DiPette D.J. The mechanisms of anti-hypertensive effects of calcium, and the role of CGRP in hypertension. Second International Symposium on CGRP, Montreal, Canada, 1994.
74. **Wimalawansa S.J.** Quantitative purification and characterization of neuropeptide Y-Y2 receptor. Vasoactive Peptides: Roles in Health and Disease of the Cardiovascular System, Newport Beach, California, 1994.
75. Sar M., Mohanty S., **Wimalawansa S.J.** Immunocytochemical localization of neuropeptide-Y receptor in rat brain. 77th Annual Meeting of the American Endocrine Society, Washington, DC, 1995.
76. **Wimalawansa S.J.** Calcitonin gene-related peptide receptor gene: A potentially useful gene for treatment of coronary ischemia. Gene Therapy for Acquired Diseases, Nashville, Tennessee, 1995.

77. D'Este L. **Wimalawansa S.J.**, Renda T.G. Amylin-immunoreactivity is co-stored in a serotonin cell subpopulation of vertebrate stomach and duodenum. Second International Malpighi Symposium, Rome, Italy, 1995.
78. Yallampalli C., Dong Y.-L., **Wimalawansa S.J.** Calcitonin gene-related peptide reverses hypertension and decreases the fetal mortality associated with L-NAME infusion in pregnant rats. Annual Scientific Meeting of the Society for Gynecologic Investigation, Atlanta, Georgia, 1996.
79. **Wimalawansa S.J.**, Gangula P.R., Dong Y.-L., Yallampalli C. Hypertension during pregnancy (pre-eclamptic toxemia) can be ameliorated with calcitonin gene-related peptide. 15th Joint Meeting of the British Endocrine Societies, Dublin, Ireland, 1996.
80. Yallampalli C., De Marco G., **Wimalawansa S.J.** Estradiol regulates the blood pressure in rats through nitric oxide. Annual Scientific Meeting of the Society for Gynecologic Investigation, Atlanta, Georgia, 1996.
81. **Wimalawansa S.J.** Microgravity-induced suppression of thyroxin and testosterone, and rapid bone loss in rats. 10th International Congress of Endocrinology, San Francisco, California, 1996.
82. Yallampalli C., Gangula P.R., Supowit S., Hallman D., DiPette D., **Wimalawansa S.J.** Estradiol and progesterone increase CGRP levels in dorsal root ganglia in rats. 10th International Congress of Endocrinology, San Francisco, California, 1996.
83. **Wimalawansa S.J.** Combined therapies with calcitonin and corticosteroids, or bisphosphonate for hypercalcemia of malignancy. 10th International Congress of Endocrinology, San Francisco, California, 1996.
84. **Wimalawansa S.J.**, Klink S.S., Wei J.N., Quast M., Westlund K.N. Use of magnetic resonance imaging to quantitate microgravity-induced musculo-skeletal losses. World Congress on Osteoporosis, Amsterdam, Netherlands, 1996.
85. **Wimalawansa S.J.**, Gangula P.R., De Marco G., Yallampalli C. Replacement therapy with nitric oxide or nitric oxide donor *in vivo*, maintains the bone mass in rats after ovariectomy. World Congress on Osteoporosis, Amsterdam, Netherlands, 1996.
86. **Wimalawansa S.J.** Beneficial effects of estrogen replacement therapy in women over 70 years of age. World Congress on Osteoporosis, Amsterdam, Netherlands, 1996.
87. Supowit S., Gangula P., Zhao H., Hallman D., **Wimalawansa S.J.**, DiPette D., Yallampalli C. Calcitonin gene-related peptides is a depressor in L-NAME-induced preeclampsia. American Heart Association, Chicago, Illinois, 1996.
88. **Wimalawansa S.J.**, Yallampalli, C. New therapy for hypertension during pregnancy (pre-eclamptic toxemia). Third International Medical Congress, Kandy, Sri Lanka, 1996.
89. **Wimalawansa S.J.** Influence of maternal nutrition, parity, and socio-economic status of the mother on birth weight and fetal survival. Third International Medical Congress, Kandy, Sri Lanka, 1996.
90. Wimalawansa S.M., Quast M., Westlund K.N., Wei J.N., **Wimalawansa S.J.** Androgen and anabolic steroids can alleviate microgravity-induced loss of muscles. 18th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, Washington, 1996.
91. **Wimalawansa S.J.** Pre-stabilization of the skeleton with pamidronate can prevent steroid-induced osteoporosis. 18th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, Washington, 1996.
92. **Wimalawansa S.J.** Assessment of microgravity-induced bone loss by MRI and DXA: Treatment effects with androgen and anabolic steroids on bone density. 18th Annual

- Meeting of the American Society for Bone and Mineral Research, Seattle, Washington, 1996.
93. Zhang R., Chapa M.T., Yallampalli C., **Wimalawansa S.J.** Steroid-induced osteoporosis can be prevented with nitric oxide. 18th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, Washington, 1996.
 94. Gangula P.R., **Wimalawansa S.J.**, Yallampalli C. Progesterone up-regulates vasodilator effects of calcitonin gene-related peptide in L-NAME-induced hypertensive rats. Annual Scientific Meeting of the Society for Gynecologic Investigation, Tennessee, 1996.
 95. Gangula P.R., Supowit S., **Wimalawansa S.J.**, Hallman D., DiPette D., Yallampalli C. Regulation of calcitonin gene-related peptide (CGRP) expression in rat dorsal root ganglia by female sex steroid hormones. 44th Annual Scientific Meeting of the Society for Gynecologic Investigation, San Diego, California, 1997.
 96. Dong Y.L., Fang L., **Wimalawansa S.J.**, Yallampalli C. Calcitonin gene-related peptide inhibits uterine contractility during pregnancy and reduces PGF2 α -induced preterm labor in rats. 44th Annual Scientific Meeting of the Society for Gynecologic Investigation, San Diego, California, 1997.
 97. **Wimalawansa S.J.** The combined estrogen and bisphosphonate therapy for established postmenopausal osteoporosis: 4-year randomized controlled study. 79th Annual Meeting, American Endocrine Society, Minneapolis, Minnesota, 1997.
 98. **Wimalawansa S.J.** Prevention of ovariectomy and corticosteroid-induced bone loss with alendronate. 79th Annual Meeting, American Endocrine Society, Minneapolis, Minnesota, 1997.
 99. **Wimalawansa S.J.**, Chapa T., Wimalawansa S., Fang L., Yallampalli C. Dose- and frequency-dependent effect of nitric oxide donor, nitroglycerin, on bone. 79th Annual Meeting, American Endocrine Society, Minneapolis, Minnesota, 1997.
 100. Wimalawansa D.M., **Wimalawansa S.J.** The Role of dietary calcium in blood pressure control. 79th Annual Meeting, American Endocrine Society, Minneapolis, Minnesota, 1997.
 101. Dong Y.L., Fang L., **Wimalawansa S.J.**, Yallampalli C. Calcitonin gene-related peptide inhibits uterine contractility during pregnancy and reduces PGF2-induced pre-term labor in rats. 44th Annual Scientific Meeting of the Society for Gynecologic Investigation, San Diego, California, 1997.
 102. Wimalawansa S.M., Quast M., Westlund K.N., Wei J., **Wimalawansa S.J.** An efficacious method of preventing weightlessness-induced musculo-skeletal losses. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, 1997.
 103. **Wimalawansa S.J.**, Davis J.P., Archer D.J. Successful therapy with pamidronate for multiple giant cell bone lesions in a patient, complicated with raised parathyroid hormone-related protein. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, 1997.
 104. **Wimalawansa S.J.** An efficacious method of treating postmenopausal osteoporosis: Combined therapy of estrogen and bisphosphonate: 4-year randomized controlled study. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, 1997.
 105. Lu Y., **Wimalawansa S.J.**, Westlund K. Calcitonin gene-related peptide receptor immunolocalization in rat brain. Meeting of the Society for Neuroscience, New Orleans, Louisiana, 1997.

106. Ye Z., **Wimalawansa S.J.**, Westlund K.N. Immunolocalization of CGRP receptors in rat spinal cord and dorsal root ganglia. Meeting of the Society for Neuroscience, New Orleans, LA., 1997.
107. Feng L, **Wimalawansa S.J.**, Dong Y.-L., Gangula P.R., Yallampalli C. Immunolocalization and expression of calcitonin gene-related peptide receptor protein in the central nervous system of pregnant rats. Annual Scientific Meeting of the Society for Experimental Biology and Medicine, San Diego, California, 1997.
108. Gangula P.R., Zhao H., Bukoski R, Supowit S., DiPette D., **Wimalawansa, S.J.** Yallampalli C. Effects of progesterone and pregnancy on hemodynamics and regional organ blood flow in rats. 45th Annual Meeting of the Society for Gynecologic Investigation, Atlanta, Georgia, 1998.
109. Gangula P.R., Zhao H., Supowit S., DiPette D., **Wimalawansa S.J.**, Yallampalli C. Pregnancy and steroid hormones enhance the vasodilatory responses to calcitonin gene-related peptide (CGRP) in rats. 45th Annual Meeting of the Society for Gynecologic Investigation, Atlanta, Georgia, 1998.
110. Gangula P.R., **Wimalawansa S.J.**, Supowit S., Zhao H., DiPette D., Yallampalli C. Enhanced calcitonin gene-related peptide (CGRP)-mediated vasodilation *in vivo* in response to pregnancy. 45th Annual Meeting of the Society for Gynecologic Investigation, Atlanta, Georgia, 1998.
111. Yallampalli C., Gangula P.R., Dong Y-L., Fang L., **Wimalawansa S.J.** Calcitonin gene-related peptide (CGRP) receptor binding and localization in non-pregnant and pregnant rat uterus and regulation by sex-steroid hormones. 45th Annual Meeting of the Society for Gynecologic Investigation, Atlanta, Georgia, 1998.
112. Gangula P.R., Magness R.R., **Wimalawansa S.J.**, Chapa M.T., Fang L., Phernetton T.M., Yallampalli C. Pregnancy and sex-steroid hormones enhance the levels of calcitonin gene-related peptide in circulation in rats and sheep. 45th Annual Meeting of the Society for Gynecologic Investigation, Atlanta, Georgia, 1998.
113. Yallampalli C., Gangula P.R., **Wimalawansa S.J.** CGRP and pregnancy: A potential therapy for pre-eclamptic toxemia. Third International Symposium on CGRP/New Horizons in CGRP and Related Peptide Research, International Symposium on CGRP '98, Shaftesbury, Dorset, United Kingdom, 1998.
114. D'Este L., **Wimalawansa S.J.**, Maeda T., Renda T.G. Amylin-immunoreactive elements in monkey (*Macaca fuscata*) hypothalamus. Third International Symposium on CGRP/ New Horizons in CGRP and Related Peptide Research, International Symposium on CGRP '98, Shaftesbury, Dorset, United Kingdom, 1998.
115. **Wimalawansa S.J.** Calcitonin gene-related peptide and its receptor gene: Novel therapy for ischemia. First Annual Meeting of the American Society for Gene Therapy, Seattle, Washington, 1998.
116. Morara S., Rosina A., **Wimalawansa S.J.** Immunolocalization of CGRP receptors in the rat cerebellar cortex. Neurosciences Meeting, San Diego, California, 1998.
117. Wimalawansa S.M., Chapa M.T., Simmons D.J., Yallampalli C., **Wimalawansa, S.J.** Biphasic dose-dependent effects of nitric oxide on osteoblasts and bone mineral density. Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, California, 1998.
118. **Wimalawansa S.J.**, Shankar V.S., Yang S., Chapa M.T., Simmons D.J. Estrogen inhibits dentin resorption by suppressing nitric oxide synthesis in osteoblast-osteoclast co-cultures.

- Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, California, 1998.
119. Shankar V.S., Yang S., Yang J., Chapa M.T., Simmons D.J., **Wimalawansa S.J.** Cyclosporine A induces dentin resorption via nitric oxide-cGMP pathway in osteoblast-osteoclast co-cultures: Mechanistic insights. Comparative Endocrinology of Calcium Regulation, Satellite Meeting of the ASBMR-IBMS Second Joint Meeting, San Francisco, California, 1998.
 120. Wimalawansa D.R., Senaratna N.A., Wimalawansa, S.M., **Wimalawansa S.J.** Combination of nitric oxide and bisphosphonates further enhances increments in bone mineral density. Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, California, 1998.
 121. **Wimalawansa S.J.** Restoration of OVX-induced bone loss by once daily percutaneous administration of nitroglycerin ointment. Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, California, 1998.
 122. **Wimalawansa S.J.** Severe osteoporosis secondary to granulomatous bone disease: Response to intravenous pamidronate. Adult Bone and Mineral Workshop, Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, California, 1998.
 123. Wimalawansa S.M., Simmons D.J., Quest M., Westlund KN, Wei J, **Wimalawansa S.J.** Testosterone and an anabolic steroid alleviate weightlessness-induced musculo-skeletal losses. American Space Research Meeting (Gravitational and Space Biology Bulletin), Houston, Texas, 1998.
 124. **Wimalawansa S.J.** An efficacious method of treating postmenopausal osteoporosis: Combined therapy of estrogen and bisphosphonate: 4-year randomized controlled study. Annual Scientific sessions, Sealy Center for Aging, Galveston, Texas, 1998.
 125. Wimalawansa D.R., Chapa T., **Wimalawansa S.J.** Comparison of the beneficial effects of various nitric oxide donor compounds on ovariectomy-induced osteopenia. Annual Scientific sessions, Sealy Center for Aging, Galveston, Texas, 1998.
 126. Wimalawansa S.M, Chapa T., Shankar V., Yang S., Simmons D., **Wimalawansa S.J.** The mechanisms of bone resorption by cyclosporin A: The involvement of nitric oxide-cGMP pathway in osteoblast-osteoclast co-cultures. Annual Scientific sessions, Sealy Center for Aging, Galveston, Texas, 1998.
 127. Gangula P.R., **Wimalawansa S.J.**, Yallampalli C. Effects of CGRP (8-37), a calcitonin gene-related peptide (CGRP) antagonist on blood pressure regulation and fetal mortality in pregnant rats. Annual Scientific sessions, Sealy Center for Aging, Galveston, Texas, 1998.
 128. Lawand N.B, **Wimalawansa S.J.**, Westlund K.N. Testosterone alleviates allodynia induced by tail suspension weightlessness model in rats. Annual Scientific Meeting of the American Pain Society, 1999.
 129. Gangula P.R.R., **Wimalawansa S.J.**, Yallampalli C. Effect of CGRP₈₋₃₇, a calcitonin gene-related peptide (CGRP) antagonist on blood pressure regulation and fetal mortality in pregnant rats. Annual Scientific Meeting of the Society for Gynecologic Investigation, Nashville, Tennessee, 1999.
 130. **Wimalawansa S.J.**, Yallampalli C. *In vivo* effects of nitric oxide donor, nitroglycerin, on bone. Annual Meeting of the American Society for Bone and Mineral Research, St. Louis, Missouri, 1999.

131. Hoff A.O., Thomas P.M., Cote G., Duvic M., High K.W., **Wimalawansa S.J.**, Bain S., Haiyan Q., Bradley A., Gagel R.F. A knockout of the CT/CGRP gene in mice leads to distinctive pattern of hair loss, analogous to alopecia areata. Annual Scientific Meeting of the American Endocrine Society, San Diego, California, 1999.
132. Wimalawansa D., Chapa M., **Wimalawansa S.J.** Comparison of the beneficial effects of nitroglycerine versus other nitric oxide donor compounds on ovariectomy-induced osteoporosis. Women's Health Forum—Annual Scientific Meeting, University of Texas Medical Branch at Galveston, 1999.
133. Wimalawansa S.M., Shankar V.S., Yang J., Simmons D.J., **Wimalawansa S.J.** Nitric oxide-cGMP pathway is involved in cyclosporine A-induced bone resorption. Women's Health Forum—Annual Scientific Meeting, University of Texas Medical Branch at Galveston, 1999.
134. **Wimalawansa S.J.** Four-year randomized controlled clinical study using combined therapy of estrogen and bisphosphonate: An efficacious method of treating postmenopausal osteoporosis. Women's Health Forum—Annual Scientific Meeting, University of Texas Medical Branch at Galveston, 1999.
135. **Wimalawansa S.J.**, Yallampalli C. The nitric oxide donor, nitroglycerin: *In vivo* effects on bone. Women's Health Forum—Annual Scientific Meeting, University of Texas Medical Branch at Galveston, 1999.
136. **Wimalawansa S.J.** Physiology and pharmacology of prevention of musculoskeletal losses in simulated microgravity. First International Symposium on Musculoskeletal Interaction, Santorini, Greece, 1999.
137. **Wimalawansa S.J.** Treatment of osteoporosis with combined therapies. First International Symposium on Musculoskeletal Interaction, Santorini, Greece, 1999.
138. Wimalawansa S.M., Shankar V., Yang S., Yang J., Simmons D.J., **Wimalawansa S.J.** The involvement of nitric oxide pathway in the mechanism of bone resorption secondary to cyclosporine A. First International Symposium on Musculoskeletal Interaction, Santorini, Greece, 1999.
139. Wimalawansa S.M., Yallampalli C., Simmons D.J., **Wimalawansa S.J.** *In vitro* (osteoblasts) and *in vivo* (bone mineral density) dose-dependent effects of nitric oxide. First International Symposium on Musculoskeletal Interaction, Santorini, Greece, 1999.
140. **Wimalawansa S.J.** Effects of nitric oxide donor nitroglycerin on prevention of osteoporosis in humans. Australian and New Zealand Bone and Mineral Society Meeting, Cairns, Australia, 1999.
141. **Wimalawansa S.J.** Yallampalli C. *In vivo* effects of the nitric oxide donor, nitroglycerin, on bone. Australian and New Zealand Society for Bone and Mineral Research, Cairns, Australia, 1999.
142. Wimalawansa D.M., **Wimalawansa S.J.** Comparison of beneficial effects of various nitric oxide donor compounds on ovariectomy-induced bone loss (Abstract SU408). American Society for Bone and Mineral Research, St. Louis, Missouri, 1999.
143. **Wimalawansa S.J.** Effects of nitric oxide donor, nitroglycerin on prevention of osteoporosis in humans: A clinical study (Abstract SA398). American Society for Bone and Mineral Research, St. Louis, Missouri, 1999.
144. Klein G.L., **Wimalawansa S.J.**, Herndon D.N. Longitudinal study of bone density in severely burned children: Possible role for pamidronate (Abstract SA127). American Society for Bone and Mineral Research, St. Louis, Missouri, 1999.

145. **Wimalawansa S.J.**, Simmons D.J., Yallampalli C. *In vivo* effects of nitric oxide donor, nitroglycerin, on bone (Abstract T180). American Society for Bone and Mineral Research, St. Louis, Missouri, 1999.
146. Bennett A.D., **Wimalawansa S.J.**, Hulsebosch C.E. Changes in the expression of calcitonin gene-related peptide and its receptors in the lumbar and cervical spinal cord. Society of Neuroscience, Miami, Florida, 1999.
147. Buchli J., Surendran S., Recinos A., **Wimalawansa S.J.** CGRP and associated receptor mRNA (RAMPs) levels in rats treated with estrogen, nitroglycerin or vitamin E. The University of Texas Undergraduate Research Forum, Galveston, Texas, 1999.
148. Vandevska-Radunovic V., Fristad I., Kavinnslund I.H., **Wimalawansa S.J.** Neuropeptide receptor expression in postnatal, developing rat molars. European Dental Meeting, 1999.
149. **Wimalawansa S.J.**, Simmons D.J., Yallampalli C. *In vivo* effects of nitric oxide donor, nitroglycerin on bone metabolism. University of Texas Forum on Aging, Galveston, Texas, 1999.
150. Fristad I., Vandevska-Radunovic V., **Wimalawansa S.J.**, Kavinnslund I.H. NK-1-, NK-2-, NK-3-, and CGRRP-expression in rat dental tissues. European Dental Meeting, 1999.
151. Gangula P.R.R., Kondapaka S.B., **Wimalawansa S.J.**, Yallampalli C. Regulation of calcitonin gene-related peptide (CGRP) receptors in non-pregnant and pregnant rat mesenteric arteries by sex-steroid hormones. 46th Annual Meeting of the Society for Gynecologic Investigation, 1999, Atlanta, Georgia.
152. Witlin A.G., Gangula P.R.R., **Wimalawansa S.J.**, Yallampalli C. Effects of adrenomedullin, an endogenous vasodilator, and L-NAME, a nitric oxide inhibitor, on blood pressure, litter size and mortality in pregnant rats. 46th Annual Meeting of the Society for Gynecologic Investigation, 1999, Atlanta, Georgia.
153. Spies M., **Wimalawansa S.J.**, Herndon D. Calcitonin gene-related peptide (CGRP) preserves bone mineral density after thermal injury. University Surgical Residents Conference (Society of University Surgeons) Annual Meeting, Washington DC, 1999.
154. Spies M., **Wimalawansa S.J.**, Herndon D. Calcitonin gene-related peptide (CGRP) prevents bone mass density loss by effects on the posttraumatic inflammatory response. Surgical Infection Society, Munich, Germany, 1999.
155. **Wimalawansa S.J.**, Yallampalli C. Nitric oxide donor, nitroglycerin is highly effective in prevention as well as treatment of ovariectomy-induced bone loss. World Congress of Osteoporosis 2000, Chicago, Illinois, 2000.
156. **Wimalawansa S.J.** Prevention of postmenopausal bone loss with nitric oxide. World Congress of Osteoporosis 2000, Chicago, Illinois, 2000.
157. Surendran S., **Wimalawansa S.J.**, Thota C., Wimalawansa, D.R., Recinos A. The effects of alpha tocopherol in prevention of ovariectomy-induced bone loss in rats. World Congress of Osteoporosis 2000, Chicago, Illinois, 2000.
158. Wimalawansa D.R., Gangula P.R., Yallampalli C., **Wimalawansa S.J.** Prevention of ovariectomy-induced bone loss with nitric oxide donor, nitroglycerin. Bone and Tooth Society Meeting, Cambridge, United Kingdom, 2000.
159. **Wimalawansa S.J.**, Surendran S., Wimalawansa S.M., Thota C., Recinos A. Prevention of ovariectomy-induced bone loss with alpha-tocopherol in rats. Bone and Tooth Society, Cambridge, United Kingdom, 2000.
160. **Wimalawansa S.J.**, Lick S., Johnson S., Garney E., MacInerney E., Lenihan D. Evaluation of the efficacy of intravenous pamidronate therapy in prevention of post-cardiac transplant

- bone loss: A randomized controlled clinical study. Transplant-induced Bone Disease, Barcelona, Spain, 2000.
161. **Wimalawansa S.J.**, Shankar V.J., Wimalawansa S.M., Simmons D.J. The involvement of nitric oxide-cGMP pathway in cyclosporine A induced dentin resorption: mechanistic insight. Transplant-induced Bone Disease, Barcelona, Spain, 2000.
 162. Surendra S., Wimalawansa D.R., Thota C., Recinos A., **Wimalawansa S.J.** Alpha tocopherol prevents ovariectomy-induced bone loss in rats. 22nd Annual Meeting, American Society for Bone and Mineral Research, Toronto, Canada, 2000.
 163. Gunaratne G., Bassler K., Mohanty K.K., **Wimalawansa S.J.** Effects of trabecular micro-architecture on the breaking strength in osteoporosis: Mathematical modeling. 22nd Annual Meeting, American Society for Bone and Mineral Research, Toronto, Canada, 2000.
 164. **Wimalawansa S.J.**, Surendran S., Thota C., Wimalawansa, D.R., Recinos A. Dose-response and the comparison of oral vs. parenteral vitamin E (dl-alpha tocopherol) in prevention of ovariectomy-induced bone loss in rats. 22nd Annual Meeting, American Society for Bone and Mineral Research, Toronto, Canada, 2000.
 165. Wimalawansa S.M., Vijay S., Simmons D.J., **Wimalawansa S.J.** Nitric oxide is essential for the cyclosporine A-induced bone resorption. 22nd Annual Meeting, American Society for Bone and Mineral Research, Toronto, Canada, 2000.
 166. Morara S., Provini L., **Wimalawansa S.J.**, Forloni G., Caretti A., Rosina A. CGRP receptor is developmentally regulated in the glia and neurons of the rat cerebellum. Neuroscience Annual Meeting, New Orleans, 2000.
 167. **Wimalawansa S.J.**, Lick S., Johnson S., MacImerney E., Garney E., Lenihan D. Efficacy of intravenous pamidronate therapy in prevention of post-cardiac transplant bone loss: A randomized controlled clinical study. Adult Bone and Mineral Workshop, 22nd Annual Meeting, American Society for Bone and Mineral Research, Toronto, Canada, 2000.
 168. Gangula P.R.R., **Wimalawansa S.J.**, Thompson M., Yallampalli C. Sex-steroid hormones up-regulate vasodilatory effects of calcitonin gene-related peptide (CGRP) in aged female rats. 48th Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada, 2001.
 169. Gangula P.R.R., **Wimalawansa S.J.**, Yallampalli C. Calcitonin gene-related peptide stimulates cyclic AMP levels in resistance blood vessels in female rats. 48th Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada, 2001.
 170. Dong Y.-L., Gangula P.R.R., Kondapaka S.B., Thompson M.L., **Wimalawansa S.J.**, Yallampalli C. Regulation of placental blood flow by calcitonin gene-related peptide. 48th Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada, 2001.
 171. Lanlua P., Kondapaka S.B., Gangula P.R.R., **Wimalawansa S.J.**, Bukoski R., Yallampalli C. Pregnancy and female steroid hormones increase CGRP-induced mesenteric vascular relaxation in rats. 48th Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada, 2001.
 172. Chauhan M.S., Kondapaka S.B., **Wimalawansa S.J.**, Rajaratnam K., Yallampalli C. Cloning, expression, and characterization of N-terminal domains of calcitonin receptor-like receptor (CRLR) and receptor activity modifying protein-1 (RAMP1). 48th Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada, 2001.
 173. Witlin A., **Wimalawansa S.J.**, Yallampalli C., Grafe M.R. Histopathological changes in day 18 rat placenta following co-infusion of adrenomedullin, an endogenous vasodilator, and L-NAME, a nitric oxide inhibitor. 48th Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada, 2001.

174. Lanlua P., Bukoski R., **Wimalawansa S.J.**, Yallampalli C. Effects of pregnancy and female sex-steroid hormones on CGRP content of the mesenteric artery in rats. 48th Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada, 2001.
175. **Wimalawansa S.J.**, Surendran S., Thota C. Prevention of ovariectomy-induced bone loss with vitamin E therapy. Annual Scientific Meeting of the American Endocrine Society, New Orleans, LA, 2001.
176. **Wimalawansa S.J.** Highly efficacious and cost-effective alendronate regimen for postmenopausal osteoporosis: A four-year clinical study. Annual Scientific Meeting of the American Endocrine Society, 2001, New Orleans, LA.
177. Wimalawansa S.M., Surendran S., Thota C., **Wimalawansa S.J.** Vitamin E prevents ovariectomy-induced bone loss. First International Conference on Bone and Mineral Research, Beijing, China, 2001.
178. **Wimalawansa S.J.** *In vivo* effects of nitric oxide donor, nitroglycerin, in prevention and treatment of ovariectomy-induced bone loss in rats and in humans. First International Conference on Bone and Mineral Research, Beijing, China, 2001.
179. **Wimalawansa S.J.** Once a week alendronate therapy: A convenient and effective way of prevention and treatment of osteoporosis. First International Conference on Bone and Mineral Research, Beijing, China, 2001.
180. Wimalawansa S.M., **Wimalawansa S.J.** Complete cessation of musculoskeletal losses in hind limb suspended rats (a model for microgravity), using the combination of an androgen and a bisphosphonate. American Society for Bone and Mineral Research, Phoenix, Arizona, 2001.
181. **Wimalawansa S.J.** Once-weekly alendronate therapy improves the compliance and decreases adverse effects, while maintaining its efficacy in comparison with the standard once-daily dose. American Society for Bone and Mineral Research, Phoenix, Arizona, 2001.
182. **Wimalawansa S.J.** Efficacy of once-weekly 30 mg of risedronate in comparison with once-weekly alendronate therapy for postmenopausal osteoporosis: One-year data. American Society for Bone and Mineral Research, Phoenix, Arizona, 2001.
183. **Wimalawansa S.J.** Intermittent, intravenous pamidronate therapy: Highly effective treatment for postmenopausal osteoporosis. American Society for Bone and Mineral Research, Phoenix, Arizona, 2001.
184. Gangula P.R., **Wimalawansa S.J.**, Yallampalli C. Sex steroid hormones enhance hypotensive responses to calcitonin gene-related peptide in aged female rats. Annual Scientific Meeting of the Society for Gynecologic Investigation, Montreal, Canada, 2002.
185. Gangula P.R., Dong Y.-L., Thota C., **Wimalawansa S.J.**, Yallampalli C. Mechanisms involved in calcitonin gene-related peptide-induced relaxation and expression of CGRP receptor components in pregnant rat uterus. Society for Gynecologic Investigation, Montreal, Canada, 2002.
186. Chauhan M.S., Kondapaka S., **Wimalawansa S.J.**, Rajarathanam K., Yallampalli C. Determination and characterization of ligand binding activity in the N-terminal extra-cellular domain of CGRP receptor components CRLR and RAMP 1. Annual Scientific Meeting of the Society for Gynecologic Investigation, Montreal, Canada, 2002.
187. **Wimalawansa S.J.** Once-weekly alendronate therapy improves the compliance and decreases adverse effects, while maintaining its efficacy in comparison with the standard once-daily dose. Research Day presentation at the Robert Wood Johnson Medical School, New Brunswick, New Jersey, 2002.

188. Chauhan M.S., Kondapaka S., Rajarathanam K., Yallampalli C., **Wimalawansa S.J.** Determination and characterization of ligand binding activity in the N-terminal extracellular domain of CGRP receptor components CRLR and RAMP-1. Research day poster presentation at the Robert Wood Johnson Medical School, New Brunswick, New Jersey, 2002.
189. **Wimalawansa S.J.** Efficacy of once-weekly 30 mg of risedronate in comparison with once-weekly alendronate therapy for postmenopausal osteoporosis: One-year data, American Society for Bone and Mineral Research, San Antonio, Texas, 2002.
190. **Wimalawansa S.J.** Intermittent, intravenous pamidronate therapy: Highly effective treatment for postmenopausal osteoporosis. Research Day presentation at the Robert Wood Johnson Medical School, New Brunswick, New Jersey, 2002.
191. **Wimalawansa S.J.** Loading dose of bisphosphonates: A new concept to improve the efficacy of bisphosphonates on BMD and to expedite fracture reduction in osteoporosis. American Society for Bone and Mineral Research, San Antonio, Texas, 2002.
192. Gunaratne G.H., **Wimalawansa S.J.** A mathematical model of bone and application to osteoporosis. American Society for Bone and Mineral Research, San Antonio, Texas, 2002.
193. Chauhan M.S., Thota C.S., Kondapaka S.B., **Wimalawansa S.J.**, Yallampalli C. A new CGRP receptor: Evidence for CGRP receptor heterogeneity. 50th Annual Meeting Society for Gynecologic Investigation, Washington DC, 2003.
194. Gangula P.R.R., Chauhan M.S., Yallampalli U., Thota C.S., Dong Y.L., **Wimalawansa S.J.**, Yallampalli C. Expression of CGRP and adrenomedullin receptor components in pregnant rat uterine artery: effects of CRLR and RAMP-1 antibodies on relaxation. 50th Annual Meeting Society for Gynecologic Investigation, Washington DC, 2003.
195. Aguirre J.I., Igal S.U., Larsen A., Quiroga A., Lausada N., Petruccioli M., Perfumo C., **Wimalawansa S.J.** Endothelial nitric oxide synthase expression decreases in the growth plate but increases in the metaphyses of bones from lactating rats in association with reduced endochondral growth and increased resorption and osteoid deposition. American Society for Bone and Mineral Research, Minneapolis, Minnesota, 2003.
196. Grimes J.P., Frempong B., Guerard C., Cosgrove N., Wilson A., **Wimalawansa S.J.** Low vitamin D levels in postmenopausal women. Society for General Internal Medicine, Orlando, Florida, 2004.
197. **Wimalawansa S.J.**, Guerard C., Wilson A., Kulkarni G., Cosgrove N., Grimes J. Relationship of serum estradiol levels with common variables in early postmenopausal women. 86th Annual Meeting of the American Endocrine Society, 2004.
198. **Wimalawansa S.J.** Anabolic effects of nitric oxide on osteoblasts. NIH/ASBMR Special Symposium on Anabolic Agents and Osteoporosis, Bethesda, Maryland, 2004.
199. Herath H., **Wimalawansa S.J.** Novel fluorescent activated cell-sorting method for *in vitro* analysis of matured osteoclast differentiation rate. 26th Annual Meeting, American Society for Bone and Mineral Research, Seattle, Washington, 2004.
200. Kulkarni G., Guerard C., Wilson A., **Wimalawansa S.J.** Prevalence of vitamin D in postmenopausal women and its relevance to i-PTH in central Jersey. 26th Annual Meeting, American Society for Bone and Mineral Research, Seattle, Washington, 2004.
201. **Wimalawansa S.J.** Prevalence of high incidences of secondary causes of osteoporosis in men and women. 26th Annual Meeting, American Society for Bone and Mineral Research, Seattle, Washington, 2004.

202. Aguirre, J.I., Igal, S.U., Larsen, A., Quiroga, N., Lausada, M., Petruccelli, C., Perfumo, S., **Wimalawansa S.J.** Endothelial nitric oxide synthase expression decreases in the growth plate but increases in the metaphyses of bones from lactating rats in association with reduced endochondral growth and increased resorption and osteoid deposition, American Society for Bone and Mineral research, Seattle, Washington, 2004.
203. **Wimalawansa S.J.** Intravenous pamidronate therapy for treatment of osteoporosis: What is the optimum dose? 26th Annual Meeting, American Society for Bone and Mineral Research, Seattle, Washington, 2004.
204. Azzez F., Herath H.M.C., **Wimalawansa S.J.** 22nd Annual Meeting of the American Association of the Physicians of Indian Origin, San Diego, California, 2004.
205. Gunaratne, G., Liebschner M.A., **Wimalawansa, S.J.** A method to identify mechanical factors causing bone degradation and to deduce diagnostics for osteoporosis. 26th Annual Meeting, American Society for Bone and Mineral Research, Seattle, Washington, 2004.
206. Kulkarni G., Cosgrove N., Grimes J., Wilson A., **Wimalawansa S.J.** The relationship of serum intact parathyroid hormone levels to serum vitamin D levels in postmenopausal women in central New Jersey. Research Day presentation at the Robert Wood Johnson, Medical School, New Brunswick, New Jersey, 2004.
207. **Wimalawansa S.J.** Optimum dose and frequency of administration of intravenous pamidronate for treatment of osteoporosis. Research Day presentation at the Robert Wood Johnson Medical School, New Brunswick, New Jersey, 2004.
208. Herath C.H.M., **Wimalawansa S.J.** *In vitro* analysis of osteoclast differentiation rate: A novel convenient fluorescent-activated cell sorting method. Research Day presentation at the Robert Wood Johnson Medical School, New Brunswick, New Jersey, 2004.
209. Grimes J., Frempong B., Guerard C., Cosgrove N., Kulkarni G., Wilson A., **Wimalawansa S.J.** Low vitamin D levels in postmenopausal women. Research Day poster presentation at the Robert Wood Johnson Medical School, New Brunswick, New Jersey, 2004.
210. **Wimalawansa S.J.** Upfront loading of bisphosphonates: Novel method to advance the beneficial effects of bisphosphonates on fracture reduction. Research Day poster presentation at the Robert Wood Johnson Medical School, New Jersey, March 2004.
211. Wang X., Farooki A., **Wimalawansa S.J.** Effects of intravenous zoledronic acid on a patient with primary hyperparathyroidism. American Endocrine Society, San Diego, California, 2005.
212. Liebschner M., Tawackoli W., **Wimalawansa S.J.**, Gunaratne G., Hussain F., Spanos P. Structural dynamics as a bone diagnostics: A preliminary study. Bone Quality: What is it and can we measure it? NIAMS–ASBMR Joint Meeting, Bethesda, Maryland, 2005.
213. **Wimalawansa S.J.**, Liebschner M., Gunaratne G. A mathematical model to identify mechanical factors leading to a fracture. Bone Quality: What is it and can we measure it? NIAMS–ASBMR Joint Meeting, Bethesda, Maryland, 2005.
214. **Wimalawansa S.J.**, Funderburk S., Farooki A., Wang X. Effects of intravenous zoledronic acid on patients with primary hyperparathyroidism: Proof of concept study. Bone and Mineral Working Group, American Society for Bone and Mineral Research, 27th Annual Meeting, Nashville, Tennessee, 2005.
215. Grimes J.P., Wilson A., Rojo G., **Wimalawansa S.J.** Risk factors associated with low vitamin D levels in postmenopausal women: baseline analysis of NOVEL clinical study. National Osteoporosis Foundation, Washington, DC, 2005.

216. **Wimalawansa S.J.** Use of upfront loading of bisphosphonates: Novel method to advance the beneficial effects of bisphosphonates on enhancing fracture reduction. 27th Annual Meeting, American Society for Bone and Mineral Research, Nashville, Tennessee, 2005.
217. **Wimalawansa S.J.**, Herath C, Goush G. Relationship of osteoclast mitochondrial mass and potential to its morphology and function. 27th Annual Meeting, American Society for Bone and Mineral Research, Nashville, Tennessee, 2005.
218. Marcella S., **Wimalawansa S.J.** Bone mineral density in men with newly diagnosed, localized prostate cancer: A possible prognostic factor. American Cancer Society, San Francisco, California, 2005.
219. Grimes J.P., Wilson A.C., Rojo G., Cosgrove N.M., **Wimalawansa S.J.** Exploring the relationship of periodontal disease and osteoporosis in postmenopausal women. Society for General Internal Medicine, Washington DC, 2006.
220. **Wimalawansa S.J.**, Herath C., Goush G. Age-related changes of mitochondrial mass, action potentials, and functions of osteoclasts. 88th Annual Meeting of the Endocrine Society Meeting, Boston, Massachusetts, 2006.
221. **Wimalawansa S.J.** Novel method to advance the beneficial effects of bisphosphonates on BMD and fracture reduction in osteoporosis: Use of front-loading doses of bisphosphonates. 86th Annual Meeting of the American Endocrine Society, Boston, Massachusetts, 2006.
222. Grimes J.P., Wilson A., **Wimalawansa S.J.** Does breastfeeding influence levels of vitamin D in postmenopausal women? Seventh International Symposium on Osteoporosis: Translating Research into Clinical Practice, Washington DC, 2007.
223. Grimes J.P., Wilson A., Rojo G., Cosgrove N., **Wimalawansa S.J.** Exploring the relationship of periodontal disease and low bone mass in postmenopausal women. Annual Meeting of the National Osteoporosis Foundation, Washington DC, 2007.
224. Grimes J.P., Wilson A.C., Marrero L., Rojo G., Cosgrove N.M., **Wimalawansa S.J.** Exploring the recruitment profiles of postmenopausal women recruited for an osteoporosis prevention trail. Annual Meeting of the Society for General Internal Medicine, Washington DC, 2007.
225. **Wimalawansa S.J.**, Bartello M., Hodapp K., Morgan K., Wagner M., Lachenmayre S. A community-based program to minimize osteoporosis and fracture risks. 29th Annual Meeting, American Society for Bone and Mineral Research, Honolulu, Hawaii, 2007.
226. **Wimalawansa S.J.**, Wang X., Ghosh J., Azeez F. Comparative analysis of osteoclast bone resorption activity and apoptosis in young and old mice. 29th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, Hawaii, 2007.
227. **Wimalawansa S.J.** Long-term administration of bisphosphonates and increase fracture incidences. 29th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, Hawaii, 2007.
228. **Wimalawansa S.J.**, Wang B., Ghosh J. Ageing and osteoporosis: Osteoclast survival and activity. 89th Annual Meeting of the Endocrine Society, Toronto, Canada, 2007.
229. **Wimalawansa S.J.** Nitric oxide: An important modulator of bone remodeling. Targeting bone remodeling for the treatment of osteoporosis. American Society for Bone and Mineral Research, Washington DC, 2007.
230. **Wimalawansa S.J.**, Grimes J., Wilson A., Chen F., Hoover D. Osteoporosis in postmenopausal women: Development of a cost-effective novel therapy—NOVEL clinical study. Targeting bone remodeling for the treatment of osteoporosis. American Society for Bone and Mineral Research, Washington DC, 2007.

231. Wilson A., Hoover D., Warusawithana A., Grimes J., **Wimalawansa S.J.** NOVEL clinical study: Prevention of postmenopausal osteoporosis using nitroglycerine. 90th Annual Meeting of the American Endocrine Society, San Francisco, California, 2008.
232. **Wimalawansa S.J.** Nitric oxide has a powerful effect of osteoclast cells. American Society for Bone and Mineral Research, Montreal, Canada, 2008.
233. **Wimalawansa S.J.** The role of nitroglycerine in prevention of postmenopausal bone loss. Rutgers University/UMDNJ Endocrinology Show Case, Piscataway, New Jersey, 2008.
234. **Wimalawansa S.J.**, Grimes J., Wilson A., Cosgrove N., Hoover D. Prevention of postmenopausal osteoporosis using nitroglycerine: NOVEL clinical study. 30th Annual Meeting, American Society for Bone and Mineral Research, Montreal, Canada, 2008.
235. **Wimalawansa S.J.**, Warusawithana A., Springer C. IGF1 is a marker for bone mineral density changes, in response to therapy with nitroglycerine. International Osteoporosis Foundation (IOF) Scientific Congress, Bangkok, Thailand, 2008.
236. **Wimalawansa S.J.**, Wilson A., Chen F., Grimes J., Hoover D. Can we use nitric oxide donor, nitroglycerine for prevention of postmenopausal bone loss? International Bone and Mineral Society, and Australian and New Zealand Bone and Mineral Societies Joint Meeting, Sydney, Australia, 2009.
237. Springer C., Warusawithana A., **Wimalawansa S.J.** Positive BMD response following nitroglycerin therapy is associated with elevation of serum IGF-1 levels. International Bone and Mineral Society, and Australian and New Zealand Bone and Mineral Societies Joint Meeting, Sydney, Australia, 2009.
238. **Wimalawansa S.J.** Mechanisms of prevention of bone loss with nitric oxide donor, nitroglycerin. American Endocrine Society, Washington DC, 2009.
239. Hoover D., Grimes J., Wilson A., **Wimalawansa S.J.** Nitroglycerin: A novel therapy for prevention of postmenopausal osteoporosis: NOVEL clinical study. American Endocrine Society, Washington DC, 2009.
240. **Wimalawansa S.J.** Provision of safe and clean drinking water for those who are in need. International Water Week, Stockholm, Sweden, 2009.
241. Patil D, **Wimalawansa S.J.** Purification of water for human consumption in conflict areas. International Water Week, Stockholm, Sweden, 2009.
242. Grimes J.P., Cosgrove N., Wilson A., Rojo G., Marrero L., Guerard C., Stalter S., Duffy E., **Wimalawansa, S.J.** Recruit and retain: Efforts to maximize a representative sample of postmenopausal women for a single-site osteoporosis prevention trial. 32nd Annual Meeting, Society for General Internal Medicine, Atlanta, Georgia, 2009.
243. **Wimalawansa S.J.**, Warusawithana A. Use of external quality control site for validation of DXA data. International Society for Clinical Densitometry, Orlando, Florida, 2009.
244. **Wimalawansa S.J.** Effects of aging on osteoclast functions. Sri Lanka Medical Association of North America, 13th Annual CME Meeting, New York, New York, 2009.
245. **Wimalawansa S.J.** Does the effect of nitric oxide donor nitroglycerin mediate through IGF-1? International Society for Clinical Densitometry, Orlando, Florida, 2009.
246. **Wimalawansa S.J.** and May R.L. Fractures due to osteoporosis in patients with developmental disabilities. 20th Annual Conference on Medical Care for Persons with Development Disabilities, New Jersey, 2009.

247. **Wimalawansa S.J.**, Bartello M., Hodapp K., Wagner M., Lachenmayr S. Community based program to minimize osteoporosis fracture risks. 14th Annual Continuing Medical Education Program of the Sri Lanka Medical Association (SLMANA), New York, New York 2009.
248. Springer C., Warusawithana A., **Wimalawansa S.J.** Changes of markers of bone turnover after nitric oxide donor therapy in postmenopausal women. 14th Annual Continuing Medical Education Program of the Sri Lanka Medical Association (SLMANA), New York, New York 2009.
249. **Wimalawansa S.J.** Unique effects of nitric oxide on osteoclast cells. 14th Annual Continuing Medical Education Program of the Sri Lanka Medical Association (SLMANA), New York, New York, 2009.
250. Springer C., Warusawithana A., **Wimalawansa S.J.** Positive changes of marker of bone turnover following nitroglycerin therapy in postmenopausal women. 31st Annual Meeting American Society for Bone and Mineral Research, Denver, Colorado, 2009.
251. **Wimalawansa S.J.** Mechanisms of the development of bisphosphonate-associated osteomyelitis of the jaw: BAOMJ. Seventh International Workshop on Muscular-skeletal and Neuronal Interactions, Cologne, Germany, 2010.
252. Wimalawansa D.R. and **Wimalawansa S.J.** Combination of nitric oxide and bisphosphonates further enhances the increments of bone mineral density. Seventh International Workshop on Muscular-skeletal and Neuronal Interactions, Cologne, Germany, 2010.
253. Wimalawansa S.M., Quast M., Westlund K.N., **Wimalawansa S.J.** Prevention of simulated weightlessness-induced musculo-skeletal losses with a combination therapy. Seventh International Workshop on Muscular-skeletal and Neuronal Interactions, Cologne, Germany, 2010.
254. **Wimalawansa S.J.** Interactions of nitric oxide and insulin-like growth factor I, in prevention of bone loss. American Society for Bone and Mineral Research, Toronto, Canada, 2010.
255. Lee E., Makjija C., **Wimalawansa S.J.** Bilateral atypical subtrochanteric femoral fractures in patients on chronic bisphosphonate therapy. Adult Bone and Mineral Workshop, American Society for Bone and Mineral Research, Toronto, Canada, 2010.
256. **Wimalawansa S.J.** Bisphosphonate-associated osteomyelitis of the jaw; BAOMJ/ONJ: potential mechanisms. American Society for Bone and Mineral Research, Toronto, Canada, 2010.
257. Springer C. and **Wimalawansa S.J.** The use of bone turnover markers in identifying responders to nitroglycerin therapy in postmenopausal women. Pioneer in Endocrinology, Third Annual Scientific Symposium, Rutgers University, New Brunswick, New Jersey, 2010.
258. Warusawithana A. and **Wimalawansa S.J.** Mechanisms of action of nitric oxide in prevention of bone loss. Pioneer in Endocrinology, Third Annual Scientific Symposium, Rutgers University, New Brunswick, New Jersey, 2010.
259. Niche J., Sagebien C., Mesilla R., Redziniak R., **Wimalawansa S.J.** Subtrochanteric femoral stress fractures in patients on chronic bisphosphonate therapy: A case series. American Society for Bone and Mineral Research, Toronto, Canada, 2010.
260. **Wimalawansa S.J.** Meditation, spirituality and health; Integrative healing, alternative medicine, and spirituality. South Asian Total Health Initiative (SATHI) and Center for Health Families and Cultural Diversity (CHFCD), Princeton, New Jersey, 2010.

261. Springer C., **Wimalawansa, S.J.** Marker of bone turnover as response to nitroglycerin therapy in postmenopausal women. International Osteoporosis Foundation, Asia Pacific Meeting, Singapore, 2010.
262. Warusawithana A. and **Wimalawansa S.J.** Nitric oxide donor, nitroglycerin increase serum IGF-1 levels in postmenopausal women. International Osteoporosis Foundation, Asia Pacific Meeting, Singapore, 2010.
263. **Wimalawansa S.J.** Non-skeletal effects of vitamin D. American endocrine society annual meeting, Boston, MA, 2011.
264. **Wimalawansa S.J.** Mechanisms of drug drug-induced osteomyelitis of the jaw, American Association of Clinical Endocrinologists, San Diego, CA, 2011.
265. **Wimalawansa S.J.** Are the beneficial effects of nitric oxide on bone is mediated through insulin-like growth factor? American Association of Clinical Endocrinologists, San Diego, CA, 2011.
266. Warusawithana, A. and **Wimalawansa S.J.** Correlations of BMD with BMI, menopausal state, estradiol smoking, & exercise. International Soc. for Clin. Densitometry, Miami, FL, 2011.
267. **Wimalawansa, S.J.** Worldwide epidemic of vitamin D deficiency. Advances and controversies of nutrition. American Society of Nutrition, Chicago, IL, 2011.
268. **Wimalawansa, S.J.**, Nitche J., Masella, R., Redziniak, D., Sagebien, C. Atypical subtrochanteric femoral fractures after potent anti-resorptive therapy. International Society for Clinical Densitometry, Miami, FL, 2011.
269. Springer C, Warusawithana, A, **Wimalawansa S.J.** Relationship of bone mineral density and biochemical markers of bone resorption in response to nitroglycerine therapy. International Society for Clinical Densitometry, Miami, FL, 2011
270. Graham P. and **Wimalawansa S.J.** Disability is an important risk factor for bone loss, low vitamin D, and osteoporosis. National Osteoporosis Foundation Annual Scientific Meeting, Las Vegas, NV, 2011
271. May P, Chahal H, Warusawithana A, May R, **Wimalawansa SJ.** Persons with developmental disabilities have a high prevalence of vitamin D deficiency and low bone density. Sri Lankan Medical Association, NA, Annual CME scientific session, NY, 2011
272. **Wimalawansa, S.J.** Drug-induced osteomyelitis (ONJ-OMJ) of jaw: Guidelines for practicing clinicians, Sri Lankan Medical Association, NA, CME scientific session, NY, 2011
273. **Wimalawansa, S.J.** Atypical subtrochanteric femoral fractures following anti-resorptive therapy. Sri Lankan Medical Association, North America, CME scientific session, NY, 2011
274. **Wimalawansa, S.J.** Vitamin D and human skeletal health in the new millennium. American Association for Clinical Endocrinology, Philadelphia, PA, 2012.
275. **Wimalawansa, S.J.** and Graham P. Chronic disabilities markedly increase bone loss and fractures. American Association for Clinical Endocrinology, Philadelphia, PA, 2012.
276. Wimalawansa, S.J. Vitamin D and human skeletal health, International Society for Clinical Densitometry, Los Angeles, CA, 2012.
277. Graham, P. and **Wimalawansa S.J.** Increased risk for bone loss and fractures in Persons with Disability. International Society for Clinical Densitometry, Los Angeles, CA, 2012.
278. **Wimalawansa, S.J.** Dietary, lifestyle, and medical choices in promoting health. FASAB - American Nutrition Society, San Diego, 2012.

279. **Wimalawansa, S.J.** Skeletal and non-skeletal benefits of vitamin D, American society for bone and mineral research, 2012.
280. **Wimalawansa, S.J.** Nitric oxide in bone works through insulin-like growth factor-I, in prevention of bone loss with nitroglycerin. American Endocrine Society, Houston, Tx, 2012.
281. **Wimalawansa, S.J.** Use of the hormone replacement therapy in the new millennium. American Endocrine Society, Houston, Tx, 2012.
282. **Wimalawansa, S.J.** Turner's syndrome: Common but neglected endocrine disorder. American Association for Clinical Endocrinology, Phoenix, AZ, 2013.
283. **Wimalawansa, S.J.** Post traumatic stress disorder: An endocrine disorder. American Endocrine Society, San Francisco, CA, 2013.
284. **Wimalawansa, S.J.** Thermogenesis: A Unique Intervention for Obesity and Type 2 Diabetes. American Endocrine Society, San Francisco, CA, 2013.
285. **Wimalawansa, S.J.** Food enrichment and fortification: Alleviating micronutrient deficiencies. 2nd Int. Conference and Exhibition on Food Processing & Technology, Kansas City, MO, 2013.
286. **Wimalawansa, S.J.** Prevention of chronic kidney disease of multi-factorial origin in Sri Lanka (CKDmfo). Dhamavijaya Foundation, Colombo, Sri Lanka, 2014.
287. Wyne, K. and **Wimalawansa, S.J.** Screening and diagnosis of chronic kidney disease of multi-factorial origin. 5th International conference of sustainable build environment; "Prevention of CKDmfo from Sri Lanka." Kandy, Sri Lanka, 2014.